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Abbrevations 
°C  Celsius 
Ac-DEVD-pNA  Acetyl-Asp-Glu-Val-Asp p-nitroanilide 
Ac-IETD-pNA Acetyl-Ile-Glu-Thr-Asp-p-nitroanilide  
APAF1  Adapter protein apoptotic protease  
activating factor 1  
AR  Androgen receptor 
ATP  Adenosine triphosphate 
BL1  Basal-like 1  
BL2  Basal-like 2  
BLBC  Basal-like breast cancer 
CA  California 
CARD  Caspase recruitment domain  
CYP  Cytochromes P450 
dATP  Deoxyadenosine triphosphate 
DED  Death‐effector domain  
DISC  Death-inducing signaling complex  
DNA  Deoxyribonucleic acid 
DR  Death receptor 
ECM  Extracellular matrix 
ER   Estrogen receptor  
ERE  Estrogen response element 
FADD  FAS‐associated death domain  
FAK  Focal adhesion kinase 
FISH  Fluorescence in situ hybridization 
h  Hour 
HER2  Human epidermal growth factor receptor 2 
HO  Hoechst 33258  
HPV  Human papillomavirus  
IAP  Inhibitors of apoptosis protein 
LAR  Luminal androgen receptor 
LEHD-pNA Leu-Glu-His-Asp- p-nitroanilide 
IHC  Immunohistochemistry  
ME  Maine 
MEK  Mitogen-activated protein kinase kinase 
MMP  Matrix metalloproteinase 
MPT  Mitochondrial permeability transition  
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide  
PARP  Poly ADP-ribose polymerase 
PBS  Phosphate-buffered saline  
pFAK  Phosphorylated focal adhesion kinase 
PI  Propidium iodide  
PI3K  Phosphoinositide 3-kinase 
PR  Progesteron receptor 
RBA  Relative binding affinities 
RIPK1                    Receptor-interacting serine/threonine-protein  
kinase 1  
RNAse A Ribonuclease  
Rpm  Revolutions per minute 
SDS-PAGE Sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis 
TNBC  Triple-negative breast cancer 
TNFR  Tumor necrosis factor receptor  
TRADD  TNF receptor‐associated death domain  
USA  United States 
WCE  Whole-cell extraction 
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1. Introduction 
1.1 Epidemiology and overview of breast and cervical tumors 
In spite of the continuously developed new therapeutical opportunities, cancer is still 
an unsolved health problem and a leading cause of death globally. Based on the database of 
Globocan 2018, 18.1 million new cases and 9.6 million tumor-related deaths were estimated 
worldwide in 2018.
1
 In 2012, the approximated new case and cancer death numbers were 14.1 
and 8.2 millions.
2
 Comparing these data to the assessment of 2018 shows the huge necessity 
for more efficient treatments.  Among women, breast malignancy was the most frequently 
diagnosed and correlating to this fact, it is the leading cause of cancer death in 103 countries.  
Another significant gynecological tumor is cervical cancer, since it takes the fourth position in 
incidence and mortality.
1
 
The presence of secondary tumors can be connected with approximately 90% of 
cancer-related deaths.
3
 Steeg et al. have evaluated the reports of US National Cancer Institute 
Surveillance, Epidemiology and End Results (SEER) registries, including data between 1995–
2000 and 2004–2010 that were reported in 2005 and 2015, It was found that patients with a 
diagnosis of metastasis had decreased overall 5-year survival rates compared to the patients 
with localised or regional disease. In addition, fewer than 20% of the patients with metastatic 
disease survived 5 years later regarding half of the examined cancer sites.  The 5-year survival 
rate is reduced in several cancer types with distant metastases between the two reporting 
periods, such as breast and cervical tumors.
4
 The assessment of results of randomized clinical 
trials covering a 30-year period could not show sustained evidence of survival improvement 
among women with metastatic breast cancer.
5
 
The heterogeneous clinical and molecular appearance of breast cancer is expansively 
established; several subtypes were determined on the basis of their expressed receptors. There 
are various available methods to identify receptor expression. Estrogen receptor (ER) and 
progesterone receptor (PR) assessment can be carried out by the means of 
immunohistochemistry (IHC), while for determination of human epidermal growth factor 
receptor 2 (HER2) expression, IHC or fluorescence in situ hybridization (FISH)  are utilized.
6
  
Breast cancer subtypes were further identified based on gene expression profiling using 
cDNA microarrays.
7,8
 Numerous genes were found to be highly expressed in estrogen 
receptor (ER) positive tumors which are also expressed by the luminal cells of breast tissue.
7
 
We can identitify luminal A and luminal B types between hormone-positive cancers, 
considering that Luminal A was featured by higher expression of ER-related genes, and the 
 6  
 
less expression of proliferative genes compared to Luminal B tumors.
8
 Another clinically 
significant class is determined by the expression of HER2.
9
  
The triple-negative subtype (TNBC) is distinguished by the lack of ER, PR and HER2 
amplification.
9
 Within this characteristic, heterogeneous molecular feature was described. The 
basal-like breast cancer (BLBC) carries the same receptor characteristic, but in addition, it is 
featured by a strong gene expression pattern, such as cytokeratin 5,6,17 and EGFR.
10,11
 The 
“basal-like” term was derived from the fact, that the genes mentioned above are featuring 
normal basal and myoepithelial cells. TNBC subtype encompasses approximately 90% of 
BLBCs.
11
 
Approximately 15-20% of the total diagnosed breast tumors are triple-negative. 
However, the fact that 25% of the total breast cancer mortality can be connected with the 
subtype shows its serious burden.
9
 The size of the tumor is typically larger, the chance of 
recurrence is higher, and metastatic spread appears in a significantly shorter period from the 
initial diagnosis than other breast cancer subtypes.
12
 Moreover, the secondary tumor of TNBC 
frequently occurs in the brain and viscera, which carries a poor prognosis. On the other hand, 
the non-TNBC metastatic evaluation mostly affects bones. Correspondingly, TNBC is 
featured by shorter median time to death (4.2 vs. 6 years) and worse overall survival.
9,13
 
Another disadvantageous fact, that TNBC patients are 5-10 years younger compared to other 
breast tumor subtypes at the time of diagnosis.
14
 
Although extensive mutational and clonal diversity was described in connection with 
the progression of primary TNBC, the clinical treatment still considers TNBC as a single 
disease entity. Standard chemotherapeutical treatment is utilized for all stages of TNBC.
11,15–
17
  The reassessment of the molecular classification of TNBC by the means of gene expression 
profiling (previously six subgroups were described by Lehmann et al. in 2011
15
) resulted in 
differing basal-like 1 (BL1), basal-like 2 (BL2), luminal androgen receptor (LAR) and 
mesenchymal intrinsic subtypes. The previously described immunomodulatory (IM) and 
mesenchymal stem-like (MSL) subtypes were demonstrated to be composed of tumors with 
low cellularity.
16
 Variable clinical courses of TNBC were observed which could be the result 
of its heterogenic molecular feature. Following the sensitivity examination of the subgroups 
towards chemotherapy, a parallel was drawn between the subtypes and TNBC cell lines with 
comparable gene expression. MDA-MB-231, a commonly studied triple-negative cell line 
was classified into the MSL subtype.
15
 Another two classification of TNBC based on gene 
expression profiling was described with both overlaps and differences compared to the work 
of Lehmann et al.
18,19
 It was reported that the response to neoadjuvant chemotherapy 
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comprising anthracycline and taxane of TNBC patients significantly varied based on their 
molecular subtype that was classified by utilizing the classification of Lehmann et al.
20
 The 
differing responses to neoadjuvant chemotherapy of the subtypes were additionally confirmed 
by the combined analysis of over 300 TNBC patients.
16
 
Several drug candidates with different mechanism of action have been examined in 
clinical trials against TNBC, such as poly ADP-ribose polymerase (PARP) inhibitors, 
phosphoinositide 3-kinase (PI3K) inhibitors, mitogen-activated protein kinase kinase (MEK) 
inhibitors, anti-androgen therapies, heat shockprotein 90 inhibitors, histone deacetylase 
inhibitors, immune-checkpoint inhibitors and their combinations. Despite the promising 
results of PARP inhibitors and immune-checkpoint inhibitors, the specific treatment of TNBC  
remains an urgent unmet medical need.
9,11
 
Cervical tumor development is featured by different factors, including the most 
significant human papillomavirus (HPV) infection and the required genetic and epigenetic 
alterations for the process.
21
 The main role of the persistent high-risk HPV type infection is 
well-established both epidemiologically and biologically; the presence of HPV was 
demonstrated in 99.7% of cervical cancers. The involvement of genetic and epigenetic 
alterations evolves the immortalization and transformation of the epithelial cells of the host.
22
  
“High-risk” HPV subtypes, such as 16, 18, 31, 33 and 45 have been shown carcinogenic 
potential in the initiation and promotion of intraepithelial and invasive cervical tumors.
23,24
 
HPV 16 and 18 are definied as the most dominant considering that 70-80% of all cervical 
cancers are affected.
25,26
 The prognostic significance of HPV-DNA prevalence and viral load 
regarding preinvazive cervical tumors was observed in several studies.
23,24
 HeLa cell line was 
derived from cervical cancer and has become the first cultured and most widely utilized 
human cell line.
27
 The presence of HPV 18 DNA in HeLa cells is well-established.
28
 
Although the numerous available therapeutical opportunities, the outcome of the disease has 
not developed significantly in the last 20 years. Additionally, the appearance of relapses (10-
60%) is  within the first 2-3 years after finishing the treatment period.
24
 
1.2 Overview of the main processes of programmed cell death  
Apoptosis or programmed cell death is characterized by specific energy-dependent 
biochemical and genetic pathways; moreover, a distinct morphological characteristic. It is 
considered critical in maintaining the balance between cell survival and cell death via 
initiating the elimination of unnecessary and damaged cells as a homeostatic mechanism. 
Apoptotic signals play an essential role in several processes, including embryonic 
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development, physiological cell turnover, development and normal functioning of the immune 
system, hormone-dependent atrophy, and chemical-induced cell death. The contribution of 
accelerated cell death has been demonstrated in immunodeficiency, acute and chronic 
degenerative diseases, and infertility. On the other hand, insufficient apoptosis can lead to 
cancer or autoimmune diseases. Programmed cell death normally has a defender function 
regarding genomic integrity, while inappropriate apoptosis can result in not only 
carcinogenesis, but evolving resistance of tumor cells to treatment.
29,30
  
Among the huge number of gene products that were identified as a participant in the 
cell cycle and cell death processes, definite regulatory proteins, enzymes, and receptors were 
connected with key regulation segments. The remarkable significance of these regulators was 
determined through the direct effect of their abnormal expression or mutation on cell cycle.
31
 
Apoptosis is determined as highly conserved since there is no alteration in the execution of 
the mechanism despite the different initiating stimuli.
29,32
 The initiation and execution of 
programmed cell death depend on the activation of a family of cysteine proteases, caspases. 
Considering their role in the apoptotic mechanism, initiator and effector caspases can be 
distinguished. Following the detection of cell damage signal, effector caspases (caspases-3, -6 
and -7) are activated by initiator caspases (caspases-8 and -9). This activation leads to a 
cascade of molecular events, such as DNA fragmentation, degradation of cytoskeletal and 
nuclear proteins, crosslinking of proteins, creation of apoptotic bodies, the expression of 
ligands for phagocytic cell receptors and finally the uptake by phagocytic cells.
29,31
  
 Two main apoptotic mechanisms are distinguished, the intrinsic or mitochondrial 
pathway, and the extrinsic or death receptor pathway. The main linkage between the 
execution of mitochondrial and death receptor-mediated processes is the identical terminal 
pathway mediated by caspase-3.
29
 The intrinsic pathway is determined by various impulses 
which influence multiple intracellular objectives in response to different stress conditions. 
Negative and positive signals can either initiate this form of apoptosis. Insufficient 
suppression of cell death process can be caused by negative signals, including the absence of 
defined growth factors, cytokines and hormones. The absence of these prosurvival factors 
afterward leads to the initiation of the apoptotic program.  On the other hand, positive signals, 
such as hypoxia, toxins, hyperthermia, viral infections, radiation, irreversible genetic damage 
and free radicals can activate the intrinsic pathway as well.
29,31
  
The mechanism is initiated by caspase-9 that binds to adapter protein apoptotic 
protease activating factor 1 (APAF1) through its caspase recruitment domain (CARD). 
Basically the CARD domain is blocked and pro-caspase-9 is unable to bind it, however, 
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stimulation by positive or negative signals leads to the alteration of the mitochondrial 
membrane that results in the opening of the mitochondrial permeability transition (MPT) pore. 
Subsequently the mitochondria release pro-apoptotic proteins, such as cytochrome-c, 
Smac/Diablo and HTrA2/Omi into the cytoplasm. Cytochrome-c binds to the WD domain of 
APAF1 monomers and causes certain conformational changes creating the ability to bind 
deoxy ATP (dATP). Following an additional conformational change in APAF1 induced by 
binding to dATP, its CARD and oligomerization domains are exposed leading to the 
formation of a complex of APAF1s called „apoptosome”. The exposed CARD domains of the 
apoptosome activate pro-caspase-9, then caspase-9 activates the executioner pro-caspase-3 to 
caspase-3 that induces the full process of the apoptotic mechanism. Smac/Diablo and 
HTrA2/Omi support the apoptotic process by suppressing the inhibitors of apoptosis proteins 
(IAPs).
29,31
 
The extrinsic or death receptor pathway of apoptosis is initiated by transmembrane 
receptor-mediated interactions. Death receptors belong to the tumor necrosis factor receptor 
(TNFR) superfamily. The structure of TNFRs mostly can be described as transmembrane 
proteins containing 2–4 similar cysteine-rich domains in the extracellular fraction. The 
presence of a ~70 amino acid “death domain” in the cytoplasmic fraction is another factor 
regarding the separation of death receptors. Six death receptors have been established as the 
direct or indirect regulators of the process of programmed cell death: DR3 (TNFRSF25), DR4 
(TNFRSF10A), DR5 (TNFRSF10B), DR6 (TNFRSF21), TNFR1 (TNFRSF1A), and 
Fas/Apo1/CD95 (TNFRSF6). The possible ligands of the TNFR superfamily are mostly 
homotrimeric transmembrane proteins and they can play a role as soluble proteins in the 
extracellular space, or as plasma membrane-anchored ligands at the surface of cells or 
secreted exosomes.
33
  
The first step of the extrinsic apoptotic process is the binding of death ligands 
produced by patrolling macrophages and natural killers to death receptors in the target cell 
membrane, which results in the activation of pro-caspase 8 to caspase 8. Binding of the 
death‐effector domain (DED) of pro-caspase 8 to a death‐inducing signal complex (DISC) 
located on the cytoplasmic domain of the ligand‐bound death receptor leads to the recruitment 
of monomeric pro-caspase 8. The adaptor protein FADD and TNF receptor‐associated death 
domain (TRADD) contained in DISC additionally promote the interaction between pro-
caspase 8 and DISC, which catalyze the dimerization of pro-caspase-8 monomers. Two sub-
pathways were distinguished based on the classification of  the apoptotic cells into type I or 
II.
31,34
 Type I cells are characterized by the fact, that caspase-8 initiates apoptosis via cleaving 
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the executioner caspases directly. When IAPs inhibit the direct activation of executioner 
caspases by caspase 8, unless IAPs are suppressed by proteins released from the 
mitochondria, cells are classified into type II.
31,35
  
1.3 Matrix metalloproteases and the focal adhesion kinase in cancer 
Tumor cell invasion into tissue is a crucial early step in the metastasis comprising 
basement membrane breach and following migration through the stroma. The occurrence of 
further steps of the process, such as intravasation of cancer cells into the vasculature, and 
extravasation of cells present in circulation into the surrounding tissue leads to the spread of 
malignant cells via the circulatory and lymphatic system, then subsequent development of 
secondary tumors. Cell migration through the extracellular matrix (ECM) is a major factor for 
a successful invasion. In most cases, epithelial cells go through the epithelial–mesenchymal 
transition process that results in reaching mesenchymal state and adoption of migratory 
phenotype. Tumor cells are capable of navigating around other cells and via the confines of 
EMC with pore ranges between 0.1 µm to 30 µm during the invasion. In order to move in the 
matrix, cells additionally able to secrete matrix metalloproteases (MMPs).
36
  
Matrix metalloproteases are calcium-dependent endopeptidases reaching their catalytic 
action through zinc ion coordination by means of three amino acids. All of them are 
synthesized in an inactive proenzyme form that is characterized by an interaction between a 
zinc-containing catalytic domain and a cysteine residue. The disruption of this interaction 
leads to partial activation of the MMP, which enhances the autocatalysis of the propeptide 
region resulting in the fully active enzyme. Numerous MMPs have been identified in humans; 
each recognizes and cleaves specific peptide sequences. The function of MMPs is complex 
considering that they are involved in both normal and pathological processes, such as 
embryogenesis, wound healing, inflammation, arthritis and cancer.
37
  
 It was reported that the expression of MMPs is elevated in most of the human 
malignancies in comparison with normal tissue.
38
 The involvement of MMPs in all stages of 
metastasis development was observed.
39
 The presence or increased expression of MMPs, such 
as MMP-1, -2, -3, -7, -9, -13, -14 in primary tumors and/or metastases were associated with 
tumor progression based on the retrospective analysis of MMP expression in cancer patients.
40
 
Due to the degradation of surrounding ECM components by MMPs, a migratory pathway is 
created that facilitates the local invasion of cancer cells. The cleavage of fibrous ECM 
proteins leads to the exposure of normally hidden sites and epitopes that can redound growth. 
Elevated MMP activity also promotes cytokine and growth factor expression subserving 
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angiogenesis, tumor growth, and metastasis. MMPs are potentially involved in localisation of 
metastases considering that they play a role in capillary wall adhesion following circulatory 
transport. They affect the formation of secondary tumors via enhancing the proteolysis of 
ECM that facilitates cancer cell motility and settling into new tissue.
39
 After learning from 
failed clinical trials with MMP-inhibitors, such as batimastat and marimastat, the development 
of anticancer agents targeting MMPs is currently ongoing.
41–43
  
Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase with multiple functions 
regarding cell signaling within the tumor microenvironment. It is involved in signaling 
pathways that facilitate cancer growth and metastasis, such as kinase-dependent control of cell 
motility, invasion, survival, and promotion of epithelial-mesenchymal transition by 
transcriptional events. Cell survival or breast tumor stem cell proliferation can be affected 
additionally by the kinase-independent scaffolding activity of FAK.
44
 Its ability to promote 
cell migration is based on bridging signals between integrin and growth-factor receptors.
45
 
The activation of FAK involves integrin receptor clustering initiated by cell binding to ECM 
proteins that may result in FAK dimerization. The following steps are auto-phosphorylation at 
Y397, binding of SRC-family kinases to the phosphorylated site, SRC-mediated 
phosphorylation of the FAK kinase domain activation loop (Y576 and Y577), and activated 
FAK-SRC complex formation.
44
 FAK kinase activity is also involved in tumor angiogenesis 
and vascular permeability.
46
 Besides its classic role in integrin and growth factor receptor 
signaling as a cytoplasmic kinase, FAK was demonstrated to be present in the nucleus. 
Nuclear FAK can facilitate p53 degradation via ubiquitination, which results in tumor cell 
growth and proliferation. FAK can be involved in the regulation of GATA4 and IL-33 
expression leading to reduced inflammatory responses and immune escape.
47
  
The gene encoding FAK is located at human chromosome 8q24, which was found to 
be amplificated and often associated with increased FAK expression in human tumor cells and 
in tumors in vivo.
48
 Increased FAK mRNA levels were shown in invasive breast tumor and 
ovarian cancer in correlation with poor patient survival by large databases. Elevated Fak 
mRNA levels were reported regarding several other tumor types as well.
44
 FAK 
overexpression or overphosphorylation was described to be responsible for cell migration, 
survival, proliferation, and adhesion in various cancer cells.
48
 The elevated expression of FAK 
was associated with the invasive and metastatic potential of several human cancers, including 
breast tumors.
49,50
  It was found that the activation of FAK elevates with tumor progression 
based on the assessment by phosphospecific antibody recognition of the Y397 auto-
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phosphorylation site.
51
 FAK inhibitors have been under investigation recently in several early 
phase clinical trials.
52–56
  
1.4 Modified estrogen derivatives in anticancer research 
The substantial impact of estrogens has been shown in the development of 
reproductive processes; moreover, they influence the progression of hormone-dependent 
cancers, such as, uterine, endometrial, breast and prostate malignancies.
57–60
  Despite that 
17β-estradiol promotes cell proliferation, the anticancer property of structurally modified 
estrogen derivatives was determined in several studies.
61–71 
 The absence of estrogenic activity 
is an essential demand during the development of estrane-based antitumor drug candidates. 
The lack of hormonal properties can be reached via the definite alteration of the estrane 
skeleton, including the substitution at C-2 or C-3. 
61,72,73
 Another option is the modification of 
ring D that leads to hormonally non-active D-homo and D-seco derivatives.
74,75
 Members of 
D-ring modified compounds were demonstrated to inhibit the enzyme aromatase CYP1A19, 
which causes reduced estrogen production. This mechanism of action enhances their potential 
beneficial effect against estrogen-dependent breast tumors.
76
  
In vitro and in vivo experiments demonstrated, that the inversion of configuration at C-
13 of estradiol leads to a low binding ability to the ER and no uterotropic action in mice.
73
 
The reason of the insignificant affinity for ERs is probably the conformational alteration 
resulting from the cis junction of rings C and D.
77,78
 The potential increase of the 
antiproliferative action of 3-benzyl ether moiety on the estrane core was demonstrated in 
previous studies.
66,79
 Triazole ring was selected based on its enhancing property regarding the 
solubility, bioavailability, and diversity of the structure. Considering the low affinity for ER 
of 13α-derivatives and the antiproliferative characteristic of previously studied triazols,80–84 
13α-estradiol series was synthesized with the incorporation of triazole ring at C-16 and 
benzyloxy function at C-3 to assess their anticancer activity.  
To prove the loss of hormonal activity, binding qualities of possible isomers of 16-
hydroxymethyl-3,17-estradiol to ER were examined using receptor protein prepared from 
rabbit uteri for radioligand-binding assay. Each estradiol-based compound was displayed 
relative binding affinities (RBA) lower than 2.0% compared to estradiol, which indicates the 
annulling impact of 16-hydroxymethyl group on affinity to ER, regardless its configuration.
85
 
Therefore, the presence of a hydroxymethylene group at C-16 notably reduces the emergence 
of estrogenic properties. These preliminary results, together with the findings mentioned 
above regarding substitution at C-3 of the estrange core, represents the applicability of 16-
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hydroxymethylene-3,17-estradiol skeleton for designing biologically active estradiol 
derivatives with the loss of hormonal feature. In order to integrate the structural modifications 
responsible for an increase in the antiproliferative and a decrease in the hormonal 
characteristic, 3-benzyl ethers bearing electronically different substituent at the 4’-position 
and containing hydroxymethyl function at C-16 were synthesized.  
Besides these molecules, the synthesis of the four possible isomers of 16- 
hydroxymethyl-3-methoxy- and 16-hydroxymethyl-3-benzyloxy-13α-estradiol derivatives 
was performed based on the previous experience regarding substituting C-3, attaching a 
hydroxymethyl group at C-16; moreover, the inversion of configuration at C-13 of the estrane 
skeleton. These alterations also serve the necessity for the lack of estrogenic activity and  
enhancement of the potential anticancer feature of the molecules.  
2. Specific Aims 
The current study aimed to determine the anticancer properties of newly synthesized 
16-hydroxymethyl-3-methoxy- and 16-hydroxymethyl-3-benzyloxy-13α-estradiol derivatives, 
16-triazolyl-13α-estradiol and their precursor molecules, furthermore 3-benzyloxy-16-
hydroxymethyl-estradiol analogs on a panel of gynecological cancer cell lines in vitro: 
 Antiproliferative screening and the assessment of cancer-selectivity of the examined 
compounds by means of MTT assay. Comparing the activity of the most potent 
analogs on different gynecological tumor cell lines and/or against breast cancer cell 
lines with different receptor status. 
 Investigating the antiproliferative activity of selected compounds by performing cell 
cycle analysis, morphological examination of the cells with Hoechst 33258 (HO) and 
propidium iodide (PI) staining, and determining the activity of key caspases. 
 Examination of the antimetastatic ability of selected agents through their activities on 
cell migration and invasion. Performing gelatin zymography and Western Blot 
analysis to further assess the antimetastatic property of the agents. Considering the 
previous results of the compounds and the unmet medical need of TNBC, MDA-MB-
231 TNBC cell line was chosen for the antimetastatic experiments. 
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3. Materials and methods 
3.1 Chemicals 
Novel 16-triazoles and their precursors in the 13α-estradiol series, the four possible 
stereoisomers of 3-benzyloxy-16-hydroxymethylene-estra-1,3,5(10)-trien-17-ol and three 
further analogs with a substituted benzyl function at C-3; moreover, the four possible isomers 
of 16- hydroxymethyl-3-methoxy- and 16-hydroxymethyl-3-benzyloxy-13α-estra-1,3,5(10)-
trien-17-ols were designed and synthesized by the Department of Organic Chemistry, 
University of Szeged, Hungary. The structures of the examined molecules are summarized in 
Figure 1-3. 
 
       
 
  
 
 
 
 
 
 
 
  
  
    
 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical structures of the tested compounds of the 16-triazolyl-13α-estradiol series. 
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Figure 2. Chemical structures of the tested 3-benzyloxy-16-hydroxymethyl-estradiol analogs. 
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Figure 3. Chemical structures of the tested of 16- hydroxymethyl-3-methoxy- and 16-hydroxymethyl-3-
benzyloxy-13α-estradiols. 
3.2 Cell cultures 
Human cancer cell lines HeLa, A2780, and A431 derived from cervical tumor, ovarian 
tumor, and epidermal carcinoma, respectively, breast cancer cell lines, including MCF7, 
T47D, MDA-MB-231, and MDA-MB-361, together with non-cancerous MRC-5 fibroblasts 
isolated from human fetal lung were obtained from the European Collection of Authenticated 
Cell Cultures (ECACC, Salisbury, UK). Minimal essential medium (MEM) supplemented 
with 10% fetal bovine serum, 1% non-essential amino acids and 1% antibiotic-antimycotic 
mixture was utilized to maintain each cell line. All the applied chemicals, if otherwise not 
specified were purchased from Lonza Group Ltd. (Basel, Switzerland) or Sigma-Aldrich Ltd. 
(Budapest, Hungary). For the storage of the cells, humidified atmosphere containing 5% CO2 
and temperature of 37 °C were provided.  
3.3 Determination of antiproliferative activities 
To assess the antiproliferative property of the test compounds against the above 
mentioned human cancer cell lines, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay was performed. Cells were seeded into 96-well plates at a 
density of 5,000 cells/well (in the case of MDA-MB-361 10,000 cells/well), and after an 
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overnight growing period, 10 µM and 30 µM of the test compounds was added during the first 
screening. In case of the selected compounds, a treatment in increasing concentration (0.1–
30.0 μM) was performed to determine their IC50 values. After incubation for 72 h under 
standard cell culture conditions, 5 mg/ml MTT solution was added into the plates for 4 h. As a 
result, formazan crystals were precipitated, and following solubilization in dimethyl sulfoxide, 
the measurement of absorbance was carried out at 545 nm with a microplate reader. Control 
samples were determined as wells containing untreated cells.
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According to the values of the assay, sigmoidal dose-response curves were fitted and 
IC50 values were calculated using GraphPad Prism 4.0 or 5.01 (GraphPad Software, San 
Diego, CA, USA). Cisplatin (Ebewe Pharma GmbH, Unterach, Austria) was used as positive 
control in the comparison of the growth-inhibitory effect of the tested compounds in the same 
concentration range. In order to characterize the selectivity of test compounds towards cancer, 
treatment on MRC-5 human fibroblasts was evaluated by the same method as well. 
3.4 Cell cycle analysis by flow cytometry 
Flow cytometry was implemented to assess the DNA content of cells. HeLa and 
MDA-MB-231 cells were seeded into 6-well plates at a density of 200,000 cells/well and 
250,000–300,000 cells/well, respectively, and allowed to grow overnight. Following 24 h, and 
in case of HeLa cells 48 h incubation with test compounds, cells were washed with 
phosphate-buffered saline (PBS) and harvested by means of trypsin (Gibco BRL, Paisley, 
U.K.). Cells were centrifuged at 1,500 rpm for 10 min, additionally washed with PBS, 
centrifuged again, then fixed in 1 ml of –20 °C , 70%  ethanol,  for not less than 30 minutes. 
In the last step of the assay, the addition of dye solution (0.1 mg/ml PI, 0.003 μl/ml Triton-X, 
0.02 mg/ml RNase A, and 1.0 mg/ml sodium citrate dissolved in distilled water) was 
performed into the samples for 1 h in the absence of light at room temperature. Partec CyFlow 
instrument (Partec GmbH, Münster, Germany) was utilized to carry out cell cycle analysis. 
20,000 cells from each well were recorded in all measurements. The percentages of cells in 
different cell cycle phases (subG1, G1, S, and G2/M) were evaluated by ModFit LT software 
(Verity Software House, Topsham, ME, USA). The subG1 phase was regarded as apoptotic 
cell population.
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3.5 Hoechst 33258 – propidium iodide double staining 
HeLa cells were seeded into 96-well plates (5000 cells/well) for overnight incubation. 
Cells were treated for 24 h with the test compound, and then final concentrations of 5 and 2 
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µg/ml of Hoechst 33258 (HO) and propidium iodide (PI) were added into the medium of cells, 
respectively. Following incubation with the dying mixture for 1 h at 37 °C in dark 
circumstances, cells were photographed by means of a Nikon ECLIPSE TS100 fluorescence 
microscope provided with the appropriate optical blocks for HO (excitation: 360/40 nm 
bandpass filter, emission: 460/50 nm bandpass filter and 400 nm dichromatic mirror) and PI 
(excitation: 500/20 nm bandpass filter, emission: 520 nm longpass filter and 515 nm 
dichromatic mirror) and a QCapture CCD camera. By means of the staining, intact, early- 
apoptotic, late-apoptotic, and necrotic cells could be identified based on the shaping of cell 
chromatin and damaging of cell membrane. HO permeates into all cells regardless of the state 
of membranes and stains the nuclei to blue. Programmed cell death was confirmed based on 
chromatin condensation and nuclear fragmentation of the nuclei. Red nuclei stained by PI 
proved the loss of cell membrane integrity, which is a marker of necrotic and late-apoptotic 
(secondary necrotic) cells. 
3.6 Investigation of the activity of key caspases 
3.6.1 Determination of in situ caspase-3 activity 
 The activity of caspase-3 enzyme was analyzed by using a commercially available 
colorimetric kit (Sigma–Aldrich, Budapest, Hungary). HeLa cells were seeded in tissue 
culture flasks (10
6
 cells/flask), maintained under standard cell culture conditions for overnight 
incubation. On the basis of the antiproliferative properties of the test compound, cells were 
treated with two selected concentrations (3 and 10 µM) for 48 h. After this duration, scraping, 
counting and resuspending of cells in lysis buffer (10 ml for 10
6
 cells) were performed. 
Samples were centrifuged, and then protein amounts of the supernatant were assessed in order 
to utilize equal amounts of protein content for the assay. Specific substrate (Ac-DEVD-pNA) 
of caspase-3 was incubated with the samples for 2 hours, which led to its cleavage by caspase-
3. The absorbance of the released p-nitroaniline (pNA) was measured at 405 nm by means of 
a microplate reader. The comparison of the absorbance of the control and treated cells 
determines the fold increase of activity of caspase-3. 
3.6.2 Determination of in situ caspase-8 activity  
Colorimetric assay kit was utilized to evaluate the activity of caspase-8 (Sigma–
Aldrich Ltd., Budapest, Hungary) with the addition of its specific substrate Ac-IETD-pNA. 
After incubation for 2 hours, the absorbance of the cleaved pNA was determined with a 
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microplate reader at 405 nm. The execution of the assay was identical to the above described 
caspase-3 assay.  
3.6.3 Determination of in situ caspase-9 activity  
Caspase-9 activity was assessed on the basis of the reaction with its specific substrate 
LEHD-pNA, provided by a commercially available colorimetric kit (Invitrogen, Carlsbad, 
CA, USA). The assay was carried out in accordance with the evaluation of the activity of 
caspase-3.  
3.7 Wound healing assay 
Wound healing assay was carried out to determine the action of selected test 
compounds from the series of 3-benzyloxy-16-hydroxymethyl-estradiols on cell migration, by 
utilizing specific wound healing assay chambers (ibidi GmbH, Martinsried, Germany). 25,000 
MDA-MB-231 cells were seeded into each chamber of inserts, and then following an 
overnight incubation for sufficient cell attachment at 37 °C under 5% CO2, inserts were 
removed. In order to remove non-adherent cells and debris a washing step with PBS was 
implemented. Test compounds were added in elevating concentrations to the cells in a 
medium containing 2% FBS for 24 h. Visualization of cell migration into the wound area was 
performed by a phase-contrast inverted microscope (Axiovert 40, Zeiss, Thornwood, NY, 
US). QCapture CCD camera was used to take images at previously designed intervals to 
observe wound closure. The rate of migration was calculated from the comparison of the ratio 
of wound closure in untreated control, and treated samples at 0 h and after 24 h of treatment.
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3.8 Boyden chamber assay 
Examination of the invasion ability of MDA-MB-231 cells was performed by means 
of a BD BioCoat Matrigel Invasion Chamber (BD Biosciences, Bedford, MA, USA) provided  
with an 8 µm pore size PET membrane and a thin layer of matrigel basement matrix. Cells 
were suspended at a density of 50,000/insert in serum-free medium and placed into the top 
insert before the tested compounds were added in sub-antiproliferative concentrations. A 
medium containing 10% FBS was used as chemoattractant in the bottom well. The inserts 
were removed after incubation for 24 h at 37 °C under 5% CO2 and the upper surface of the 
membrane was cleaned from non-invading cells with a cotton swab. After a washing step with 
PBS, the insert was fixed with cold 100% methanol, washed with PBS again, and stained with 
crystal violet solution. The invading and stained cells were counted under a phase-contrast 
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inverted microscope. To assess the rate of invasion, the number of treated cells and untreated 
controls were counted and compared to each other. 
3.9 Gelatin zymography  
In order to assess how the test compounds influence the activity of matrix 
metalloprotease-2 (MMP-2) and -9 (MMP-9), the gelatin zymography assay was performed.
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In experimental dishes, MDA-MB-231 cells were seeded at approximately 80% confluency 
and maintained overnight under standard cell culture conditions. After the overnight 
incubation period, cells were washed with PBS, and treated with increasing concentration of 
test compounds in serum-free medium for 24 h. The supernatant comprising the secreted 
MMP-2 and MMP-9 enzymes was gathered from above the cells; afterward, it was 
centrifuged at 6,000 rpm at 4 °C for 2 minutes, and then collected again. Equal amounts of the 
samples mixed with bromophenol blue dye in 5:1 ratio were separated by SDS-PAGE 
containing 0.1% gelatin via electrophoresis at 120 V for 90 minutes. Major forms of MMPs 
were identified by Prism Ultra Protein Ladder molecular size marker (Abcam Cambridge, 
U.K.). After a cleaning step using 2.5% Triton X-100 solution, the reaction between the gel 
and a solution containing 50mM Tris-HCl (pH 7.5), 150 mM NaCl, and 5 mM CaCl2 was 
performed. Following incubation for 24 h, the gel was stained with Coomassie brilliant blue 
G-250 (SimplyBlue
TM 
Safestain, Thermo Fisher Scientific, Waltham, MA, USA) for 60 
minutes and washed with distilled water twice. At last, the gel was captured by a Luminescent 
Image Analyzer System (LAS 4000 mini, Fujifilm, Tokyo, Japan).  
3.10 Western Blot assay 
A Western Blot assay was carried out with the aim of assessing the influence of the tested 
compounds on the expression of focal adhesion kinase (FAK) and its phosphorylated form 
(pFAK) in MDA-MB-231 cells. In experimental dishes, approximately two million cells were 
seeded, and following an overnight incubation, medium containing increasing concentration 
of the examined compounds and 2% FBS was added into the dishes. Cells were detached 
from the dishes by a rubber scraper, centrifuged at 7,000 rpm, 4 °C for 2 minutes, washed 
with PBS, and then centrifuged again. In order to prepare whole-cell extracts (WCEs), cells 
were  re-suspended in TEGN lysis buffer (10 mM Tris pH 7.5, 1 mM EDTA, 420 mM NaCl, 
10% glycerol and 0.5% NP40) supplemented with 1 mM DTT and a cocktail of protease and 
phosphatase inhibitor (Roche Applied Science, Penzberg, Germany). Samples were 
maintained on ice for 10 minutes, centrifuged (13,000 rpm, 4 °C, 10 minutes), and then the  
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protein content of the supernatant was mixed with bromophenol blue dye in 2:1 ratio. Equal 
amounts of  WCE per well were separated by SDS-PAGE via electrophoresis for 1 h at 160 
V, and transferred from gels to nitrocellulose membranes for overnight at 20 V, 4 °C. After 
blocking of the samples, incubation with a primary antibody followed by appropriate 
secondary antibody was executed. The utilized antibodies were FAK pY397 (Becton 
Dickinson, Franklin Lakes, NJ, USA), FAK (Cell Signaling Technology, Danvers, MA, 
USA), β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and GAPDH (Cell 
Signaling Technology). Visualization of the blots was performed by means of enhanced 
chemiluminescence (ECL-Plus, GE Healthcare Life Sciences, Little Chalfont, UK) 
implementing a Luminescent Image Analyzer System (LAS 4000 mini, Fujifilm, Tokyo, 
Japan). 
3.11 Statistical analysis 
GraphPad Prism 4.0 was implemented for the statistical evaluation of measured data in 
each experiment, with the exception of the analysis of 3-benzyloxy-16-hydroxymethyl-
estradiol analogs, where the statistical evaluation was carried out by means of Graphpad 
Prism 5.01. One-way ANOVA with Dunnett post-test for comparison of multiple groups was 
carried out to assess statistical significance. A p-value of less than 0.05 was considered 
statistically significant. 
4. Results 
4.1 Antiproliferative activity of the tested compounds 
Several examined estradiol analogs have shown significant antiproliferative property 
determined by MTT-assay. At first, screening of 16-triazolyl-13α-estradiol derivatives and 
their precursors on cell lines derived from different organs (HeLa, MCF7, A2780, and A431) 
(Table 1.) was performed. The precursor molecules (1-5) were proven to be modestly 
inhibiting cancer cell proliferation, since the most effective cell-growth inhibition after 
treatment with 10 µM was 39.0±1.0% (5). Compounds from the series of 16β,17α isomers 
(7c-g) that displayed the most potent cell-growth inhibition were selected for testing against a 
panel of breast cancer cell lines with different receptor status (T47D, MDA-MB-231, MDA-
MB-361) (Table 2.). Based on the findings, 16β,17α isomers bearing p-alkyl substituents on 
the triazolyl-phenyl function showed the most significant antiproliferative potency (7e, 7f). 
Selectivity towards cancer of the compound with the most effective IC50 value (7e) from the 
 21  
 
series was tested by utilizing non-cancerous human fibroblast MRC-5 cell line. 22.2 ± 2.9% 
growth-inhibition of MRC-5 cells was assessed after treatment with 30 µM, the same 
concentration of the reference agent cisplatin caused a more considerable inhibition (70.7 ± 
1.3%). Considering that 7e did not influence the proliferation of MRC-5 cells significantly at 
30 µM, and its calculated IC50 values on cancer cell lines were 2.4–6.5 µM, it can be declared 
as a cancer-selective agent. Based on the findings of the MTT-assay, 7e was selected for 
further investigation from the 16-triazolyl-13α-estradiol series. 
Regarding the 3-benzyloxy-16-hydroxymethyl-estradiol derivatives, MTT assay to 
determine their growth-inhibitory effects against breast cancer cell lines with distinct receptor 
status was carried out (T47D, MDA-MB-231, MCF-7 and MDA-MB-361) (Table 3.). Based 
on the results, the configuration of the substituent at positions 16 and 17 has a narrow 
influence on the antiproliferative feature of the compounds. However, certain substituents, 
especially the p-chloride group on the benzyl function at C-3 may increase the 
antiproliferative activity (9a, 9b). Additionally, the examination of cancer-selectivity was 
performed against MRC-5 cells. Despite that the selectivity towards cancer could not be 
proved, the antiproliferative feature of test compounds was comparable to that of cisplatin. On 
the basis of the obtained data, the compound with the most potent IC50 value (9a) and its 
related, unsubstituted analog (9) were selected for additional examinations in order to 
characterize their mechanism of action. 
In the set of 16- hydroxymethyl-3-methoxy- and 16-hydroxymethyl-3-benzyloxy-13α-
estradiols, the 3-benzyl ethers (15, 16, 19, 20) were demonstrated to be more potent compared 
to their 3-methyl ether counterparts (13, 14, 17, 18). The calculated IC50 values of the 
mentioned 3-benzyl ethers were between 10 µM and 20 µM against breast cancer cell lines, 
while in the case of A2780 and HeLa cell lines, their antiproliferative activity was more 
notable. Compounds 20 and 15 were selected for the investigation of cancer selectivity by 
utilizing the MRC-5 human fibroblast cell line due to their potent antiproliferative feature 
against each examined cancer cell population. It was found that the proliferation of tumor cell 
lines was at least twice much inhibited by 20, than that of the non-cancerous fibroblast cells. 
Regarding 15, its calculated IC50 value against MRC-5 cells was similar to its action on breast 
cancer cells; nevertheless, in comparison with the results of A2780 and HeLa cells, a modest 
cancer selectivity could be assessed (Table 4.). 
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Table 1. Antiproliferative properties of 16-triazolyl-13α-estradiol derivatives 
 Inhibition (%) ± SEM 
[calculated IC50 value
1
 (µM)] 
Comp. Conc. 
(µM) 
HeLa MCF7 A2780 A431 
1  10  –
2
 – – – 
30 – 27.3 ± 1.6 24.6 ± 0.4 – 
2 
 
10 – – – – 
30 28.9 ± 0.8 48.3 ± 1.2 36.3 ± 1.0 46.7 ± 1.1 
3 
 
10 – – – – 
30 39.9 ± 1.4 48.8 ± 1.3 44.8 ± 0.6 68.8 ± 1.2 
4 
 
10 21.5 ± 0.7 36.2 ± 1.4 33.3 ±0.8 – 
30 98.3 ± 0.1 90.3 ± 0.4 96.4 ±0.2 97.7 ± 0.1 
5 
 
10 20.4 ± 0.5 34.6 ± 1.4 39.0 ±1.0 – 
30 96.0 ± 0.4 77.3 ± 1.3 96.0 ±0.4 82.3 ± 1.1 
6a 
 
10 64.7 ± 1.7 – 46.5 ±1.1 44.9 ± 0.9 
30 80.3 ± 0.4 – 50.7 ±2.0 36.1 ± 1.3 
6b 
 
10 23.9 ± 0.9 28.3 ± 1.0 38.9 ±0.2 – 
30 27.4 ± 1.0 30.0 ± 0.5 38.6 ±0.4 – 
6c 
 
10 57.3 ± 2.4 35.2 ± 2.0 46.9 ±0.8 – 
30 55.5 ± 1.0 37.6 ± 2.0 56.5 ±0.9 36.6 ± 0.4 
6d 
 
10 58.3 ± 1.0 42.9 ± 1.2 53.5 ±1.5 25.5 ± 2.6 
30 56.7 ± 1.2 43.6 ± 0.4 55.4 ±1.1 19.0 ± 4.4 
6e 
 
10 28.1 ± 1.4 30.4 ± 0.6 41.4 ±0.5 – 
30 24.1 ± 1.2 28.7 ± 2.3 40.5 ±0.3 – 
6f 
 
10 46.2 ± 2.4 36.4 ± 1.4 43.6 ±0.7 38.7 ± 0.4 
30 52.0 ± 2.4 39.6 ± 2.1 51.0 ±1.4 37.0 ± 1.1 
6g 10 61.2 ± 2.7 22.9 ± 1.5  38.8 ± 0.98 18.5 ± 2.8 
 30 65.1 ± 2.0 27.9 ± 1.0 39.8 ± 1.2 33.7 ± 2.1 
  [2.0]    
6h 10 55.5 ± 1.0 22.3 ± 2.0 40.2 ± 2.2 13.1 ± 0.5 
 30 62.8 ± 2.2 23.4 ± 0.8 36.8 ± 1.4 26.2 ± 2.8 
7a 
 
10 45.7 ± 2.7 – 33.3 ±1.6 – 
30 84.9 ± 0.5 74.7 ± 0.7 81.7 ±0.8 53.4 ± 0.4 
7b 
 
10 58.4 ± 0.1 41.5 ± 1.9 56.4 ±0.6 – 
30 79.3 ± 0.4 66.8 ± 1.5 82.9 ±1.0 – 
7c 
 
10 72.0 ± 2.0 82.0 ± 0.9 80.9 ±2.3 49.3 ± 1.3 
30 88.3 ± 1.3 93.6 ± 0.3 88.8 ±1.5 64.8 ± 2.4 
  [7.6] [6.0] [6.0 ] [10.2] 
7d 
 
10 75.8 ± 1.0 67.7 ± 2.6 69.5 ±2.6 44.9 ± 0.5 
30 89.2 ± 0.9 94.3 ± 0.2 90.7 ±1.8 46.8 ± 1.1 
  [8.8] [9.3] [7.5]  
7e  
 
10 93.5 ± 0.2 83.3 ± 2.1 92.7 ±0.2 87.5 ± 0.7 
30 97.3 ± 0.1 89.5 ± 1.1 96.9 ±0.1 92.3 ± 0.6 
  [2.6] [2.4] [2.6] [2.9] 
7f 
 
10 76.0 ± 0.8 73.5 ± 0.9 88.4 ±0.9 68.6 ± 0.6 
30 89.6 ± 0.5 84.8 ± 0.5 95.0 ±0.3 76.6 ± 0.3 
  [3.4] [2.9] [2.9] [3.2] 
7g 10 60.5 ± 1.1 35.1 ± 2.6 47.8 ± 1.0 31.2 ± 1.2 
 30 86.3 ± 0.9 73.5 ± 1.2 58.5 ± 2.1 42.6 ± 1.4 
  [8.5]    
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 Inhibition (%) ± SEM 
[calculated IC50 value
1
 (µM)] 
Comp. Conc. 
(µM) 
HeLa MCF7 A2780 A431 
7h 10 31.6 ± 2.4 18.4 ± 2.4 16.7 ± 2.4 4.3 ±1.4 
 30 49.6 ± 0.4 34.2 ± 2.3 38.1 ± 1.7 12.8 ± 2.8 
8 10 24.3 ± 1.6 8.8 ± 1.0 9.9 ± 0.9 4.6 ± 1.1 
 30 24.5 ± 1.9 57.9 ± 0.9 39.0 ± 1.0 30.0 ± 1.3 
Cisplatin 10 42.6 ± 2.3 53.0 ± 2.3 83.6 ± 1.2 88.6 ± 0.5 
 30 99.9 ± 0.3 86.9 ± 1.3 95.0 ± 0.3 90.2 ± 1.8 
  [12.4] [9.6] [1.3] [2.8] 
1 
 Mean value from two independent experiments with five parallel wells; standard deviation <15%. 
2 
 Inhibition values <20% are not presented.  
 
Table 2. Antiproliferative properties of 7c–g.  
  Inhibition (%) ± SEM 
[calculated IC50 value
3
 (µM)] 
Comp. Conc. 
(µM) 
T47D MDA-MB-231 MDA-MB-361 
7c 
 
10 85.9 ± 1.1 84.5 ± 1.01 83.6 ±_ 0.6 
30 92.0 ± 0.4 94.5 ± 0.5 89.2 ± 0.5 
  [5.9] [6.5] [5.3] 
7d 
 
10 58.4 ± 0.9 41.8 ± 2.5 57.2 ± 1.8 
30 90.9 ± 0.5 82.2 ± 0.7 74.1 ± 1.2 
  [9.7] [10.3] [9.7] 
7e  
 
10 85.6 ± 0.6 85.3 ± 1.8 74.1 ± 0.9 
30 92.0 ± 0.4 92.4 ± 0.9 83.6 ± 1.6 
  [5.9] [6.5] [5.4] 
7f 
 
10 65.4 ± 0.8 57.0 ± 1.3 61.4 ± 0.3 
30 87.7 ± 0.6 84.5 ± 0.7 74.3 ± 1.2 
  [6.2] [8.3] [6.6] 
7g 10 56.5 ± 1.0 48.5 ± 1.5 56.0 ± 2.0 
 30 81.1 ± 1.4 76.9 ± 1.9 73.7 ± 1.3 
  [9.0] [10.3] [8.8] 
Cisplatin 10 51.0 ± 2.0 20.08 ± 0.8 67.5 ± 1.0 
 30 57.9 ± 1.4 71.7 ± 1.2 87.7 ± 1.1 
  [9.8] [19.1] [3.7] 
3
 Mean value from two independent determinations with five parallel wells; standard deviation  <15%. 
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Table 3. Antiproliferative properties of 3-benzyloxy-16-hydroxymethyl-estradiol derivatives 
 Inhibition (%) ± SEM 
[calculated IC50 value
4
 (µM)] 
 
Comp. Conc. 
(µM) 
MDA-MB-231 MCF7   T47D MDA-MB-361 MRC-5 
9  10 
30 
31.5 ± 1.8 
94.9 ± 0.5 
[12.7] 
60.2 ± 1.6 
97.2 ± 0.4 
[8.2] 
54.5 ± 0.3 
90.0 ± 0.4 
[8.4] 
93.1 ± 0.5 
93.3 ± 1.1 
[4.6] 
78.0 ± 2.6 
96.5 ± 0.2 
[6.7] 
10 
 
10 93.8 ± 0.5 91.5 ± 0.6 82.7 ± 1.6       93.8 ± 0.7 94.8 ± 0.5 
30      96.2 ± 0.3 97.8 ± 0.2 82.1 ± 0.5 94.0± 0.3 96.9 ± 0.2 
  [3.9] [5.1] [4.6] [3.8] [5.5] 
11 
 
10 76.4 ± 0.7 27.0 ± 1.3 38.8 ± 2.0 62.7 ± 2.2 39.1 ± 3.2 
30 92.2 ± 0.6 88.6 ± 1.2 90.3 ± 0.6 86.2 ± 0.9 92.6 ± 0.2 
  [5.9] [13.6] [15.7] [7.2] [10.2] 
12 
 
10      84.3 ± 1.2      56.6 ± 2.2 47.5 ± 2.4 79.1 ± 2.7 53.7 ± 3.4 
30 92.8 ± 0.3 86.9 ± 0.9 94.6 ± 0.7 89.9 ± 1.0 76.8 ± 2.2 
  [5.5] [9.1] [10.4] [5.4] [7.3] 
9a 
 
10 
30 
89.5 ± 0.8 
87.7 ± 0.3 
[4.6] 
96.5 ± 0.7 
96.7 ± 0.2 
[3.5] 
95.6 ± 0.3 
95.3 ± 0.9 
[2.8] 
81.1 ± 1.8 
87.0 ± 1.3 
[1.3] 
76.5 ± 2.3 
79.8 ± 1.0 
[6.7] 
9b 
 
10 61.1 ± 2.4 72.7 ± 0.8 80.2 ± 2.1 76.8 ± 1.2 61.0 ± 2.8 
30 82.8 ± 0.9 89.1 ± 0.9 87.0 ± 1.5 81.1 ± 1.7 78.1 ± 1.8 
  [7.5] [4.2] [3.0] [4.7] [1.5] 
9c 
 
10 30.9 ± 2.4 39.3 ± 0.7 34.7 ± 1.4   
30 68.8 ± 1.7 57.7 ± 0.8 52.7 ± 3.1 -5 - 
  - - -   
Cisplatin 10 
30 
     20.8 ± 0.8       53.0 ± 2.3      51.0 ± 2.0        67.5 ± 1.0      60.3 ± 3.3 
      74.5 ± 1.2       87.0 ± 1.2      58.0 ± 1.5        87.8 ± 1.1      61.9 ± 1.0 
        [19.1]     [5.8]    [9.8]    [3.7] [6.2] 
4
 IC50 values were calculated from two experiments with 5 parallel wells if the growth inhibition of the 
compound was >75% at 30 μM. 
5
 Not determined. 
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Table 4. Antiproliferative properties of 16-hydroxymethyl-3-methoxy- and 16-hydroxymethyl-3-benzyloxy-13α-
estradiol derivatives  
 Inhibition (%) ± SEM 
[calculated IC50 value
6
 µM] 
 
Comp. Conc. 
(µM) 
MDA-MB-
231 
MCF7 T47D 
MDA-MB-
361 
HeLa A2780 
13 
 
10 <10 <10 20.2 ± 1.7 22.9 ± 2.6 17.4 ± 2.0 23.6 ± 1.3 
30 32.1 ± 2.5 21.6 ± 2.3 36.7 ± 0.8 31.2 ± 2.9 58.6 ± 1.7 54.4 ± 2.0 
  -
7
 - - - [24.7] [23.2] 
14 
 
10 10.1 ± 1.7 11.9 ± 2.1 31.7 ± 1.2 <10 55.4 ± 2.1 38.7 ± 0.7 
30 40.4 ± 1.2 43.2 ± 1.6 57.0 ± 1.8 26.0 ± 1.3 66.0 ± 0.9 71.4 ± 0.6 
  - - [22.5] - [8.4] [13.3] 
15 10 18.2 ± 2.7 40.4 ± 1.7 46.3 ± 1.3 11.1 ± 1.9 50.9 ± 2.4 50.8 ± 0.8 
 30 89.0 ± 1.5 96.7 ± 0.2 93.7 ± 0.3 96.5 ± 0.5 97.5 ± 0.1 94.9 ± 0.7 
  [17.4] [10.7] [10.6] [17.4] [8.8] [9.3] 
16 
 
10 20.6 ± 0.9 26.4 ± 1.6 29.7 ± 0.7 15.7 ± 2.9 76.7 ± 0.7 51.9 ± 1.4 
30 94.2 ± 0.6 93.6 ± 0.7 46.8 ± 1.4 75.2 ± 1.1 89.6 ± 0.5 75.3 ± 0.7 
  [16.0] [14.6] - [13.5] [3.4] [7.7] 
17 10 27.1 ± 3.0 15.0 ± 2.2 28.0 ± 2.0 17.1 ± 1.3 56.5 ± 1.4 47.9 ± 1.9 
 30 42.8 ± 2.1 31.3 ± 1.4 44.3 ± 2.1 39.3 ± 2.5 56.4 ± 1.5 63.7 ± 1.3 
  - - - - [4.8] [10.7] 
18 10 <10 <10 16.7 ± 1.4 <10 47.5 ± 1.1 36.1 ± 0.9 
 30 30.1 ± 1.0 26.8 ± 1.8 38.0 ± 0.7 17.8 ± 1.7 58.4 ± 1.5 55.2 ± 2.3 
  - - - - [11.0] [16.2] 
19 10 22.3 ± 2.2 27.1 ± 2.0 44.3 ± 1.0 20.3 ± 2.8 55.3 ± 2.4 54.9 ± 1.9 
30 94.4 ± 0.7 95.4 ± 0.2 94.1 ± 0.9 88.1 ± 0.9 96.8 ± 0.5 93.7 ± 0.5 
  
[11.6] [14.6] [11.2] [12.3] [7.0] [8.7] 
20 10 24.4 ± 2.9 37.3 ± 1.5 44.3 ± 1.2 15.2 ± 2.3 70.5 ± 1.3 54.6 ± 1.3 
 30 88.3 ± 1.4 97.4 ± 0.3 93.5 ± 0.5 93.7 ± 0.3  98.1 ± 0.2 94.5 ± 0.8 
  [11.5] [12.0] [10.3] [13.2] [4.9] [7.9] 
 
 MRC-5 
20 10 <10  15 
 
10 <10  
30 84.7 ± 0.1  30 86.9 ± 0.6  
  [26.0]    [15.7]  
6
 IC50 values were calculated from two experiments with 5 parallel wells if the growth inhibition of the 
compound at 30 µM was> 75%. 
7
 Not determined. 
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4.2 Cell cycle analysis by flow cytometry 
Flow cytometry was performed to specify the activity of the selected compounds on 
the cell cycle phase distributions. The utilized concentrations were selected based on the 
calculated IC50 value of the compounds. The analysis of 7e was carried out after 24 and 48h 
incubation against HeLa cervical cancer cell line.  
The reduction of cell population in the G1 phase along with the increase in the S and 
G2/M phase was found to be significant after treatment with 10 µM for 24 h. This result may 
indicate a blockage in the G2/M phase. A similar alteration of the cell cycle was assessed after 
48 h; however, the hypodiploid subG1 population was significantly elevated, which shows the 
proapoptotic potency of the tested compound (Fig. 4.). 
 
 
 
 
 
 
 
 
 
Figure 4. Compound 7e causes disturbance in the cell cycle distribution of HeLa cells after incubation for 24 or 
48 h. Results are mean values ± SEM from two measurements. ** and *** indicate p <0.01 and p <0.001, 
respectively, as compared with the control cells. 
Compound 9 and 9a induced a significant elevation of the cell population in G1 phase, 
with concomitant decrease in the G2/M phase. A remarkable effect on the cell cycle was 
observed by 9 even at 5 μM in spite of its relatively high IC50 value. The proapoptotic 
property of both compounds was demonstrated based on the significant but modest increase in 
the subG1 population, which was induced in all tested concentrations (Fig. 5.).  
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Figure 5. Effects of compounds 9 and 9a on the MDA-MB-231 cell cycle after incubation for 24 h. Results are 
mean values ± SEM from three measurements. *, ** and *** indicates p <0.05, p <0.01 and p <0.001 as 
compared with the control cells, respectively. 
4.3 Hoechst 33258 – propidium iodide double staining 
 Nuclear morphology and membrane integrity of the investigated cells were utilized as 
indicators of the presence of apoptosis or necrosis. Treatment of Hela cells was performed 
with 7e for 24 or 48 h incubation period. Photographs were separated by the means of 
appropriate optical blocks for HO and PI. Chromatin condensation and nuclear fragmentation 
of nuclei were used as indicators for apoptosis, while the loss of membrane integrity proved 
necrosis (Fig. 7.).  
Based on the quantitative results, exposure to 10 μM leads to the significant elevation 
of the ratio of early apoptotic and secondary necrotic cells after 24 h incubation. Treatment 
with the same concentration for 48 h resulted in a similar but more substantial alteration in the 
ratio of the cell populations (Fig. 6.). 
 
 
 
 
 
 
 
Figure 6.  Compound 7e elicits apoptosis and necrosis in HeLa cells after incubation for 24 or 48 h. ** 
indicates p < 0.01 as compared with the control conditions. 
 28  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Representative photographs utilized for the investigation of the effects of compound 7e on HeLa cells 
after treatment with 3 µM and 10 µM  for24 h. A: The cell population was stained by HO. B: The cell population 
was stained by PI. Chromatin condensation and nuclear fragmentation are indicated by white arrows on 
photographs stained by HO or PI. 
4.4 Determination of in situ caspase-3, caspase-8 and caspase-9 activity 
The investigation of the activity of caspase-3 supported the proapoptotic potency of 
7e. HeLa cells were treated with 3 µM and 10 µM of 7e for 48 h, which resulted in a 
significant concentration-dependent increase of caspase-3 activity. To determine the 
involvement of the mitochondrial pathway in the apoptotic process, the activity of caspase-9 
was examined under the same conditions.  
The significant increase in the concentration of caspase-9 indicates that mitochondrial 
damage may play a role in the mechanism of action of 7e. The possible function of the death 
receptor pathway in the apoptotic property of 7e was assessed as well via the determination of 
caspase-8 activity. Since there was no change in the activity of caspase-8, the extrinsic 
pathway may not be involved in the programmed cell death process induced by 7e (Fig. 8.). 
A 
B 
Control 10 µM 
 
 
3 µM 
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Figure 8. Compound 7e induces caspase-3 and caspase-9 but not caspase-8 activities after incubation for 48 h. 
The activities of the untreated cells were taken as one unit. * and *** indicate p < 0.05 and p < 0.001, 
respectively, as compared with the control cells. 
4.5 Wound healing assay 
Inhibition of cell motility is another substantial segment of the anticancer activity of a 
potential drug candidate. Wound healing assay was utilized to assess the migration ability of 
MDA-MB-231 cells after treatment for 24 h with elevating concentrations of 9 and 9a. 
Movement of untreated MDA-MB-231 cells within the wound of the chambers was 
considered as 100% in the statistics. A significant, concentration-dependent decrease was 
observed in the migration ability of MDA-MB-231 cells. It is considerable that sub-
antiproliferative concentrations caused reduced cell migration as well (Fig. 9-10.). 
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Figure 9. Representative images of the migrating MDA-MB-231 cells in 0 hour and after 24 h treatment with 9 
(upper panels) and 9a (lower panels).    
 
 
 
 
 
 
 
Figure 10.  Effect of 9 (A) and 9a (B) on the migration ability of MDA-MB-231 cells.  The rates of the migration 
were evaluated after incubation for 24 h. Results are mean values ± SEM from three measurements. *** 
indicates p < 0.001 as compared with the untreated control samples . 
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4.6 Boyden chamber assay 
As another important aspect of the antimetastatic property, the influence of the tested 
compounds on the invasion ability of MDA-MB-231 cells was investigated by the means of 
Boyden chambers containing Matrigel Matrix-coated membrane (8.0 μm pore diameter). 
Invasive cells are capable of migrating through the membrane, while the crossing of non-
invasive cells is blocked. After treatment with elevating concentrations for 24 h, the invasion 
of the examined cells was blocked by 9 and 9a in a concentration-dependent manner (Fig. 11-
12.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Images from a visual field of one representative experiment that show the influence of compound 9 
and 9a on the invasion of MDA-MB-231 cells after 24 h treatment with increasing concentrations.  
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Figure 12. Effects of compounds 9 and 
9a on the cell-invasion capacity of 
MDA-MB-231 cells. Statistical analyses 
of the percentage of invasive cells after 
incubation for 24 h with the test 
compounds. Results are mean values ± 
SEM from three measurements. ** and 
*** indicates p<0.01 and p<0.001 as 
compared with the untreated control 
samples, respectively. 
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4.7 Gelatin zymography  
To characterize the mechanism of the antimetastatic feature of 9 and 9a, the activities 
of MMP-2 and MMP-9 released by MDA-MB-231 cells were assessed by a gelatin 
zymography assay. The base of the method that the active enzymes damage the gelatin and 
create a light patch on the blue staining. As a result, no significant inhibition was observed by 
the examined compounds on the activity of the enzymes even in 2 µM (9a) and 4 µM (9) 
concentrations indicating that MMP-2 and MMP-9 may not be involved in the antimetastatic 
property of 9 and 9a. (Fig. 13.) 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 13.  Effects of compounds 9 and 9a on the activities of MMP-9 (pro-MMP-9, MMP-9 and its complex 
form) and MMP-2 (pro-MMP-2, MMP-2). Results are mean values ± SEM from three measurements. The 
activities presented in graphs are expressed as the % of vehicle control group. None of the treatment-related 
differences are significant. A representative zymogram (right bottom panel). 
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4.8 Western Blot assay 
Since FAK and its phosphorylated form (pFAK) are possible targets for metastasis 
inhibition, the influence of the tested compounds on the expression of FAK and pFAK 
proteins was investigated. A significant concentration-dependent decrease was observed in the 
level of pFAK regarding both 9 (0.5–2 μM) and 9a (1–4 μM), while the total amount of FAK 
was not altered. These findings demonstrate that 9 and 9a inhibited the phosphorylation of 
FAK protein. (Fig.14.) 
 
 
 
 
 
 
 
 
 
 
Figure 14. Effects of compounds 9 and 9a on the expression of phosphorylated and total FAK protein in MDA-
MB-231 cells (upper panels). Results are mean values ± SEM from three measurements. *** indicates p<0.001 
as compared with the untreated control samples. Representative results of the Western blot analysis (lower 
panels). 
5. Discussion 
The first reported estrogen analog possessing considerable antiproliferative property 
with the lack of the binding ability to the ER was 2-methoxyestradiol (2-ME), an endogenous 
metabolite of 17β-estradiol.90 The pharmacology of 2-ME has been extensively investigated 
in several studies proving its antiproliferative, pro-apoptotic, antiangiogenic, antitubulin and 
antimetastatic effects.
90–101
 The mechanism of action of 2-ME comprises several actions, 
including the inhibition of microtubule disruption and neoangiogenesis; furthermore, 
upregulation of the extrinsic and intrinsic apoptotic pathways. 2-ME has exerted growth-
inhibition on numerous human cancer cell lines, notably against breast tumor (MCF7, MDA-
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MB-231, MDA-MB-435, ZR-75, T47D), lung cancer (A549, H460, HOP64), ovarian cancer 
(OVCAR-3), prostate cancer (LNCaP, DU-145), cervical malignancy (HeLa, HeLaS3), 
pancreatic cancer (PaTu8902, PaTu8988s, PaTu8988t), stomach tumor (SC-MI, NUGC-3), 
and several others.
102
 Breast cancer was reported to be the most sensitive for 2-ME 
considering its concentration-dependent antiproliferative effect against both ER negative 
(MDA-MB-231 and MDA-MB-435) and ER-positive (MCF7 and T47D) cells.
102,103
 
Inducing blockade and arresting the cell cycle in the G2/M phase by inhibiting tubulin 
polymerisation through binding to colchicine binding site of the tubulin is one of the most 
important segments of the antiproliferative property of 2-ME.
95,104,105
 Marked early up-
regulation of cyclin B1 and Cdc2 proteins together with rapid nuclear accumulation of these 
two proteins; moreover, the development of nuclear chromosomal condensation and 
segregation were described in both ER-positive and negative breast cancer cells following 
exposure to 2-ME, which indicate a mitotic arrest in prometaphase. A close correlation was 
found between the time-dependent alterations in 2-ME-induced prometaphase arrest and the 
level of the G2/M population. These results suggest that besides the potent antitubulin activity 
of 2-ME, this effect is independent of the presence of estrogen receptors.
106
 This coincides 
with the fact, that the relative affinity of 2-ME for ER is very low.
90
 The protection against 
ovariectomy-induced bone loss of 2-ME is not suppressed by competitive inhibitors of ER, 
supporting that the activity of the compound is not influenced by ER.
107
 In clinical trials, 2-
ME was well-tolerated both as monotherapy and in combination with other anticancer agents; 
however, the exhibited activity was modest even in a NanoCrystal Dispersion (NCD) 
formulation due to its not sufficient bioavailability.
108–110
  
As a result of the extensive experiments on the anticancer activity, selectivity, and 
toxicity of 2-ME with promising findings, drug candidates with estrone skeleton became a 
new focus of the research and development of agents for the treatment of malignant diseases, 
such as 2-substituted 17β-hydroxy/17-methylene estratrienes, 16-modified 2-ME analogs, 2-
alkoxy and 2-benzyloxy analogues of estradiol, and antitumor pharmacophores combined 
with 2-ME.
111–114
 The structure of 2-ME was utilized for designing quinazolinone-based 
anticancer agents that were proven to be potent microtubule disruptors with promising in vivo 
findings.
115
  
It was described that natural 17β-estradiol is able to bind DNA directly not only 
through the estrogen response element (ERE), but influencing random DNA sequences. By 
forming aromatic interactions with the base pairs 17β-estradiol intercalates between them.116 
These results may be related to the hormonal receptor-independent activity of the estrogen-
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based molecules with possible antitumor activity, comprising the examined compounds of the 
present thesis. 
The criteria of binding to ER are known and well-founded, thus the structural 
modifications to develop molecules with low receptor binding affinities (RBA) are stated as 
well. A methyl substituent at C-3 is enough by itself to lose estrogenic property
72
, inversion of 
configuration at C-13 of estradiol leads to a low binding ability to the ER and no uterotropic 
action in mice 
73
; furthermore, hydrophilic functional groups attached to ring D also results in 
molecules with low RBA.  
Our present analogs can be selected into three groups based on their structural 
modifications. The set of 16-triazolyl-13α-estradiol analogs and their precursors were 
designed by inverting the configuration at C-13 and with a benzyloxy function at C-3, the 3-
benzyloxy-16-hydroxymethyl-estradiol derivatives were synthesized with a benzyloxy 
substituent at C-3, and a hydrophilic function at C-16. The four possible isomers of 16- 
hydroxymethyl-3-methoxy- and 16-hydroxymethyl-3-benzyloxy-13α-estradiols also contain 
inverted configuration at C-13; moreover, a hydrophilic group at C-16, and a methoxy or 
benzyloxy substituent at C-3. Considering these alterations in the estrane skeleton, the loss of 
estrogenic activity can be expected. The lacking hormonal property of 16-hydroxymethyl-
3,17-estradiol analogs was demonstrated through radioligand-binding assays.
85
 Our research 
group reported the antiproliferative activity of compounds with the previously described 
modifications of the estrange skeleton in several studies.
66,79,83,84
 Based on these results, we 
have continued the investigation of the antitumor activity of A- and D-ring modified estradiol 
analogs against numerous gynecological cancer cell lines. 
  In the set of 16-triazolyl-13α-estradiols and their precursors, the latter molecules (1-5) 
merely exerted a modest cell-growth inhibition considering that at 10 µM the maximum 
inhibition of the cell proliferation was 39.0±1.0% (5). On the other hand, compounds 
containing triazolyl function displayed more robust antiproliferative activity (6-7). The 
influence of the configuration of substituents at C-16 and C-17 was notable, 16β,17α (7) 
isomers generally showed more potent activity in comparison with their 16α,17β counterparts, 
with the exception of halogenated analogs (6g, 6h). The important role of benzyloxy function 
at C-3 was demonstrated, since compound 8 with a hydroxyl group at C-3 did not show any 
significant antiproliferative property. The most active molecules were additionally 
investigated against a panel of breast cancer cell lines differing in receptorial status (MDA-
MB-231 triple-negative cells, MDA-MB-361 cells expressing ER and HER2, and T47D cells 
bearing ER, PR, and AR). Only a modest difference between the activities of the molecules 
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was observed regarding the various cell lines. Compounds containing p-alkyl function, 
especially ethyl and tert-butyl on the triazolyl-phenyl substituent were demonstrated the most 
potent antitumor activities (7e, 7f). Bearing alkyl group, such as ethyl, propyl, or tert-butyl 
function on the triazolyl-phenyl ring of the estradiol skeleton was reported previously to 
increase the antiproliferative effect, and our result correlates with this finding.
83
 Cancer 
selectivity of compound 7e with p-ethyl substituent on its triazolyl-phenyl ring was assessed 
based on its lowest IC50 value from the series. Since the proliferation of MRC-5 cell 
population was not interfered significantly even after exposure to 30 µM of 7e; moreover, its 
growth-inhibitory value at 30 µM was at least 3.5 times higher against all types of the 
examined cancerous cells, it can be considered as a cancer-selective molecule. 
Regarding the 3-benzyloxy-16-hydroxymethyl-estrane derivatives, we determined the 
antiproliferative activity of the molecules against breast cancer cell lines with distinct receptor 
status in order to investigate their potential selectivity.  Most compounds of the series (9, 10, 
12, 9a, 9b) generally induced notable inhibition of proliferation of breast tumor cells 
indicating no significant selectivity between the examined cell lines. Configuration of 
substituents at C-16 and C-17 displayed a limited affection on the antiproliferative potency; 
nevertheless, 16β,17β isomers were more outstanding in the series, except for compound 10. 
Certain p-substituents on the benzyl ether function at C-3 were shown to increase the 
antiproliferative potency (9a, 9b). Compound 9a containing p-chloride substituent on the 
benzyloxy group at C-3 was demonstrated to be the most potent from the series considering 
its antiproliferative activity on the examined cancerous cells. 
The antiproliferative activity of 3-benzyloxy-13α-estradiols was found to be more 
pronounced compared to their 3-methyl ether counterparts considering the results of all 
examined cancer cell lines. All benzyl ethers displayed notable activity on HeLa and A2780 
cells, the 16β,17β-isomer (20) was the most potent against breast cancer cells based on its 
IC50 values regarding each four cell lines. The 16β,17α-isomer (16) was proven to be the most 
effective and selective towards HeLa and A2780 cell lines. Cancer-selectivity of compound 
20 and 15 (16β,17β) was detemined due to their generally potent antiproliferative 
characteristic on all investigated tumorous cell lines by using MRC-5 cells. Both compounds 
exterted a dose-dependent activity, 20 inhibited the proliferation of MRC-5 cells at least 2 
times lesser compared to its activity on cancer cell lines. 15 showed a modest selectivity on 
HeLa and A2780 cells; however, regarding breast cancer cell lines, the IC50 value of the 
compound was similar to its activity against non-cancerous cells.  
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In summary of structure-activity relationships of all three groups of the examined 
compounds, benzyl ether function at C-3 enhanced the antiproliferative potency, the 
configuration of substituents at C-16 and C-17 exerted a varying influence on the activity of 
the molecules; 16β,17β and 16β,17α isomers were proven to be the most potent estradiol 
analogs in general.  The activity of the most potent compounds (7e, 7f, 9, 9a, 9b, 10, 20) was 
comparable with cisplatin that is currently used in gynecological cancer therapy protocols, 
such as cervix and breast cancer protocols.
117–119
 
To characterize the antiproliferative activity of the selected compounds on cell cycle 
distributon, flow cytometry analysis was performed. The effect of 7e was examined after a 24 
h and 48 h treatment on HeLa cervical tumor cells due to its potent activity against this type 
of cancer cell line. Exposure for 24 h to 10 µM 7e generated a marked elevation in the ratio of 
cells in S and G2/M phases while the ratio of cells in the G1 phase was decreased. Treatment 
for 48 h led to the elevation of G2/M cells at the expense of the G1 population again; 
furthermore, the significant increase of the subG1 population indicating a blockade of the cell 
cycle at the G2/M phase and the induction of programmed cell death. The blockage in the 
G2/M phase induced by 7e was additionally supported based on the measurement of the 
mRNA levels of p21, one of the key regulators of a G2/M arrest by QPCR. The induction of 
p21 was determined after 24 and 48 h treatment with 7e. G2/M phase arrest was also reported 
regarding other structurally modified estradiol analogs i.e. D-secoestrone-triazole 
88
 and D-
homoestrone.
120
 
 G1 cell population was significantly elevated together with the decrease of the ratio of 
cells in the G2/M phase after treatment with the increasing concentrations of compound 9 for 
24h in MDA-MB-231 cancer cells. An increase in the percentage of subdiploid cells was 
detected, even at 5 µM concenration. This tendency was observed regarding 9a as well; 
however, the alterations were less pronounced. These findings correlate with previously 
described G1 phase arrests induced by estrone analogs, such as unsubstituted 16-oxime-
estrone molecules and oxadiazole derivatives of estrone.
79,121
 
Hoechst 33258 – propidium iodide double staining was performed utilizing the HeLa 
cell line to confirm the presence of apoptotic cells following exposure to 7e. The treatment 
induced the siginificant elevation of the ratio of early apoptotic and secondary necrotic cells, 
while a decrease was observed in the population of intact cells. During the development of 
anticancer agents, apoptosis-inducing molecules are preferred
122
, since mainly there is no 
inflammatory reaction in connection with the apoptotic process or the removal of the 
apoptotic cells.
123,124
 On the other hand, the loss of membrane integrity of necrotic cells 
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results in the release of the cytoplasmic constituents into the surrounding interstitial tissue and 
subsequent inflammation.
125
 Secondary necrosis is the outcome when in vitro cultured non-
phagocytic cells undergo programmed cell death.
29,126
 Treatment with 7e led to both early 
apoptotic and secondary necrotic cells according to our results.  
The apoptosis-inducing property of 7e against HeLa cervical cancer cells was 
additionally supported by the findings of the investigation of the activity of caspase-3, the 
execution enzyme of the programmed cell death. A significant elevation of caspase-3 
concentration was observed in a dose-dependent manner after exposure to the test compound. 
The involvement of the intrinsic pathway of the apoptotic process was revealed through the 
increased activity of caspase-9, while the unaltered concentration of caspase-8 indicates that 
the extrinsic pathway does not play a role in the activity of 7e. 
 Metastasis is the major cause of malignancy-related deaths; it can be connected with 
approximately 90% of the fatal cases.
3
 Consequently, developing innovative agents with anti-
metastatic potency is a huge need to control cancer-related mortality. The metastatic process 
involves several steps, such as the local migration and invasion of cancer cells into adjacent 
tissue, infiltrating into the vasculature, surviving and seceding from the circulation system, 
and then the following proliferation in distant organs that results in colonization.
127
  Triple-
negative breast cancer is characterized by higher chance of recurrence, shorter median time to 
death and worse overall survival compared to other breast cancer subtypes.
9,12
  The high risk 
of developing visceral metastases in a short time after the diagnosis of patients with TNBC is 
responsible in a large part for the poorer prognosis in connection with the phenotype.
128
  
Compounds 9 and 9a were additionally investigated regarding their activity on triple-
negative MDA-MB-231 cell migration and invasion, the intitial steps of metastatic spread. 
Significant inhibiton of cell migration was observed at even 0.25 µM, indicating the potency 
of the compounds in sub-antiproliferative concentration. The inhibitory action of compound 9 
on cell invasion capacity was demonstrated to be more pronounced as evaluated by the 
Boyden chamber assay. 
Degradation and subsequent rearrangement of ECM induced by matrix 
metalloproteinases participate in multiple steps of the processes of metastasis, including 
invasion of the basement membrane at primary and metastatic sites, invasion through the 
stroma; moreover, intra- and extravasation.
129
  The significantly elevated activity of the latent 
and active forms of MMP-2 and MMP-9 in breast tumoral tissues was demonstrated as 
compared to the non-tumoral adjacent tissues. Evaluation by distant metastasis-free survival 
in the Kaplan-Meier plotter database showed that overexpression of MMP-2 and MMP-9 
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mRNA are correlated with poor outcome.
130
 The increased expression of MMP-2 and MMP-9 
at the mRNA level was reported in MDA-MB-231 cells compared to non-cancerous 
HS578Bst breast cells. A close correlation between overexpression of the two mentioned 
metalloproteinases and lymph node metastasis; moreover, tumor staging was assessed from 
the examination of breast cancer tissues derived from patients with clinically diagnosed breast 
tumors.
131
  
After the treatment of triple-negative MDA-MB-231 cells for 24 h, we found that 
compound 9 and 9a did not exhibit a notable influence on the level of MMP-2 and MPP-9, 
demonstrating that these enzymes do not play a crucial part in the mechanism of action of the 
examined estradiol analogs. 
Most  types of cells and tissues express focal adhesion kinase that is involved in the 
processes of cell spreading, differentation, cell cycle, cell migration, and cell death; therefore, 
it is an enzyme with a notably extensive function. The activation of FAK is mainly based on 
the autophosphorylation on tyrosine Y397 executed by the clustering of integrins.
132
 The role 
of the enzyme in the process of cell migration was reported in several studies; moreover, its 
elevated activity was demonstrated in several tumor types, such as breast cancer. In addition, 
the rate of its upregulation was associated with a poorer prognosis and metastatic spread.
133,134
   
Another important finding that overexpression of FAK occurred in the early stage of 
tumorigenesis, even before cell invasion in ductal carcinoma in situ.
135
 Overexpression of the 
enzyme enhanced the migration of Chinese hamster ovary (CHO) cells, while downregulation 
of FAK led to weak cell migration in response to chemotactic and haptotactic signals.
136
 
Several studies reported that FAK contributes to the development and progression of various 
cancer types, including breast cancer; moreover, the deletion of FAK suppressed tumor 
formation and progression in mouse models of breast cancer. It was demonstrated that FAK 
plays a role in the intercellular communication between cancer-associated fibroblasts in the 
tumor microenvironment and mammary tumor cells important for cancer cell migration and 
metastasis development. The deletion of FAK led to the suppressed ability of cancer-
associated fibroblasts to promote tumor cell migration.
137
  
A dose-dependent decrease was observed in the level of pFAK Y397 in MDA-MB-
231 cells after treatment with 9 and 9a in sub-antiproliferative concentrations. The expression 
of total FAK was not influenced by the treatment indicating that the compounds inhibited the 
phosphorylation of the enzyme.  
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6. Summary 
In summary, the present work revealed that numerous compounds from the set of 16-
triazolyl-13α-estradiols, 3-benzyloxy-16-hydroxymethyl-estradiols, and 16-hydroxymethyl-3-
benzyloxy-13α-estradiols are potent antiproliferative agents against gynecological cancer cell 
lines, especially breast and cervical tumors.  
Apoptosis-induction was observed in cervical cancer cells bearing HPV 18 DNA by 
16-triazolyl-13α-estradiol 7e through G2/M phase blockage and involving the mitochondrial 
apoptotic pathway, while showing a beneficial cancer-selectivity. 9 and 9a 3-benzyloxy-16-
hydroxymethyl-estradiols caused programmed cell death and G1 phase increase in TNBC 
cells.  
TNBC cell line was utilized for the investigation of the antimetastatic capacity of test 
compounds due to the unmet medical need of the subtype. 9 and 9a exerted substantial dose-
dependent inhibition on cell migration and invasion; furthermore, on the phosphorylation of 
focal adhesion kinase, an important target in antimetastatic research. The treatment proved to 
be potent in sub-antiproliferative concentrations that indicates the advantageous cancer 
selectivity of the compounds.  
 Our findings demonstrate that molecules with modified estradiol structure can be 
regarded as promising candidates in the development of new anticancer agents exerting 
antiproliferative and antimetastatic properties.  
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A B S T R A C T
Despite emerging new therapeutic opportunities, cancer is still a major health problem and a leading cause of
death worldwide. Breast tumors are the most frequently diagnosed female malignancies, and the triple-negative
subtype is associated with poorer prognosis and lower survival rates than other breast cancer types. The aims of
the present study were to determine the anticancer potency of a set of C-3 and C-16 modified estradiol-deri-
vatives against a panel of breast cancer cell lines, and to characterize the mechanism of action of two selected
compounds (1 and 5) against the MDA-MB-231 triple-negative breast cancer cell line. Growth-inhibitory
properties were investigated by an MTT-assay. Cell cycle analysis by flow cytometry has revealed G1 phase
accumulation and indicated the proapoptotic effect of 1 and 5 through the elevation of the apoptotic subG1
phase on MDA-MB-231 cells after 24 h treatment. The antimetastatic activities of these compounds were ex-
amined by wound healing and Boyden chamber assays, and both compounds were shown to significantly inhibit
the migration and invasion of MDA-MB-231 cells at sub-antiproliferative concentrations. Gelatin zymography
assay has indicated that matrix metalloproteinase-2 and -9 are not involved in the antimetastatic action of the
molecules. Western blot analysis was performed with 24 h incubation to examine the possible changes in the
level of focal adhesion kinase (FAK), and both compounds were found to inhibit the phosphorylation of FAK in a
concentration-dependent manner in MDA-MB-231 cells. The results of this study demonstrate that C-3 and C-16
modified estradiol derivatives are potent antiproliferative and antimetastatic compounds against a triple-ne-
gative breast cancer cell line with a mechanism of action involving the inhibition of FAK, a novel anticancer
therapeutic target. Therefore, these findings can be utilized in the development of promising anticancer agents
with steroid skeleton.
1. Introduction
Cancer is a crucial cause of morbidity and mortality worldwide,
with the incidence of malignant diseases rising both in highly devel-
oped and less developed countries. In 2012, 14.1 million new patients
and 8.2 million cancer-related deaths were estimated globally, and>
3.14 million new cancer cases were diagnosed in Europe. Amongst
women, the most common cancer type is breast cancer, characterized
by the highest incidence and mortality rates, comprising 25% of all
diagnosed cancer cases and causing 15% of all cancer-related deaths
(Steliarova-Foucher et al., 2015; Torre et al., 2015).
Triple-negative breast cancer (TNBC) is a subtype of breast tumors
described by the downregulation of estrogen receptor (ER), proges-
terone receptor (PR) and human epidermal growth factor receptor 2
(HER2). Approximately 15–20% of all breast cancers are triple-negative
tumors, and this subtype is responsible for 25% of breast cancer-related
deaths (Lee and Djamgoz, 2018). TNBC patients are typically
5–10 years younger than other breast cancer patients at the time of
diagnosis (Newman et al., 2015). Indicators for the aggressive behavior
of TNBC include a high recurrence rate and faster metastatic spread,
leading to poorer prognosis amongst all breast cancer subtypes. Re-
garding recurrence, the secondary tumor usually occurs within 5 years
from the initial diagnosis, with the brain and viscera being affected
more often than in case of non-TNBC primaries which usually cause
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metastasis to bone. Compared to other subtypes, TNBC has a shorter
median time to death (4.2 vs. 6 years) and worse overall survival. Both
of these basic triple-negative features and the possible molecular di-
versity within TNBCs hamper the development of targeted therapies.
Although several novel pharmacological groups of drugs, like poly
(ADP-ribose) polymerase inhibitors and immunotherapeutic agents
have shown promising results in clinical trials, developing specified
treatment for TNBC is still an urgent unmet medical need (Lee and
Djamgoz, 2018; Lin et al., 2008).
Estrogens have an essential influence on the evolution of re-
productive processes. Furthermore, they play a role in the development
of hormone-dependent tumors of the reproductive organs, such as
breast, ovarian, endometrial, uterine and prostate cancers (Ascenzi
et al., 2006; Chen et al., 2008; Nelles et al., 2011; Pearce and Jordan,
2004). Although the proliferation-stimulating activity of 17β-estradiol
is well-established, numerous studies have also investigated the antic-
ancer potential of structurally modified estrogen derivatives (Bodnár
et al., 2016; Cadot et al., 2007; Cushman et al., 1997; Jourdan et al.,
2011; Mernyák et al., 2014; Mernyák et al., 2015; Möller et al., 2009;
Szabó et al., 2016).
A fundamental requirement for estrane-based anticancer drug can-
didates is the lack of their hormonal activity. Certain structural mod-
ifications, such as substitution at C-2 or C-3 of the estrane skeleton lead
to the loss of the estrogenic properties of the compounds (Anstead et al.,
1997; Cushman et al., 1997; Wölfling et al., 2003). Additionally,
modification of the D-ring of the estrange skeleton leading to D-homo
and D-seco derivatives results complete loss of estrogenic activity
(Jovanovic-Santa et al., 2003; Jovanovic-Santa et al., 2015). Moreover,
some of such agents may additionally interact with the enzyme ar-
omatase (CYP1A19) indicating a secondary way of intervention in the
estrogen-dependent proliferative disorders including gynecological
cancers, endometriosis (Trifunovic et al., 2017).
In a previous study, the binding abilities of possible isomers of 16-
hydroxymethyl-3,17-estradiol to estrogen receptor were investigated by
radioligand-binding assay, utilizing receptor protein prepared from
rabbit uteri. The relative binding affinities (RBA) of each estradiol de-
rivative was lower than 2.0% of that of estradiol, indicating that the
introduction of a 16-hydroxymethyl group abolishes the affinity in-
dependently of its configuration (Tapolcsányi et al., 2002). Conse-
quently, the presence of a hydroxymethylene group at C-16 is detri-
mental concerning the estrogenic activity of the tested compounds.
Based on these preliminary findings, it can be stated that the 16-hy-
droxymethylene-3,17-estradiol core might be suitable for the design of
biologically active estrone derivatives lacking hormonal activity.
We have recently reported that the presence of a 3-benzyl ether
function on the estrane core may enhance the antiproliferative potential
of the steroid (Mernyák et al., 2014; Mernyák et al., 2015). In order to
combine the structural moieties responsible for an increase in the an-
tiproliferative and a decrease in the estrogenic actions, here we have
synthesized additional 3-benzyl ethers bearing electronically different
substituents at the 4′-position.
The aim of the current investigation was to characterize the antic-
ancer properties of these 16-hydroxymethyl-estradiol analogs on a
panel of breast cancer cell lines in vitro. The most promising agents
were selected for further analyses in order to describe the mechanism of
the action against the MDA-MB-231 triple-negative breast cancer cell
line. Although the hormonal receptor status of the utilized cell lines was
different we aimed to describe hormone-independent antiproliferative
properties. The effects of the selected molecules on cancer cell migra-
tion were also evaluated.
2. Materials and methods
2.1. Chemicals
The four possible stereoisomers of 3-benzyloxy-16-hydro-
xymethylene-estra-1,3,5(10)-trien-17-ol (1–4) were synthesized and
characterized as reported previously (Tapolcsányi et al., 2002). Three
further analogs with a substituted benzyl function at C-3 have also been
prepared (5–7). The synthesis and chemical characterization of the
molecules are available as Supplementary material (Fig. 1).
2.2. Cell cultures
Human breast cancer cell lines, including MCF7, T47D, MDA-MB-
231 and MDA-MB-361, as well as non-cancerous fibroblasts (MRC-5)
were purchased from the European Collection of Authenticated Cell
Cultures (ECACC, Salisbury, UK). All cell lines were maintained in
minimal essential medium (MEM) supplemented with 10% fetal bovine
serum, 1% non-essential amino acids and 1% antibiotic-antimycotic
mixture, and were stored in humidified air containing 5% CO2 at 37 °C.
All utilized components were obtained from Lonza Group Ltd. (Basel,
Switzerland).
2.3. Determination of antiproliferative activities
To determine the antiproliferative action of the tested compounds
against four malignant breast cancer cell lines (MCF-7, T47D, MDA-MB-
231 and MDA-MB-361), an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide) assay was carried out. Cells were seeded at
a density of 5000 cells/well into 96-well plates (in the case of MDA-MB-
361 10,000 cells/well), treated with increasing concentrations of 16-
Fig. 1. Chemical structures of the synthesized and investigated estradiol analogs.
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hydroxymethyl-estranes (0.1–30.0 μM) under cell culturing conditions
for 72 h. At the end of incubation, 5mg/ml MTT solution was added to
the samples. Precipitated formazan crystals were solubilized in di-
methyl sulfoxide and absorbance was measured at 545 nm with a mi-
croplate reader. Wells containing untreated cells were used as control
(Mosmann, 1983).
Based on these results, sigmoidal dose-response curves were fitted
and IC50 values were calculated using GraphPad Prism 5.01 (GraphPad
Software, San Diego, CA, USA). The growth-inhibitory effects of the
tested compounds were compared to cisplatin (Ebewe Pharma GmbH,
Unterach, Austria) in the same concentration range. MRC-5 human fi-
broblasts were also examined by the same method to verify the se-
lectivity of the test compounds towards cancer.
2.4. Cell cycle analysis by flow cytometry
Cellular DNA content was determined by flow cytometry. MDA-MB-
231 cells were seeded into 6-well plates at a density of
250,000–300,000 cells/well. After 24 h incubation cells were washed
with phosphate-buffered saline (PBS) and gathered with trypsin. The
samples were centrifuged at 1500 rpm for 10min, additionally washed
and centrifuged again, and fixed in 1ml of 70% ethanol,−20 °C, for at
least 30min. The dye solution (0.1 mg/ml PI, 0.003 μl/ml Triton-X,
0.02mg/ml RNase A, and 1.0 mg/ml sodium citrate dissolved in dis-
tilled water) was then added to the samples for 60min. The cell cycle
analysis was carried out by a Partec CyFlow instrument (Partec GmbH,
Münster, Germany). In all measurements, 20,000 cells were analyzed.
The percentages of cells in different cell cycle phases (subG1, G1, S and
G2/M) were determined by the ModFit LT software (Verity Software
House, Topsham, ME, USA). The subG1 fraction was considered as the
apoptotic cell population (Vermes et al., 2000).
2.5. Wound healing assay
The action of the selected compounds on cell migration was assessed
by a wound healing assay. The assay was performed with specific
wound assay chambers (ibidi GmbH, Martinsried, Germany). MDA-MB-
231 cells were trypsinized and 25,000 cells were seeded into each
chamber of the inserts. After an overnight incubation for appropriate
cell attachment at 37 °C under 5% CO2, the culture insert was removed.
A washing step with PBS was performed to remove non-adherent cells
and debris. Cells were treated with increasing concentrations of each
test compound in a medium containing 2% FBS for 24 h. Migration of
the cells to the wound site was visualized by a phase-contrast inverted
microscope (Axiovert 40, Zeiss, Thornwood, NY, US). Images were
taken by a CCD camera at planned intervals to assess wound closure.
The rate of migration was calculated as the ratio of wound closure in
treated samples after 24 h and 0 h, respectively, as compared with the
ratio of the wound closure in untreated control samples after 24 h and
0 h, respectively (Bózsity et al., 2017).
2.6. Boyden chamber assay
Invasion ability of MDA-MB-231 cells was investigated by a BD
BioCoat Matrigel Invasion Chamber (BD Biosciences, Bedford, MA,
USA) containing an 8 μm pore size PET membrane and a thin layer of
matrigel basement matrix. Fifty thousand cells were suspended in
serum-free medium and were injected into the top insert before the
tested compounds were added in sub-antiproliferative concentrations.
A medium containing 10% FBS was used as chemoattractant in the
bottom well. The inserts were removed after incubation for 24 h at
37 °C under 5% CO2 and the upper surface of the membrane was
cleaned from non-invading cells with a cotton swab. After a washing
step with PBS, the insert was fixed with cold 100% methanol, washed
with PBS again and stained with crystal violet solution. The invading
and stained cells were counted under a phase-contrast inverted
microscope. To determine the rate of invasion, the number of treated
samples and untreated controls were counted and compared to each
other.
2.7. Gelatin zymography assay
A gelatin zymography assay was utilized to determine how the test
compounds affect the activities of matrix metalloprotease-2 (MMP-2)
and −9 (Snoek-van Beurden and Von den Hoff, 2005). MDA-MB-231
cells were seeded in experimental dishes at approximately 80% con-
fluency and were allowed to grow overnight. After a washing step with
PBS the test compounds were added in serum-free medium and in-
cubated for 24 h. Then the supernatant containing the secreted MMP-2
and MMP-9 enzymes were collected from above the cells and was
centrifuged at 6000 rpm at 4 °C for 2min, then collected again. Equal
amounts of the samples mixed with bromophenol blue dye in 5:1 ratio
were separated by SDS-PAGE containing 0.1% gelatin via electrophor-
esis at 120 V for 90min. Major forms of MMPs were identified by Prism
Ultra Protein Ladder molecular size marker (Abcam Cambridge, U.K.).
The gel was washed twice by 2.5% Triton X-100 solution, then treated
with the reaction solution containing 50mM Tris-HCl (pH 7.5), 150mM
NaCl and 5mM CaCl2. After incubation for 24 h the gel was stained
with Coomassie brilliant blue G-250 (SimplyBlue™ Safestain, Thermo
Fisher Scientific, Waltham, MA, USA) for 60min and washed by dis-
tilled water twice. Finally, the gel was captured by a Luminescent
Image Analyzer System (LAS 4000 mini, Fujifilm, Tokyo, Japan).
2.8. Western blot assay
A Western Blot assay was performed to evaluate the antimetastatic
properties of the examined compounds. Two million cells were seeded
in small experimental dishes, and the tested compounds were added in
medium containing 2% FBS the next day. Cells were detached from the
dishes by a rubber policeman and centrifuged at 7000 rpm, 4 °C for
2min, washed with PBS and centrifuged again. Whole cell extracts
(WCEs) were prepared by re-suspending cells in TEGN lysis buffer
(10mM Tris pH 7.5, 1 mM EDTA, 420mM NaCl, 10% glycerol and 0.5%
NP40) supplemented with 1mM DTT and a cocktail of protease and
phosphatase inhibitor (Roche Applied Science, Penzberg, Germany).
After 10min on ice and centrifugation (13,000 rpm, 4 °C, 10min) the
protein content of the supernatant was mixed with bromophenol blue
dye in 2:1 ratio. Equal amounts of WCEs were first separated by SDS-
PAGE with electrophoresis for 1 h at 160 V, transferred onto ni-
trocellulose membranes for overnight at 20 V, 4 °C. Afterwards, the
samples were blocked and incubated with a primary antibody followed
by an appropriate secondary antibody. The antibodies utilized were
FAK pY397 (Becton Dickinson, Franklin Lakes, NJ, USA), FAK (Cell
Signaling Technology, Danvers, MA, USA), β-actin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and GAPDH (Cell Signaling
Technology). Blots were visualized by enhanced chemiluminescence
(ECL-Plus, GE Healthcare Life Sciences, Little Chalfont, UK) using a
Luminescent Image Analyzer System.
2.9. Statistical analysis
GraphPad Prism 5.01 was used for the statistical evaluation of
measured data in each experiment. To determine statistical sig-
nificance, one-way ANOVA with Dunnett post-test for comparison of
multiple groups was utilized. A p value < 0.05 was regarded as sta-
tistically significant.
3. Results
3.1. Antiproliferative activity of the tested compounds
Several 16-hydroxymethyl-estranes proved to be potent
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antiproliferative agents against various breast cancer cell lines. The
calculated IC50 values representing their growth-inhibitory effects are
presented in Table 1. As shown by our results, the configuration of the
substituents at positions 16 and 17 play a limited role in the agents'
antiproliferative properties. On the other hand, substituents, especially
the p-methoxy group on the benzyl function at C-3 may enhance the
anticancer potency. The compounds were additionally tested against
the non-cancerous MRC-5 cells in order to obtain data concerning their
selectivity towards cancer. In this regard, our compounds were not
selective towards cancer cells but they were comparable to the re-
ference agent cisplatin. Based on these results the analog with the
lowest IC50 value (5) and its related, unsubstituted analog (1) were
selected for additional investigations.
3.2. Cell cycle analysis by flow cytometry
In order to characterize the mechanism of action of the selected
compounds against the MDA-MB-231 cell line, flow cytometry was
carried out and the cell cycle phase distributions were analyzed after
24 h of incubation. The applied concentrations were determined based
on the calculated IC50 values. Both compounds elicited a significant and
concentration-dependent increase of the cell population in the G1
phase, on the expense of the reduction of those in the G2/M phase
(Fig. 2). In spite of its substantially higher calculated IC50 1 elicited
remarkable cell cycle disturbance even at 5 μM. Additionally, 1 and 5
induced a modest but significant elevation of the hypodiploid (subG1)
cell population at all the applied concentrations indicating the proa-
poptotic potential of these compounds.
3.3. Wound healing assay
As another means of investigating the anticancer activity of the
tested estradiol derivatives, the possible motility inhibiting properties
were examined by a wound healing assay. Migration of untreated MDA-
MB-231 cells within the wound of the chambers was considered as
100% after 24 h incubation. Treatment with 1 and 5 significantly re-
duced the movement ability of MDA-MB-231 cells even at sub-anti-
proliferative concentrations (Fig. 3).
3.4. Boyden chamber assay
Besides the anti-migratory effect, the influence on the invasion
Table 1
Antiproliferative effects of the tested compounds (1–7) on human breast cancer cell lines and MRC-5.
Growth inhibition (%) ± SEM
[calculated IC50 value (μM)a]
MDA-MB-231 MCF7 T47D MDA-MB-361 MRC-5
1 10 μM 31.52 ± 1.82 60.16 ± 1.56 54.49 ± 0.27 93.07 ± 0.52 78.02 ± 2.63
30 μM 94.90 ± 0.46 97.20 ± 0.41 89.95 ± 043 93.25 ± 1.09 96.50 ± 0.20
IC50 (μM) 12.70 8.15 8.41 4.60 6.73
2 10 μM 93.82 ± 0.49 91.54 ± 0.56 82.73 ± 1.63 93.80 ± 0.70 94.78 ± 0.49
30 μM 96.21 ± 0.34 97.83 ± 0.24 82.10 ± 0.50 93.98 ± 0.26 96.88 ± 0.21
IC50 (μM) 3.91 5.05 4.58 3.81 5.53
3 10 μM 76.41 ± 0.65 27.02 ± 1.28 38.76 ± 2.02 62.73 ± 2.20 39.10 ± 3.23
30 μM 92.17 ± 0.59 88.57 ± 1.23 90.29 ± 0.58 86.15 ± 0.93 92.63 ± 0.15
IC50 (μM) 5.93 13.57 15.73 7.21 10.20
4 10 μM 84.34 ± 1.22 56.64 ± 2.23 47.49 ± 2.41 79.06 ± 2.70 53.67 ± 3.39
30 μM 92.79 ± 0.26 86.85 ± 0.89 94.56 ± 0.73 89.85 ± 1.02 76.84 ± 2.19
IC50 (μM) 5.47 9.05 10.44 5.38 7.33
5 10 μM 89.54 ± 0.82 96.46 ± 0.65 95.58 ± 0.26 81.08 ± 1.77 76.50 ± 2.28
30 μM 87.73 ± 0.32 96.68 ± 0.17 95.26 ± 0.90 86.97 ± 1.26 79.75 ± 0.95
IC50 (μM) 4.59 3.45 2.75 1.26 6.67
6 10 μM 61.13 ± 2.35 72.68 ± 0.79 80.22 ± 2.10 76.84 ± 1.24 61.03 ± 2.82
30 μM 82.84 ± 0.92 89.08 ± 0.94 87.03 ± 1.45 81.08 ± 1.72 78.09 ± 1.79
IC50 (μM) 7.48 4.24 2.98 4.65 1.46
7 10 μM 30.94 ± 2.42 39.34 ± 0.86 34.70 ± 1.42 n.d. n.d.
30 μM 68.82 ± 1.68 57.70 ± 0.75 52.69 ± 3.13
IC50 (μM) n.d. n.d. n.d.
Cisplatin 10 μM 20.84 ± 0.81 53.03 ± 2.29 51.00 ± 2.02 67.51 ± 1.01 60.25 ± 3.31
30 μM 74.47 ± 1.20 86.90 ± 1.24 57.95 ± 1.45 87.75 ± 1.10 61.92 ± 1.01
IC50 (μM) 19.13 5.78 9.78 3.74 6.19
n.d.: not determined.
a IC50 values were calculated from two experiments with 5 parallel wells if the growth inhibition of the compound was> 75% at 30 μM.
Fig. 2. Effects of compounds 1 and 5 on the MDA-MB-231 cell cycle after incubation for 24 h. Results are mean values ± SEM from three measurements. *, ** and
*** indicates p < 0.05, p < 0.01 and p < 0.001 as compared t with the control cells, respectively.
I. Sinka et al. European Journal of Pharmaceutical Sciences 123 (2018) 362–370
365
capacity of tumor cells is another important descriptor of the anti-
metastatic property. The Matrigel Matrix-coated membrane (8.0 μm
pore diameter) in Boyden chambers allows invasive cells to cross the
membrane while it blocks the migration of non-invading cells. The in-
vasion of MDA-MB-231 cells was found to be blocked by the compounds
tested, in a concentration as low as 0.5 μM of 1 and 2 μM of 5, and the
effect size increased with higher concentrations (Fig. 4).
3.5. Gelatin zymography assay
In order to find a possible explanation for the metastasis-inhibitory
effect of compounds 1 and 5, the activities of released MMP-2 and
MMP-9 were determined by a gelatin zymography assay. The active
enzymes break down gelatin leaving a light patch on the blue back-
ground. None of our compounds exerted a significant influence on the
activity of either MMP-2 or MMP-9 up to the concentrations of 2 μM (1)
or 4 μM (5), suggesting that the antimetastatic activity of the tested
compounds are independent of these enzymes (Fig. 5).
3.6. Western blot assay
The inhibition of focal adhesion kinase (FAK) and its phosphory-
lated form (pFAK) is another possible mechanism to block metastatic
processes. Therefore the changes elicited by the tested compounds in
the levels of proteins FAK and pFAK proteins were determined. Both
compounds 1 (0.5–2 μM) and 5 (1–4 μM) reduced the level of phospho-
Fig. 3. Effects of compounds 1 and 5 on the migratory capacity of MDA-MB-231 cells (upper panels). The rates of the migration were evaluated after incubation for
24 h. Results are mean values ± SEM from three measurements *** indicates p < 0.001 as compared with the untreated control samples. Representative images of
the migrating cells in 0 and 24 h (lower panels).
Fig. 4. Effects of compounds 1 and 5 on the cell-invasion
capacity of MDA-MB-231 cells (upper panels). Statistical
analyses of the percentage of invasive cells after incuba-
tion for 24 h with the test compounds. Results are mean
values ± SEM from three measurements. *, ** and ***
indicates p < 0.05, p < 0.01 and p < 0.001 as com-
pared with the untreated control samples, respectively.
Images from a visual field of one representative experi-
ment (lower panels).
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FAK in a concentration-dependent manner, without exerting any action
on the total amount of FAK, indicating that the phosphorylation of FAK
protein is inhibited by the compounds tested (Fig. 6).
4. Discussion
An endogenous derivative of 17β-estradiol (E2), 2-methoxyestradiol
(2-ME) was discovered as the first estrane analog with potent growth-
inhibitory effect, but without binding to the estrogen receptor (ER)
(LaVallee et al., 2002). Since the possible mechanism of action,
pharmacokinetic properties, selectivity and toxicity of 2-ME have been
widely investigated, potential antiproliferative agents with an estrane
skeleton are a new focus of the research and development of anticancer
drug candidates (Kumar et al., 2016). Several studies have demon-
strated that the antitumor mechanism of action of 2-ME comprises
antiproliferative, antitubulin, antiangiogenic, antimetastatic and proa-
poptotic effects (Minorics and Zupkó, 2018; Pribluda et al., 2000; Zhu
and Conney, 1998). Growth inhibition induced by 2-ME treatment in
numerous malignant cell lines, including lung, colon, breast, prostate,
eye, kidney, esophagus, stomach and pancreas cancers, as well as
Fig. 5. Effects of compounds 1 and 5 on the activities of MMP-9 (pro-MMP-9, MMP-9 and its complex form) and MMP-2 (pro-MMP-2, MMP-2). Results are mean
values ± SEM from three measurements. The activities presented in graphs are expressed as the % of vehicle control group. None of the treatment-related differences
are significant. A representative zymogram (right bottom panel).
Fig. 6. Effects of compounds 1 and 5 on the expression of phosphorylated and total FAK protein in MDA-MB-231 cells (upper panels). Results are mean
values ± SEM from three measurements. *** indicates p < 0.001 as compared with the untreated control samples. Representative results of the Western blot
analysis (lower panels).
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tumors of the nervous system, melanoma, gynecologic malignancies,
angiosarcoma and carcinoma of the musculature, was confirmed.
Amongst the examined cell lines, breast carcinoma was found to be the
most sensitive against 2-ME (Mueck and Seeger, 2010). It has been
reported that its antiproliferative action against various cancer cell lines
is mainly based on inducing blockade in the G2/M phase of cell cycle in
various cancer cell lines (Carothers et al., 2002; Li et al., 2004; Pribluda
et al., 2000; Qadan et al., 2001).
Treatment with 2-ME resulted in mitotic arrest in the prometaphase
through the intense early up-regulation of cyclin B1 and Cdc2 proteins
in both ER-positive and negative breast cancer cell lines. A close cor-
relation was observed between the time-dependent variations of the
prometaphase arrest and the level of the G2/M population. These re-
sults suggest not only the potent anti-microtubule effect of 2-ME but
also demonstrate that this action is not influenced by the presence of
estrogen receptor (Choi and Zhu, 2012). Despite 2-ME was well-toler-
ated in clinical trials, both as monotherapy and in combination with
other anticancer agents, its activity was modest, even in a NanoCrystal
Dispersion (NCD) formulation possessing more advantageous bioavail-
ability (Harrison et al., 2011; Kumar et al., 2016; Matei et al., 2009).
Despite this failure these studies showed that the modification of the
estrane skeleton may yield promising anticancer agents. The structure
of 2-ME has been recently utilized to design and synthesize a set of
quinazolinone-based microtubule disruptors indicating the unexploited
potency of the estrange skeleton as a base for innovative anticancer
agents (Dohle et al., 2018).
Natural 17β-estradiol has been recently demonstrated to bind to
DNA directly and that binding is not limited to the estrogen response
element but it can affect random DNA sequences. This binding involves
the intercalation of the steroid between base pairs of DNA, forming
aromatic interactions with these base pairs (Hilder and Hodgkiss,
2017). These findings may serve as an explanation for the hormonal
receptor independent character of a wide range of estrogen-related
potential antiproliferative molecules including our present analogs.
Since the requirements of binding to the estrogen receptors are well-
established, it is also known that a methlyl substitution at C-3 by itself is
sufficient for the loss of the estrogenic activity (Anstead et al., 1997).
Another opportunity to configure estrogen derivatives with low re-
ceptor binding affinities (RBA) is the specific substitution at C-16 with a
polar or large group, such as hydroxymethyl. The compounds we ex-
amined contain a benzyloxy function at C-3 and a hydroxymethyl at C-
16, therefore the lack of hormonal activity can be expected. This feature
of the isomers of 16-hydroxymethyl-3,17-estradiol analogs was con-
firmed by radioligand-binding assays (Tapolcsányi et al., 2002). Pre-
viously we have reported on the antiproliferative action of estradiol-
based compounds containing several distinct modifications at C-3 and
C-16. The 16-triazole compounds of the 13α-estrone series were found
to be effective against seven different cancer cell lines (Mernyák et al.,
2015). Furthermore, a set of 16-hydroxymethyl-3-methoxy- and 16-
hydroxymethyl-3-benzyloxy-13α-estradiol derivatives were demon-
strated to exert potent anticancer activity against several gynecological
cell lines (Kiss et al., 2018).
These previous accomplishments have encouraged us to continue
the experiments with estradiol-derivatives, leading to the examination
of the growth-inhibitory potential of a set of 16-hydroxymethyl-estra-
diols against various human adherent breast cancer cell lines.
Based on our data, the configurations of the substituents at positions
16–17 have a limited role in the agents' antiproliferative potency, while
the benzyloxy function with p-substituent at position C-3 enhance the
antiproliferative effect. Concerning the antiproliferative activities of the
tested agents compound 5 proved to be the most potent and in terms of
acting on non-cancerous cells it was comparable with cisplatin, which is
currently used in breast cancer therapy protocols (Carey, 2015).
Although 5 and its precursor molecule 1 showed appreciable
growth-inhibitory effects against all of the cell lines examined (MCF-7,
MDA-MB-231, MDA-MB-361, T47D), our primary purpose was to
characterize its effects and mechanism of action against MDA-MB-231,
a triple-negative breast tumor cell line. In spite of the different re-
ceptorial status of the utilized cancer cell lines the IC50 values de-
termined for a given agent were not crucially different. The aim of our
study was to describe antiproliferative actions which are unrelated to
receptorial status and our experimental system was optimized for this
purpose. The medium contained phenol red which has some estrogenic
action and it was also supplemented with usual fetal bovine serum in-
stead of charcoal stripped fetal bovine serum which contains no re-
sidual steroids.
Performing cell cycle analyses by flow cytometry revealed that
treatment with these agents caused G1 phase accumulation with sig-
nificantly elevated apoptotic cell population. These results are in line
with previously described G1 blockades by estradiol-related compounds
such as two unsubstituted 16-oxime estrone analogues and oxadiazole
derivatives of estrone (Berényi et al., 2013; Mernyák et al., 2013).
Approximately 90% of human cancer deaths are related to cancer
metastases (Mehlen and Puisieux, 2006). This multi-step process in-
volves local migration and invasion of tumor cells into adjacent tissues,
entering into the vasculature, surviving and leaving the circulation
system, with subsequent proliferation in distant organs that leads to
colonization (Eger and Mikulits, 2005). Therefore, besides the cytotoxic
and apoptosis-inducing approaches currently utilized in oncotherapy,
innovative drugs with an antimetastatic capacity are eagerly needed to
control cancer-related mortality. Besides their antiproliferative activity,
the compounds tested in our experiments also inhibited cell migration
and invasion, the initial steps of metastatic spread. Moreover, this sig-
nificant reduction in cell migration was observed at a sub-anti-
proliferative concentration as low as 0.25 μM, after treatment for 24 h.
The inhibitory action of compound 1 on cell invasion capacity proved
to be more pronounced as determined by the Boyden chamber assay.
The role of matrix metalloproteinases (MMPs), a family of zinc-de-
pendent endopeptidases have been extensively investigated, since their
expression and activity are increased in almost all human cancer
compared with normal tissue (Egeblad and Werb, 2002). The increased
expression of MMP-2 and MMP-9 at the mRNA level was demonstrated
in MDA-MB-231 cells compared to normal HS578Bst breast cells.
Moreover, high expression of MMP-2 and MMP-9 in cancerous breast
tissues has a close correlation with lymph node metastasis and tumor
staging (Li et al., 2017). Based on our results of the gelatin zymography
assay, none of the examined compounds influenced substantially the
level of MMP-2 and MMP-9, indicating that these metalloproteinases
are not crucially involved in the mechanism of action of 1 and 5.
Focal adhesion kinase (FAK) is expressed in most cell types and
tissues and has a complex function in various processes including cell
spreading, differentiation, cell cycle, migration and cell death. The
activation of FAK principally occurs via autophosphorylation on tyr-
osine 397 by clustering of integrins (McLean et al., 2005). Several
studies have demonstrated its role in the regulation of cell migration.
The up-regulation of FAK was reported in various cancer types, in-
cluding malignancy of the breast, and its elevated activity correlates
with metastatic spread and poor prognosis of the disease (Miyazaki
et al., 2003; Recher et al., 2004). In breast cancer, FAK overexpression
is regarded as an early event in tumorigenesis which precedes cell in-
vasion and metastasis in ductal carcinoma in situ (DCIS) (Lightfoot Jr.
et al., 2004). On the contrary, the lack of FAK-activity is reported to
result in poor cell migration in response to chemotactic and haptotactic
signals, while overexpression of FAK increases cell migration in Chinese
hamster ovary (CHO) cells (Parsons et al., 2000). Our present com-
pounds decreased the level of pFAK (Y397) in a concentration-depen-
dent manner, whereas total FAK level was unaffected, demonstrating
that the phosphorylation of the kinase enzyme was inhibited. These are
the first reported estrogen-related compounds which proved to be ef-
fective in the inhibition of FAK phosphorylation.
In summary, our study revealed that 3-substituted C16-hydro-
xymethyl-estradiols are potent antiproliferative agents against breast
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cancer cell lines. In MDA-MB-231 triple-negative cell lines 2 test com-
pounds caused programmed cell death and G1 phase elevation.
Furthermore, the molecules significantly and concentration-depen-
dently inhibited cell migration and invasion, as well as the phosphor-
ylation of focal adhesion kinase in sub-antiproliferative concentration.
These results indicate that modified estradiol-derivatives can be re-
garded as promising candidates in the design of new anticancer agents.
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A B S T R A C T
The reduction of 16-hydroxymethylene-3-methoxy-13α-estra-1,3,5(10)-trien-17-one (14) and 16-hydro-
xymethylene-3-benzyloxy-13α-estra-1,3,5(10)-trien-17-one (16) yielded a mixture of two diastereomeric diols,
the 16α-hydroxymethyl,17β-hydroxy and 16β-hydroxymethyl,17α-hydroxy isomers (17a-20a) in a ratio of 6:1.
We describe a straightforward synthetic route to transform the isomers with trans functional groups attached to
ring D (17a-20a) into isomers with cis functional groups (25a-28a).
We determined the in vitro antiproliferative activities of compounds 17a–20a and 25a–28a by means of MTT
assays against a panel of human adherent cancer cell lines HeLa, A2780, MCF-7, T47D, MDA-MB-231 and MDA-
MB-361.
1. Introduction
Breast cancer is the most frequently diagnosed cancer in women
worldwide [1]. Since estrogens are known to play a role in the devel-
opment of many breast cancers, a logical approach to the treatment of
estrogen-sensitive breast cancer is the use of anti-estrogens that block
the interaction of estrogens with their specific receptor. The literature
provides evidence that inversion of the configuration of estra-1,3,5(10)-
trien-17-one at C-13 may lead to the loss of estrogenic activity [2,3].
These investigations revealed that the C-13 epimers of estradiols pos-
sess low affinity for the estrogen receptor, with no uterotropic activity
when tested on mice. The probable explanation of the negligible re-
ceptor binding ability of the 13-epi-estradiols of ring C and D [4]. 13α-
Estrone is readily available from natural estrone by the epimerization
method developed by Yaramenko and Khvat, using 1,2-phenylenedia-
mine and acetic acid [5]. As 13α-estradiols possess low affinity for the
estrogen receptor and are readily available, we have chosen these
compounds as scaffolds for the design of 13α-estrone derivatives as
potential antitumor agents.
Hydrophilic functional groups attached to ring D in the steroid
skeleton have strong effect on biological properties of these compounds.
Earlier we reported preparation and configuration determinations of
the four possible isomers of 16-hydroxymethyl-estra-1,3,5(10)-trien-
3,17-diol [6], and their 3-methyl [7,8] and 3-benzyl ethers [6].
We describe here the preparation of four possible isomers of 16-
hydroxymethyl-3-methoxy- and 16-hydroxymethyl-3-benzyloxy-13α-
estra-1,3,5(10)-trien-17-ols (17a-20a and 25a-28a).
The reduction of 16-hydroxymethylene-3-methoxy-13α-estra-
1,3,5(10)-trien-17-one (14) and 16-hydroxymethylene-3-benzyloxy-
13α-estra-1,3,5(10)-trien-17-one (16) with NaBH4 in ethanol yielded a
mixture of two diastereomeric diols 17a-20a in a 6:1 ratio. The si-
multaneous development of the two chiral centers permits formation of
the four isomers (17a-20a and 25a-28a). However, only two isomers
(17a-20a) were detected by thin-layer chromatography [9,10].
Here, we describe a straightforward synthetic route to transform the
isomers with trans functional groups attached to ring D (17a-20a) into
isomers with cis functional groups (25a-28a).
We set out to obtain answers to the following questions: (1) how the
antiproliferative activities in the 16-hydroxymethyl-13α-estrane-3-
methoxy- and 16-hydroxymethyl-3-benzyloxy series differ, and (2) how
the antiproliferative activities are influenced by the relative steric po-
sitions of the 16-hydroxymethyl and 17-hydroxy groups.
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2. Experimental
2.1. General
Melting points (mp) were determined on Kofler block and are un-
corrected. Specific rotations were measured in CHCl3 (c 1 in CHCl3) at
20 °C with a POLAMAT-A (Zeiss-Jena) polarimeter and are given in
units of 10−1 deg cm2 g−1. Elementary analysis data were determined
with PerkinElmer CHN analyzer model 2400. The reactions were
monitored by TLC on Kieselgel (Merck Si 254 F) layers (0.25 mm thick);
solvent system: (A) acetone/toluene/hexane (30:35:35 v/v), (B) diiso-
propyl ether. The spots were detected by spraying with 5% phospho-
molybdic acid in 50% aqueous H3PO4. The Rf values were determined
for the spots observed by illumination at 254 and 365 nm. Flash chro-
matography: silica gel 60, 40–63 μm. All solvents were freshly distilled
prior to use. NMR spectra were recorded on a Bruker DRX 500 instru-
ment at 500 (1H NMR) or 125MHz (13C NMR). Chemical shifts are
reported in ppm (δ scale), and coupling constants (J) are in Hz. For the
determination of multiplicities, the J-MOD pulse sequence was used.
2.2. 3-Methoxy-13α-estra-1,3,5(10)-trien-17-one (13)
A mixture of compound 1 (25 g, 87.9 mmol) in acetic acid (250ml)
and o-phenylenediamine (13.5 g, 125mmol) was treated at reflux
temperature for 3 h. After cooling, the mixture was slowly poured onto
ice and the resulting precipitate was filtered off, washed with water and
dried. The solid was dissolved in CH2Cl2 (300ml), the solution was
washed with water (3×250ml), dried (Na2SO4) and the solvent eva-
porated. The crude product was dissolved in methanol (200ml) and
Girard-P reagent (18.8 g, 100mmol) and acetic acid (20ml) were added
to the solution. The reaction mixture was heated at reflux for 3 h, and
then allowed to stand at room temperature overnight. After white
crystals formed, the mixture was neutralized with a dilute Na2CO3 so-
lution. The precipitate was filtered off and dissolved in CH2Cl2
(250ml), the solution was washed with water (3×250ml), dried
(Na2SO4) and the solvent evaporated Yield of pure 13: 23.7 g (95%). It
is identical with the compound described in ref. [9].
2.3. 16-Hydroxymethylidene-3-methoxy-13α-estra-1,3,5(10)-trien-17-one
(14)
Compound 13 (25 g, 88mmol) was dissolved in anhydrous toluene
(200ml), then NaOMe (9.5 g, 0.18mmol) and freshly distilled ethyl
formate (100ml, 1.3mol) were added to the solution. The mixture was
stirred for 6 h at 50 °C and allowed to stand overnight at room tem-
perature. It was then diluted with water (1000ml) and carefully poured
onto a mixture of ice (100 g) and concentrated HCl (25ml). The white
precipitate separating out was filtered off, washed thoroughly with
water and dried. Recrystallization from CH2Cl2/hexane gave 14 (25.2 g,
90%). Mp: 103–107 °C; Rf = 0.70 (ss A); [α]D25=+72 (c 1 in CHCl3).
(Found: C, 76.93; H, 7.52. C20H24O3 (312.17) requires: C, 76.89; H,
7.74%). 1H NMR (δ, ppm, CDCl3): 1.12 (s, 3H, 18-H3), 2.82 (m, 2H, 6-
H2), 3.76 (s, 3H, 3-OCH3), 6.60 (s, 1H, 4-H), 6.70 (d, 1H, J=8.5 Hz, 2-
H), 7.10 (s, 1H, 16-CH), 7.19 (d, 1H, J=8.5 Hz, 1-H). 13C NMR (δ,
ppm, CDCl3): 25.3 (C-18), 25.7, 28.2, 28.6, 30.4, 31.6, 41.2, 41.9, 48.9,
50.8 (C-13), 55.2 (3-OCH3), 62.1, 111.1 (C-16), 111.7 (C-2), 113.5 (C-
4), 126.8 (C-1), 131.9 (C-10), 138.0 (C-5),157.5 (C-3), 159.3 (16-CH),
213.9 (C-17).
2.4. 16α-Hydroxymethyl-3-methoxy-13α-estra-1,3,5(10)-trien-17β-ol
(17a) and 16β-hydroxymethyl-3-methoxy-13α-estra-1,3,5(10)-trien-17α-
ol (18a)
Compound 14 (15 g, 48mmol) was suspended in MeOH (300ml)
and then KBH4 (13 g, 240mmol) was added in small portions at room
temperature. The mixture was allowed to stand for 6 h, then poured
onto ice (1000 g) and acidified with dilute HCl to pH 3. The precipitate
separating out was filtered off, washed until free from acid and dried.
The mixture obtained consisted of diols 17a and 18a in a ratio of 6:1
(yield 15 g, 98%) [9].
2.5. 17β-Hydroxy-3-methoxy-13α-estra-1,3,5(10)-trien-16α-ylmethyl
acetate (17b) and 17α-hydroxy-3-methoxy-13α-estra-1,3,5(10)-trien-16β-
ylmethyl acetate (18b)
A mixture of 17a and 18a (10 g, 31.6 mmol) was dissolved in pyr-
idine (40ml) and a solution of Ac2O (3.2ml, 32 mmol) in pyridine
(60ml) was added dropwise with cooling in salt-ice bath. The mixture
was allowed to stand for 5 h at room temperature, and then poured onto
a mixture of ice (400 g) and concentrated H2SO4 (40ml). The pre-
cipitate separating out was filtered off and dissolved in CH2Cl2 (60ml).
The solution was washed with water, dried over Na2SO4 and evapo-
rated in vacuo. The residue obtained was subjected to chromatographic
separation (silica gel, hexane/CH2Cl2 (75:25, v/v)) to give 17c and 18c
as oil (2.4 g, 18.8%). Continued elution with CH2Cl2 and CH2Cl2/ethyl
acetate (95:5, v/v) resulted in 17b as a white powder (5.6 g, 50%), 18b
as an oil (1.1 g, 10%), and a residual mixture of 17a and 18a (2.0 g,
20%). After alkaline methanolysis of the mixture of diacetates (17c and
18c), the resulting mixture of diols (17a and 18a) was recycled.
17b: Mp: 104–105 °C; Rf = 0.45 (ss A); [α]D25=+91 (c 1 in
CHCl3). (Found: C, 73.86; H, 8.32. C22H30O4 (358.48) requires: C,
73.71; H, 8.44%). 1H NMR (δ, ppm, CDCl3): 1.08 (s, 3H, 18-H3), 2.08 (s,
3H, Ac-H3), 2.78 (m, 2H, 6-H2), 3.77 (s, 3H, 3-OCH3), 4.17 (m, 2H, 16a-
H2), 6.60 (s, 1H, 4H); 6.72 (t, 1H, J=6.0 Hz, 2-H), 7.16 (d, 1H,
J=8.5 Hz, 1-H). 13C NMR (δ, ppm, CDCl3): 21.0 (C-18), 27.9, 28.8,
29.0, 29.3 (Ac-CH3), 30.4, 38.5, 40.8, 43.5 (C-13), 44.9, 50.2, 55.2 (3-
OCH3), 66.9 (C-16a), 84.6 (C-17), 112.0 (C-2), 113.2 (C-4), 127.5 (C-1),
133.6 (C-10), 137.9 (C-5), 157.2 (C-3), 171.3 (Ac-C=O). 18b: Oil;
Rf = 0.40 (ss A); [α]D25=+19 (c 1 in CHCl3). (Found: C, 73.92; H,
8.25. C22H30O4 (358.48) requires: C, 73.71; H, 8.44%). 1H NMR (δ,
ppm, CDCl3): 0.98 (s, 3H, 18-H3), 2.03 (s, 3H, Ac-H3), 2.79 (m, 2H, 6-
H2), 3.78 (s, 3H, 3-OCH3), 3.94 (m, 1H, 17-H), 4.10 (dd, 1H,
J=10.9 Hz, J=6.1 Hz, 16a-H2), 4.20 (dd, 1H, J=10.9 Hz,
J=5.5 Hz, 16-H2), 6.62 (d, 1H, J=2.7 Hz, 4-H), 6.73 (dd, 1H,
J=8.6 Hz, J=2.7 Hz, 2-H), 7.23 (d, 1H, J=8.6 Hz, 1-H). 13C NMR (δ,
ppm, CDCl3): 20.8 (Ac-CH3), 22.9 (C-18), 26.5, 28.1, 28.3, 30.4, 33.0,
42.1, 42.3, 43.2, 43.8 (C-13). 48.7, 55.0 (3-OCH3), 67.5 (C-16a), 75.8
(C-17), 111.7 (C-2), 113.5 (C-4), 126.8 (C-1), 132.1 (C-10), 137.9 (C-5),
171.1 (Ac-C=O).
2.6. 3-Methoxy-17-oxo-13α-estra-1,3,5(10)-trien-16α-ylmethyl acetate
(21)
Compound 17b (2 g, 5.6 mmol) was dissolved in acetone (50ml),
and Jones reagent (2 ml) was added dropwise with cooling in ice. The
reaction mixture was poured onto ice and the precipitate separating out
was filtered off and dried. The substance obtained was crystallized from
acetone/hexane to give pure 21 (1.1 g, 57%). Mp: 117–119 °C;
Rf = 0.60 (ss A); [α]D25=−21 (c 1 in CHCl3). (Found: C, 74.35; H,
8.04. C22H28O4 (356.48) requires: C, 74.13; H, 7.92%). 1H NMR (δ,
ppm, CDCl3): 1.04 (s, 3H, 18-H3), 2.04 (s, 3H, Ac-H3), 2.84 (s, 2H, 6-
H2), 3.76 (s, 3H, 3-OCH3), 4.29 (d, 2H, J=3.0 Hz, 16a-H2), 6.61 (s, 1H,
4-H), 6.70 (d, 1H, J=6.5 Hz, 2-H), 7.18 (d, 1H, J=8.0 Hz, 1-H). 13C
NMR (δ, ppm, CDCl3): 20.8 (C-18), 24.5 (Ac-CH3), 25.5, 28.4, 28.5,
30.3; 32.8, 41.4 (C-8), 41.9 (C-9), 45.2 (C-14), 47.6 (C-16), 50.2 (C-13),
55.2 (3-OCH3), 63.3 (C-16a), 111.7 (C-2), 113.6 (C-4), 126.9 (C-1),
131.7 (C-10), 137.9 (C-5), 157.5 (C-3), 170.8 (Ac-C=O), 219.7 (C-
17C=O).
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2.7. 3-Methoxy-17-oxo-13α-estra-1,3,5(10)-trien-16β-ylmethyl acetate
(22)
Compound 18b (2 g, 5.6mmol) was dissolved in acetone (100ml)
and a solution of Jones reagent (2 ml) was added dropwise with cooling
in ice. The mixture was poured onto ice. The oily substance separating
out was extracted with CH2Cl2, dried over Na2SO4 and evaporated in
vacuo, giving product 22 (1.2 g, 60%). Mp: 144–145 °C; Rf = 0.60 (ss
A); [α]D25=−18 (c 1 in CHCl3). (Found: C, 74.35; H, 8.04. C22H28O4
(356.48) requires: C, 74.13; H, 7.92%). 1H NMR (δ, ppm, CDCl3): 0.90
(s, 3H, 18-H3), 2.04 (s, 3H, Ac-H3), 2.90 (m, 2H, 6-H2), 3.78 (s, 3H, 3-
OCH3), 4.33 (s, 2H, 16a-H2), 6.65 (s, 1H, 4-H), 6.72 (d, 1H, J=7.5 Hz,
2-H), 7.20 (d, 1H, J=8.5 Hz, 1-H). 13C NMR (δ, ppm, CDCl3): 13.1 (Ac-
CH3), 20.8 (C-18), 25.7, 25.9, 26.7, 29.6, 31.9, 37.8, 44.1, 48.2 (C-13),
48.8, 48.9, 55.2 (3-OCH3), 63.1 (C-16a), 111.6 (C-2), 113.9 (C-4), 126.2
(C-1), 131.9 (C-10), 137.6 (C-5), 157.6 (C-3), 170.7 (Ac-C=O), 218.8
(C-17C=O).
2.8. 16α-Hydroxymethyl-3-methoxy-13α-estra-1,3,5(10)-trien-17α-ol
(25a)
LiAlH4 (1.2 g, 32mmol) was suspended in anhydrous diethyl ether
(100ml), then t-BuOH (9ml, 96mmol) was added carefully during
stirring and cooling with salt-ice. Compound 21 (2.3 g, 6.4mmol) dis-
solved in diethyl ether (100ml) was added dropwise to the suspension.
The reaction mixture was stirred for 3 h and was decomposed by the
careful addition of water (75ml) during stirring and cooling. Next, it
was acidified with dilute HCl to pH 5. The organic phase was separated
and the aqueous phase was extracted with diethyl ether. The substance
obtained on washing, drying and evaporation of the solvent was sub-
jected to chromatographic separation on silica gel with CH2Cl2/ethyl
acetate (99:1, v/v) to give pure compound 25a (630mg, 31%). Mp:
124–125 °C; Rf = 0.35 (ss A); [α]D25=+22 (c 1 in CHCl3). (Found:
76.03; H, 8.74. C20H28O3 (316.44) requires: C, 75.91; H, 8.92%). 1H
NMR (δ, ppm, CDCl3): 1.03 (s, 3H, 18-H3), 2.81 (d, 2H, J=5.0 Hz, 6-
H2), 3.78 (s, 3H, 3-OCH3), 6.62 (s, 1H, 4-H), 6.72 (d, 1H, J=7.0 Hz, 2-
H), 7.22 (d, 1H, J=8.5 Hz, 1-H). 13C NMR (δ, ppm, CDCl3): 23.7 (C-
18), 26.9, 28.7, 30.4, 34.1, 41.7, 40.7, 40.7, 44.7 (C-13), 50.2 (C-16),
55.2 (3-OCH3), 64.4 (C-16a), 76.2 (C-17), 111.7 (C-2), 113.5 (C-4),
126.9 (C-1), 132.5 (C-10), 138.2 (C-5), 157.4 (C-3). Further elution
with CH2Cl2/ethyl acetate (95:5) gave 17a (1.35 g, 67%).
2.9. 16α-Hydroxymethyl-3-methoxy-13α-estra-1,3,5(10)-trien-17α-ol
acetonide (25c)
Compound 25a (663mg, 2mmol) was dissolved in acetone (10ml)
in the presence of a catalytic amount of p-toluenesulfonic acid. The
reaction mixture was treated at reflux temperature for 1 h. It was then
neutralized with morpholine, diluted with CH2Cl2 (50ml) and washed
with water. The organic layer was dried over Na2SO4 and evaporated in
vacuo. Recrystallization from methanol gave compound 25c (680mg,
95%). Mp: 138–140 °C; Rf = 0.85 (ss B); [α]D25=+18 (c 1 in CHCl3).
(Found: C, 77.68; H, 8.92. C23H32O3 (356.50) requires: C, 77.49; H,
9.05%). 1H NMR (δ, ppm, CDCl3): 1.08 (s, 3H, 18-H3), 1.35 and 2.80
(two s, 6H, (CH3)2C), 2.80 (m, 2H, 6-H2), 3.78 (s, 3H, 3-OCH3), 6.61 (s,
1H, 4-H), 6.73 (d, 1H, J=8.5 Hz, 2-H), 7.20 (d, 1H, J=8.5 Hz, 1-H).
13C NMR (δ, ppm, CDCl3): 22.7 and 24.2 (two C, (CH3)2C), 27.0, 27.8
(C-18), 29.0, 30.1, 30.4, 33.2, 37.1, 40.1, 40.8, 45.1 (C-13), 50.7, 55.2
(3-OCH3), 75.1 (C-17), 98.2 (C-20), 111.9 (C-2), 113.4 (C-4), 127.1 (C-
1), 133.2 (C-10), 138.0 (C-5), 157.3 (C-3).
2.10. 16α-Hydroxymethyl-3-methoxy-13α-estra-1,3,5(10)-trien-17α-ol
phenylboronate (25d)
Compound 25a (95mg, 0.3mmol) was dissolved in ethanol (5 ml)
and phenylboronic acid (45mg, 0.3mmol) was added. The precipitate
formed in 15min was filtered off and dried (25d: 116mg, 86%). Mp:
128–130 °C; Rf = 0.70 (ss B); [α]D25=+8.5 (c 1 in CHCl3). (Found: C,
77.86; H, 7.98. C26H31BO3 (402.35) requires: C, 77.62; H, 7.77%). 1H
NMR (δ, ppm, CDCl3): 1.36 (s, 3H, 18-H3), 2.77 (m, 2H, 6-H2), 3.64 (d,
1H, J=10.5 Hz, 16a-H2), 3.78 (s, 3H, 3-OCH3), 3.90 (t, 1H,
J=10.5 Hz, 16a-H2), 4.33 (dd, 1H, J=10.5 Hz, J=5.0 Hz, 17-H),
6.59 (s, 1H, 4-H), 6.74 (dd, 1H, J=8.5 Hz, J=2.0 Hz, 2-H), 7.15 (d,
1H, J=8.5 Hz, 1-H), 7.36 (t, 2H, J=7.0 Hz, 3′- and 5′-H), 7.41 (t, 1H,
J=7.5 Hz, 1′-H), 7.82 (d, 2H, J=7.5 Hz, 2′-H and 6′-H).
2.11. 17α-Hydroxy-3-methoxy-13α-estra-1,3,5(10)-trien-16α-ylmethyl p-
toluenesulfonate (29)
Compound 25a (316mg, 1mmol) was dissolved in anhydrous pyr-
idine (10ml) and then a solution of p-toluenesulfonyl chloride (285mg,
1.5 mmol) in anhydrous pyridine (5 ml) was added dropwise during
cooling with ice. The reaction mixture was allowed to stand for 24 h
and then poured onto a mixture of ice (100 g) and sulfuric acid (5ml).
The precipitate separating out was filtered off and recrystallized from a
mixture of acetone/hexane to give 29 (415mg, 88%). Mp: 120–123 °C;
Rf = 0.55 (ss A). (Found: C, 69.05; H, 7.36. C27H34O5S (470.63) re-
quires: C, 68.90; H, 7.28%). 1H NMR (δ, ppm, CDCl3): 0.96 (s, 3H, 18-
H3), 2.45 (s, 3H, Ts-H3), 2.78 (m, 2H, 6-H2), 3.77 (s, 3H, 3-OCH3), 4.06
(dd, 1H, J=9.0 Hz, J=7.0 Hz, 16a-H2), 4.12 (d, 1H, J=9.0 Hz, 17-
H), 4.28 (dd, 1H, J=9.0 Hz, J=7.0 Hz, 16a-H2), 6.60 (s, 1H, 4-H),
6.71 (dd, 1H, J=9.0 Hz, J=2.5 Hz, 2-H), 7.18 (d, 1H, J=8.5 Hz, 1-
H), 7.35 (d, 2H, J=8.0 Hz, 3′-H and 5′-H), 7.80 (d, 2H, J=8.0 Hz, 2′-
H and 6′-H). 13C NMR (δ, ppm, CDCl3): 21.6 (C-18), 23.3 (Ts-CH3),
26.8, 28.8, 30.2, 30.3, 33.1, 39.2, 40.5, 40.7, 44.8 (C-13), 49.7 (C-14),
55.2, 71.9 (C-16a), 75.4 (C-17), 111.9 (C-2), 113.4 (C-4), 127.0 (C-1),
129.8 (C-2′ and C-6′), 132.6 (C-3′ and C-5′), 132.6 (C-16), 133.1 (C-1′),
138.0 (C-5), 144.7 (C-4′), 157.4 (C-3).
2.12. 17α,16α-Epoxymethano-3-methoxy-13α-estra-1,3,5(10)-triene (33)
Compound 29 (380mg, 1mmol) was dissolved in methanol (15ml)
and heated at reflux with NaOCH3 (162mg, 3mmol) for 2 h. The re-
action mixture was diluted with water, the precipitate separating out
was filtered off, dried and crystallized from a mixture of acetone/
hexane to give 33 (265mg, 88%). Mp: 115–116.5 °C; Rf = 0.75 (ss A);
[α]D25=+19 (c 1 in CHCl3). (Found: C, 80.76; H, 8.92. C20H26O2
(298.42) requires: C, 80.50; H, 8.78%). 1H NMR (δ, ppm, CDCl3): 1.25
(s, 3H, 18-H3), 2.80 (m, 2H, 6-H2), 3.19 (m, 1H, 16-H), 3.77 (s, 3H, 3-
OCH3), 4.15 (t, 1H, J=6.0 Hz, 16a-H2), 4.77 (t, 1H, J=6.0 Hz, 16a-
H2), 4.84 (d, 1H, J=6.0 Hz, 17-H), 6.60 (d, 1H, J=2.0 Hz, 4-H); 6.72
(dd, 1H, J=8.5 Hz, J=2.5 Hz, 2-H); 7.19 (d, 1H, J=8.5 Hz, 1-H). 13C
NMR (δ, ppm, CDCl3): 23.3 (C-18), 27.2, 29.1, 30.5, 32.1, 35.8, 37.3,
39.2, 42.4, 45.2 (C-13), 53.4, 55.2, (3-OCH3), 75.8 (C-16a), 94.2 (C-17),
111.8 (C-2), 113.4 (C-4), 127.2 (C-1), 133.0 (C-10), 137.9 (C-5), 157.3
(C-3).
2.13. 16β-Hydroxymethyl-3-methoxy-13α-estra-1,3,5(10)-trien-17β-ol
(26a)
Compound 22 (356mg, 1mmol) was dissolved in methanol (15ml)
and NaBH4 (378mg, 10mmol) was added in small portions at room
temperature. The reaction mixture was allowed to stand for 24 h, then it
was diluted with water and the precipitate was collected by filtration
and recrystallized from acetone/hexane to obtain 26a (260mg, 82%).
Mp: 104–106 °C; Rf = 0.30 (ss A); [α]D25=+24 (c 1). (Found: C,
75.83; H, 8.77. C20H28O3 (316.44) requires: C, 75.91; H, 8.92%). 1H
NMR (δ, ppm, CDCl3): 0.95 (s, 3H, 18-H3), 2.79 (m, 2H, 6-H2), 3.72 (t,
1H, J=7.5 Hz, 17-H), 3.77 (s, 3H, 3-OCH3), 3.85 (d, 1H, J=3.0 Hz,
16a-H2), 3.88 (d, 1H, J=4.5 Hz, 16a-H2), 6.60 (s, 1H, 4-H), 6.71 (d,
1H, J=7.0 Hz, 2-H), 7.19 (d, 1H, J=8.5 Hz, 1-H). 13C NMR (δ, ppm,
CDCl3): 28.9, 29.3, 30.0 (C-18), 30.4, 30.5, 32.1, 40.2, 43.3, 43.3, 45.3
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(C-13), 51.2, 55.1 (3-OCH3), 63.1 (C-16a), 85.4 (C-17), 111.8 (C-2),
113.3 (C-4), 127.4 (C-1), 133.2 (C-10), 138.3 (C-5), 157.2 (C-3).
2.14. 16β-Hydroxymethyl-3-methoxy-13α-estra-1,3,5(10)-trien-17β-ol
acetonide (26c)
Compound 26a (663mg, 2mmol) was dissolved in acetone (10ml)
in the presence of a catalytic amount of p-toluenesulfonic acid. The
reaction mixture was treated at reflux temperature for 1 h. It was then
neutralized with morpholine, the solution was diluted with CH2Cl2
(50ml) and washed with water. The organic layer was dried over
Na2SO4 and evaporated in vacuo. Recrystallization from methanol gave
compound 26c (665mg, 93%). Mp: 137–139 °C; Rf = 0.80 (ss B);
[α]D25=+15.5 (c 1 in CHCl3). (Found: C, 77.58; H, 9.23. C23H32O3
(356.50) requires: C, 77.49; H, 9.05%). 1H NMR (δ, ppm, CDCl3): 1.23
(s, 3H, 18-H3), 1.36 and 2.17 (two s, 6H, (CH3)2C), 3.14 (m, 2H, 6-H2),
3.77 (s, 3H, 3-OCH3), 6.60 (d, 1H, J=3.0 Hz, 4-H), 6.71 (dd, 1H,
J=9.0 Hz, J=3.0 Hz, 2-H), 7.19 (dd, 1H, J=17.0 Hz, J=9.0 Hz, 1-
H). 13C NMR (δ, ppm, CDCl3): 8.6, 19.8 (C-18), 28.5, 29.7, 29.8, 30.8,
32.5, 33.7, 36.4, 41.2, 44.5, 46.2, 51.5, 55.1, 55.2 (3-OCH3), 62.1 (C-
16a), 81.7 (C-17), 98.1 (C-20), 111.7 (C-2), 113.3 (C-4), 127.5 (C-1),
133.2 (C-10), 138.5 (C-5), 157.1 (C-3).
2.15. 16β-Hydroxymethyl-3-methoxy-13α-estra-1,3,5(10)-trien-17β-ol
phenylboronate (26d)
Compound 26a (79mg, 0,25mmol) was dissolved in ethanol (5 ml)
and phenlyboronic acid (38mg, 0.25mmol) was added. The precipitate
formed in 15min was filtered off and dried (26d: 125mg, 93%). Mp:
87–89 °C; Rf = 0.75 (ss B); [α]D25=+6 (c 1 in CHCl3). (Found: C,
77.83; H, 7.96. C26H31BO3 (402.35) requires: C, 77.62; H, 7.77%). 1H
NMR (δ, ppm, CDCl3,): 1.16 (s, 3H, 18-H3), 2.81 (m, 2H, 6-H2), 3.79 (s,
3H, 3-OCH3), 3. 87 (dd, 1H, J=11.0 Hz, J=7.0 Hz, 16a-H2), 4.23 (d,
1H, J=7.0 Hz, 17-H), 4.27 (dd, 1H, J=6.0 Hz, J=11.0 Hz, 16a-H2),
6.62 (s, 1H, 4-H), 6.75 (dd, 1H, J=1.5 Hz, J=8.0 Hz, 2-H), 7. 21 (d,
1H, J=8.5 Hz, 1-H), 7. 37 (t, 2H, J=7.5 Hz, 3′-H and 5′-H), 7. 43 (d,
1H, J=7.5 Hz, 4′-H), 7.86 (d, 2H, J=7.5 Hz, 2′-H and 6′-H). 13C NMR
(δ, ppm, CDCl3): 23.8 (C-18), 26.7, 29.1, 30.4, 30.5, 32.4, 35.9, 39.3,
41.4, 45.2 (C-13), 49.5, 55.2 (3-OCH3), 63.9 (C-16a), 78.5 (C-17), 112.0
(C-2), 113.3 (C-4), 127.4 (C-1), 127.5 (C-2′ and C-6′), 130.6 (C-4′),
133.2 (C-10), 133.9 (C-3′ and C-5′), 137.8 (C-5), 157.3 (C-3).
2.16. 17β-Hydroxy-3-methoxy-13α-estra-1,3,5(10)-trien-16β-ylmethyl p-
tolenesulfonate (30)
Compound 26a (316mg, 1mmol) was dissolved in anhydrous pyr-
idine (10ml) and then a solution of p-toluenesulfonyl chloride (285mg,
1.5 mmol) in anhydrous pyridine (5 ml) was added dropwise during
cooling with ice. The reaction mixture was allowed to stand for 24 h
and then poured onto a mixture of ice (100 g) and sulfuric acid (5ml).
The precipitate was filtered, dissolved in dichloromethane and chro-
matographed on silica gel with a mixture of dichloromethane/hexane
(1:1, v/v) to obtain 30 (340mg, 72%). Mp: 138–140 °C; Rf = 0.50 (ss
A). (Found: 68.98; H, 7.41. C27H34O5S (470.63) requires: C, 68.90; H,
7.28%). 1H NMR (δ, ppm, CDCl3): 0.96 (s, 3H, 18-H3), 2.45 (s, 3H, Ts-
H3), 2.78 (m, 2H, 6-H2), 3.77 (s, 3H, 3-OCH3), 4.07 (dd, 1H,
J=12.0 Hz, J=8.0 Hz, 16a-H2), 4.12 (d, 1H, J=11.0 Hz, 17-H), 4.28
(dd, 1H, J=12.0 Hz, J=8.0 Hz, 16a-H2), 6.60 (d, 1H, J=3.5 Hz, 4-
H), 6.71 (dd, 1H, J=10.5 Hz, J=3.5 Hz, 2-H), 7.18 (d, 1H,
J=10.5 Hz, 1-H), 7.35 (d, 2H, J=10.5 Hz, 3′-H and 5′-H), 7.80 (d, 2H,
J=10.5 Hz, 2′-H and 6′-H). 13C NMR (δ, ppm, CDCl3): 21.6 (C-18),
23.3 (Ts-CH3), 26.8, 28.8, 29.7, 30.3, 30.3, 33.1, 39.2, 40.5, 40.7, 44.8
(C-13), 49.8 (C-14), 55.2, 71.9 (C-16a), 75.5 (C-17), 111.9 (C-2), 113.4,
(C-4), 127.0 (C-1), 127.9 (C-2′ and C-6′), 129.8 (C-3′ and C-5′), 132.6
(C-10), 133.2 (C-1), 138.0 (C-5), 144.7 (C-4′), 157.4 (C-3).
2.17. 17β,16β-Epoxymethano-3-methoxy-13α-estra-1,3,5(10)-triene (34)
Compound 30 (570mg, 1.5mmol) was dissolved in methanol
(15ml) and heated at reflux with NaOCH3 (243mg, 4.5 mmol) for 2 h.
The reaction mixture was diluted with water, the precipitate separating
out was filtered off, dried and crystallized from a mixture of acetone/
hexane to give 34 (390mg, 87%). Mp: 105–106 °C; Rf = 0.80 (ss A);
[α]D25=+28 (c 1 in CHCl3). (Found: C, 8.31; H, 8.96. C20H26O2
(298.42) requires: C, 80.50; H, 8.78%). 1H NMR (δ, ppm, CDCl3): 1.25
(s, 3H, 18-H3), 2.80 (m, 2H, 6-H2), 4.15 (t, 1H, J=5.5 Hz, 16a-H2),
4.77 (t, 1H, J=6.5 Hz, 16a-H2), 4.84 (d, 1H, J=6.5 Hz, 17-H), 6.60
(d, 1H, J=3.0 Hz, 4-H), 6.72 (dd, 1H, J=9.0 Hz, J=3.0, Hz 2-H),
7.19 (d, 1H, J=9.0 Hz, 1-H). 13C NMR (δ, ppm, CDCl3): 23.3 (C-18),
27.2, 29.2, 30.5, 32.1, 35.9, 37.3, 39.2, 42.4, 45.2 (C-13), 53.4, 55.2 (3-
OCH3), 75.8 (C-16a), 94.3 (C-17), 111.8 (C-2), 113.4 (C-4), 124.2 (C-1),
133.0 (C-10), 137.9 (C-5), 157.3 (C-3).
2.18. 16α-Acetoxymethyl-3-methoxy-13α-estra-1,3,5(10)-trien-17β-
acetate (17c), 16β-acetoxymethyl-3-methoxy-13α-estra-1,3,5(10)-trien-
17α-acetate (18c), 16α-acetoxymethyl-3-methoxy-13α-estra-1,3,5(10)-
trien-17α-acetate (25b) and 16β-acetoxymethyl-3-methoxy-13α-estra-
1,3,5(10)-trien-17β-acetate (26b)
2.18.1. General procedure
Compound 17a, 18a, 25a or 26a (150mg, 0.47mmol) was dis-
solved in a mixture of pyridine (3 ml) and acetic anhydride (3 ml) and
the solution was allowed to stand at room temperature for 12 h Then it
was diluted with water and the oil separating out was extracted with
CH2Cl2 (3×15ml). The organic phase was washed with NaHCO3 so-
lution, and then with water, dried and evaporated in vacuo. The residual
oil was chromatographed on silica gel with a mixture of CH2Cl2/hexane
(1:3, v/v). 17c: Oil (186mg, 98%); Rf = 0.65 (ss B); [α]D25=+37.4 (c
1 in CHCl3). (Found: 72.14; H, 8.27. C24H32O5 (400.51) requires: C,
71.97; H, 8.05%). 1H NMR (δ, ppm, CDCl3): 1.08 (s, 3H, 18-H3), 2.00 (s,
3H, Ac-H3), 2.05 (s, 3H, Ac-H3), 2.84 (d, 2H, J=3.0 Hz, 6-H2), 3.79 (s,
3H, 3-OCH3), 4.15 (d, 2H, J=6.0 Hz, 16a-H2), 4.81 (d, 1H J=5.0 Hz,
17-H), 6.63 (s, 1H, 4-H), 6.73 (dd, 1H, J=8.5 Hz, J=2.5 Hz, 2-H),
7.20 (d, 1H, J=8.5 Hz, 1-H). 13C NMR (δ, ppm, CDCl3): 20.9 (Ac-CH3);
21.30 (Ac-CH3), 28.4, 29.1, 29.6, 29.8 (C-18), 30.4, 33.1, 40.4 (C-8),
40.8 (C-9), 44.1 (C-13), 44.7 (C-14), 51.9 (C-16), 55.2 (3-OCH3), 66.4
(C-16a), 84.6 (C-17), 111.9 (C-2), 113.4 (C-4), 127.3 (C-1), 132.7 (C-
10), 138.2 (C-5), 157.4 (C-3), 170.6 (C=O), 171.0 (C=O). 18c: Oil
(179mg, 95%); Rf = 0.65 (ss B); [α]D25= 0.0 (c 1 in CHCl3). (Found: C,
71.63; H, 8.24. C24H32O5 (400.51) requires: C, 71.97; H, 8.05%). 1H
NMR (δ, ppm, CDCl3): 1.02 (s, 3H, 18-H3), 2.00 (s, 3H, Ac-H3), 2.07 (s,
3H, Ac-H3), 2.82 (m, 2H, 6-H2), 3.77 (s, 3H, 3-OCH3), 4.05 (m, 2H, 16a-
H2), 5.30 (d, 1H, J=9.0 Hz, 17-H), 6.61 (d, 1H, J=3.5 Hz, 4-H), 6.71
(dd, 1H, J=8.5 Hz, J=2.5 Hz, 2-H), 7.22 (d, 1H, J=8.5 Hz, 1-H). 13C
NMR (δ, ppm, CDCl3): 20.9 (Ac-CH3), 21.0 (Ac-CH3), 23.8 (C-18), 26.2;
28.3, 30.5, 33.1, 39.7, 42.1, 42.9, 44.1 (C-13), 48.8, 55.2 (3-OCH3),
66.9 (C-16a), 76.5 (C-17), 111.7 (C-2), 113.6 (C-4), 127.0 (C-1), 132.1
(C-10), 137.9 (C-5), 170.7 (C=O), 170.8 (C=O). 25b: Oil (90mg,
95%); Rf = 0.72 (ss B); [α]D25=−5.5 (c 1 in CHCl3). (Found: C, 72.08;
H, 8.28. C24H32O5 (400.51) requires: C, 71.97; H, 8.05%). 1H NMR (δ,
ppm, CDCl3): 1.05 (s, 3H, 18-H3), 2.02 (s, 3H, Ac-H3), 2.06 (s, 3H, Ac-
H3), 2.81 (t, 2H, J=5.0 Hz, 6-H2), 3.77 (s, 3H, 3-OCH3), 4.12 (m, 2H,
16a-H2), 5.34 (d, 1H, J=9.5 Hz, 17-H), 6.61 (s, 1H, 4-H), 6.71 (dd, 1H,
J=8.5 Hz, J=2.5 Hz, 2-H), 7.19 (d, 1H, J=8.5 Hz, 1-H). 13C NMR (δ,
ppm, CDCl3): 20.9 (18-CH3), 20.9 (Ac-CH3), 24.2 (C-18), 26.6, 28.7
(Ac-CH3), 29.3, 30.3, 30.5, 33.4, 36.9 (C-8), 40.5 (C-9), 41.1 (C-14),
44.3 (C-13), 49.7 (C-16), 55.2 (3-OCH3), 65.1 (C-16a), 111.8 (C-2),
113.5 (C-4), 126.9 (C-1), 132.4 (C-10), 137.9 (C-5), 157.4 (C-3), 170.8
(C=O), 170.9 (C=O). 26b: Oil (109mg, 96%); Rf = 0.70 (ss B);
[α]D25=+26 (c 1 in CHCl3). (Found: C, 72.15; H, 8.27. C24H32O5
(400.51) requires: C, 71.97; H, 8.05%). 1H NMR (δ, ppm, CDCl3): 1.08
(s, 3H, 18-H3), 1.98 (s, 3H, Ac-H3), 2.02 (s, 3H, Ac-H3), 2.81 (m, 2H, 6-
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H2), 3.77 (s, 3H, 3-OCH3), 4.01 (dd, 1H, J=11.0 Hz, J=6.5 Hz, 16a-
H2); 4.10 (t, 1H, J=11.0 Hz, 16a-H2), 5.12 (d, 1H, J=5.0 Hz, 17-H),
6.61 (d, 1H, J=3.0 Hz, 4-H), 6.72 (dd, 1H, J=8.5 Hz, J=3.0 Hz, 2-
H), 7.17 (d, 1H, J=8.5 Hz, 1-H). 13C NMR (δ, ppm, CDCl3): 20.8 (Ac-
CH3), 21.2 (Ac-CH3), 28.6, 29.7, 30.0 (C-18), 30.4, 31.3, 32.4, 39.8,
40.2, 43.5, 44.9 (C-13), 55.1 (3-OCH3), 63.9 (C-16a), 83.4 (C-17), 111.9
(C-2), 113.0 (C-4), 127.5 (C-1), 132.8 (C-10), 138.0 (C-5), 157.3 (C-3),
170.4 (C=O), 171.0 (C=O).
2.19. 3-Benzyloxy-13α-estra-1,3,5(10)-trien-17-one (15)
A mixture of compound 3 (25 g, 70 mmol) in acetic acid (200ml)
and o-phenylenediamine (20 g, 183mmol) was treated at reflux tem-
perature for 3 h. After cooling, the mixture was carefully poured onto
ice, the precipitate formed was filtered off, washed with water and
dried. The solid was dissolved in CH2Cl2 (300ml) and the solution was
washed with water (3× 250ml), dried over Na2SO4 and evaporated in
vacuo. The crude product was dissolved in methanol (250ml) and
Girard-P reagent (18.8 g, 100mmol) and acetic acid (20ml) were added
to the solution. The reaction mixture was heated at reflux for 3 h and
then allowed to stand overnight at room temperature. After neu-
tralization with dilute Na2CO3, the precipitate was filtered off. The
precipitate was dissolved in CH2Cl2 (250ml) and the solution was
washed with water (3×250ml) to remove the water-soluble derivative
of residual normal estrone-3-benzyl ether. After drying over Na2SO4,
the solvent was evaporated in vacuo to give 15 (24.4 g, 97%). 15 is
identical with the compound described in ref. [10].
2.20. (Z)-3-Benzyloxy-16-hydroxymethylidene-13α-estra-1,3,5(10)-trien-
17-one (16)
Compound 15 (28 g, 77.7mmol) was dissolved in anhydrous to-
luene (100ml) and then NaOMe (10.6 g, 0.2mmol) and freshly distilled
ethyl formate (100ml, 1.3mmol) were added. The mixture was stirred
for 6 h at 50 °C and allowed to stand overnight at room temperature. It
was then diluted with water (1 L) and carefully poured onto a mixture
of ice (100 g) and concentrated HCl (22ml). The white precipitate se-
parating out was filtered off, washed thoroughly with water and dried.
Recrystallization from CH2Cl2/hexane gave 16 (27.5 g, 91%), as white
crystals. Mp: 180–182 °C; Rf = 0.75 (ss A); [α]D25=−34 (c 1 in
CHCl3). (Found: C, 80.56; H, 7.12. C26H28O3 (388.51) requires: C,
80.38; H, 7.26%. 1H NMR (δ, ppm, CDCl3): 1.15 (s, 3H, 18-H3), 2.81 (m,
2H, 6-H2), 5.02 (s, 2H, Bn-H2), 6.68 (d, 1H, J=2.4 Hz, 4-H), 6.77 (dd,
1H, J=8.6 Hz, J=2.4 Hz, 2-H), 7.09 (s, 1H, =CH), 7.18 (d, 1H,
J=8.6 Hz, 1-H), 7.30 (t, 1H, J=7.3 Hz, 4′-H), 7.37 (t, 2H, J=7.3 Hz,
3′- and 5′-H), 7.41 (d, 2H, J=7.3 Hz, 2′-H and 6′-H). 13C NMR (δ, ppm
CDCl3): 24.7, 25.9 (C-18), 27.7, 27.9, 30.4, 30.9, 41.1, 43.6, 44.6, 47.8,
51.2 (C-13), 62.1, 64.4, 69.9, 112.7 (C-2), 114.6 (C-4), 127.0 (C-1),
127.4 (C-2′ and -6′), 127.8 (C-4′), 128.5 (C-3′ and -5′), 132.1 (C-10),
137.2 (C-1′), 138.0 (C-5), 156.8 (C-3), 223.4 (C=O). 16 is identical
with the compound described in ref. [10].
2.21. 3-Benzyloxy-16α-hydroxymethyl-13α-estra-1,3,5(10)-trien-17β-ol
(19a) and 3-benzyloxy-16β-hydroxymethyl-13α-estra-1,3,5(10)-trien-
17α-ol (20a)
Compound 16a (9 g, 23.2 mmol) was suspended in MeOH (300ml),
and KBH4 (6.2 g, 116mmol) was added in small portions at room
temperature. The mixture was allowed to stand for 5 h, then poured
onto ice (750 g) and acidified with dilute HCl to pH 5. The precipitate
separating out was filtered off, washed until free from acid and dried.
The mixture of 19a and 20a (8.0 g, 98%) was obtained in a ratio of 6:1.
20a is identical with the compound described in ref. [10].
2.22. 17β-Hydroxy-3-benzyloxy-13α-estra-1,3,5(10)-trien-16α-ylmethyl
acetate (19b) and 17α-hydroxy-3-benzyloxy-13α-estra-1,3,5(10)-trien-
16β-ylmethyl acetate (20b)
A mixture of 19a and 20a (10 g, 25.5 mmol) was dissolved in pyr-
idine (40ml) and a solution of Ac2O (2.6ml) in pyridine (55ml) was
added dropwise with cooling in salt-ice. The mixture was allowed to
stand for 5 h at room temperature, and then poured onto a mixture of
ice (400 g) and concentrated H2SO4 (40ml). The precipitate separating
out was filtered off and dissolved in CH2Cl2 (60ml), and the solution
was washed with water (3×60ml), dried over Na2SO4 and evaporated
in vacuo. The mixture of products was subjected to chromatographic
separation (silica gel, CH2Cl2/hexane 25:75, v/v) to give 19c and 20c
as oil (2.1 g, 17%). Continued elution with CH2Cl2 and CH2Cl2/ethyl
acetate (99:1, v/v) resulted in 19b as an oil (5.6 g, 51%), 20b as a white
powdery compound (1.0 g, 9%), and a residual mixture of 19a and 20a
(2.0 g, 20%). After alkaline methanolysis of the mixture of diacetates
(19c and 20c) and diols (19a and 20a), the products formed were re-
cycled. 19b: Oil; Rf = 0.45 (ss A); [α]D25=+75 (c 1 in CHCl3).
(Found: C, 77.46; H, 7.96. C28H34O4 (434.58) requires: C, 77.39; H,
7.89%). 1H NMR (δ, ppm, CDCl3): 1.08 (s, 3H, 18-H3), 2.08 (s, 3H, Ac-
H3), 2.79 (m, 2H, 6-H2), 3.51 (d, 1H, J=7.5 Hz, 17-H), 4.12 (dd, 1H, ,
J=11.0 Hz, J=6.5 Hz, 16a-H2), 4.23 (dd, 1H, J=11.0 Hz,
J=6.0 Hz, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.68 (s, 1H, 4-H), 6.79 (dd,
1H, J=8.5 Hz, J=2.5 Hz, 2-H), 7.16 (d, 1H, J=8.5 Hz, 1-H), 7.32 (t,
1H, J=7.5 Hz, 4′-H), 7.37 (t, 2H, J=7.5 Hz, 3′-H and 5′-H), 7.42 (d,
2H, J=7.5 Hz, 2′-H and 6′-H). 20b: Mp: 66–68 °C; Rf = 0.35 (ss A);
[α]D25=+17 (c 1 in CHCl3). (Found: C, 77.52; H, 8.02. C28H34O4
(434.58) requires: 77.39; H, 7.89%). 1H NMR (δ, ppm, CDCl3): 0.99 (s,
3H, 18-H3), 2.08 (s, 3H, Ac-H3), 2.79 (m, 2H, 6-H2), 3.65 (d, 1H,
J=7.5 Hz, 17-H), 4.05 (dd, 1H, J=11.0 Hz, J=5.0 Hz, 16a-H2), 4.37
(m, 1H, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.68 (d, 1H, J=2.2 Hz, 4-H),
6.77 (dd, 1H, J=8.5 Hz, J=2.2 Hz, 2-H), 7.19 (d, 1H, J=8.5 Hz, 1-
H), 7.29 (t, 1H, J=7.2 Hz, 4′-H), 7.35 (t, 2H, J=7.2 Hz, 3′- and 5′-H),
7.40 (d, 2H, J=7.2 Hz, 2′-H and 6′-H). 13C NMR (δ, ppm, CDCl3): 21.0
(Ac-CH3), 28.9, 29.0 30.3 (C-18), 30.4, 31.8, 32.0, 39.9, 42.3, 43.8,
44.9 (C-13), 51.9, 64.5 (C-16a), 69.9 (Bn-CH2), 82.2 (C-17), 112.7 (C-
2), 114.3 (C-4), 127.4 (C-1), 127.6 (C-2′ and -6′), 127.8 (C-4′), 128.5 (C-
3′ and -5′), 133.7 (C-10), 137.4 (C-1′), 138.1 (C-5), 156.4 (C-3), 171.8
(Ac-C=O).
2.23. 3-Benzyloxy-17-oxo-13α-estra-1,3,5(10)-trien-16α-ylmethyl acetate
(23)
Compound 19b (3 g, 8.4 mmol) was dissolved in acetone (100ml)
and Jones reagent was added dropwise during cooling with ice. The
reaction mixture was poured onto ice (300 g) and extracted with
CH2Cl2. The CH2Cl2 solution was washed with water, dried and eva-
porated. The substance obtained was crystallized from acetone/hexane
to give 13 (1.1 g, 60%) as white crystals. Mp: 153–155 °C; Rf = 0.55 (ss
A); [α]D25=−32.8 (c 1 in CHCl3). (Found: C, 77.81; H, 7.65. C28H32O4
(432.56) requires: C, 77.75; H, 7.46%). 1H NMR (δ, ppm, CDCl3): 1.05
(s, 3H, 18-H3), 2.05 (s, 3H, Ac-H3), 2.84 (m, 2H, 6-H2), 4.30 (d, 2H,
J=4.0 Hz, 16a-H2), 5.02 (s, 2H, Bn-H2), 6.70 (d, 1H, J=2.0 Hz, 4-H),
6.78 (dd, 1H, J=2.0 Hz, J=8.5 Hz, 2-H), 7.18 (d, 1H, J=8.5 Hz, 1-
H), 7.31 (t, 1H, J=7.0 Hz, 4′-H), 7.38 (t, 2H, J=7.5 Hz, 3′-H and 5′-
H), 7.42 (d, 2H, J=7.5 Hz, 2′-H and 6′-H). 13C NMR (δ, ppm, CDCl3):
20.8 (C-18), 24.5 (Ac-CH3), 25.6, 28.5, 30.3, 32.8, 41.4, 41.8, 45.2,
47.6, 50.2 (C-13), 63.3 (C-16a), 69.9 (Bn-CH2), 112.6 (C-2), 114.6 (C-
4), 126.9 (C-1), 127.4 (C-2′ and C-6′), 127.8 (C-4′), 128.5 (C-3′ and C-
5′), 132.0 (C-10), 137.2 (C-1′), 137.9 (C-5), 156.8 (C-3), 170.8 (Ac-
C=O), 219.6 (C-17C=O).
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2.24. 3-Benzyloxy-17-oxo-13α-estra-1,3,5(10)-trien-16β-ylmethyl acetate
(24)
Compound 20b (2 g, 5.6 mmol) was dissolved in acetone (80ml)
and Jones reagent was added dropwise during cooling in ice. The re-
action mixture was poured onto ice (300 g) and extracted with CH2Cl2.
The organic solution was washed with water, dried and evaporated. The
residue is oily product 24 (1.45 g, 60%); Rf = 0.50 (ss A);
[α]D25=−8.5 (c 1 in CHCl3). (Found: 77.63; H, 7.67. C28H32O4
(432.56) requires: C, 77.75; H, 7.46%). 1H NMR (δ, ppm, CDCl3): 1.14
(s, 3H, 18-H3), 1.96 (s, 3H, Ac-H3), 2.83 (m, 2H, 6-H2), 4.18 (dd, 1H,
J=11.0 Hz, J=6.5 Hz, 16a-H2), 4.30 (dd, 1H, J=11.0 Hz,
J=4.5 Hz, 16a-H2), 5.02 (s, 2H, Bn-H2), 6.69 (s, 1H, 4-H), 6.78 (d, 1H,
J=8.5 Hz, 2-H), 7.18 (d, 1H, J=9.0 Hz, 1-H), 7.32 (t, 1H, J=7.0 Hz,
4′-H), 7.38 (t, 2H, J=7.5 Hz, 3′-H and 5′-H), 7.42 (d, 2H, J=7.5 Hz,
2′- H and 6′-H). 13C NMR (δ, ppm, CDCl3): 20.9 (C-18), 25.2, 26.1 (Ac-
CH3), 27.8, 27.9, 29.7, 30.3, 31.0, 41.0, 42.6, 42.9, 47.6, 50.4 (C-13),
64.3 (C-16a), 69.9 (Bn-CH2), 112.6 (C-2), 114.5 (C-4), 127.0 (C-1),
127.4 (C-2′ and C-6′), 127.8 (C-4′), 128.5 (C-3′ and C-5′), 132.2 (C-10),
137.2 (C-1′), 137.8 (C-5), 156.7 (C-3), 170.8 (Ac-C=O), 218.5 (C-
17C=O).
2.25. 3-Benzyloxy-16α-hydroxymethyl-13α-estra-1,3,5(10)-trien-17α-ol
(27a)
LiAlH4 (850mg, 22.5 mmol) was carefully suspended in anhydrous
diethyl ether (70ml), then t-BuOH (6.3ml, 67.5 mmol) was added
dropwise during stirring and cooling with salt-ice. The mixture was
allowed to warm up to room temperature, then the solution of com-
pound 23 (2.3 g, 4.5 mmol) in a mixture of diethyl ether/THF (35ml,
15 ml) was added slowly dropwise to the suspension. The reaction
mixture was stirred for 3 h and then decomposed by the careful addition
of water (50ml) during stirring and cooling with salt-ice. Next, it was
acidified with dilute HCl to pH 5 and then extracted with diethyl ether.
The substance obtained on washing, drying and evaporation of the
solvent was purified by column chromatography on silica gel. Elution
with CH2Cl2/ethyl acetate (95:5, v/v) gave pure compound 27a
(530mg, 30%). Mp: 124–126 °C; Rf = 0.55 (ss A); [α]D25=+25.8 (c 1
in CHCl3). (Found: C, 79.67; H, 8.34. C26H32O3 (392.54) requires: C,
79.56; H, 8.22%). 1H NMR (δ, ppm, DMSO): 0.88 (s, 3H, 18-H3), 2.71
(d, 2H, J=5.5 Hz, 6-H2), 5.03 (s, 2H, Bn-H2), 6.68 (s, 1H, 4-H), 6.75 (d,
1H, J=8.5 Hz, 2-H), 7.18 (d, 1H, J=8.5 Hz, 1-H), 7.31 (t, 1H,
J=5.5 Hz, 4′-H), 7.37 (t, 2H, J=7.5 Hz, 3′-H and 5′-H), 7.41 (d, 2H,
J=7.5 Hz, 2′-H and 6′-H). 13C NMR (δ, ppm, DMSO): 24.2 (C-18),
26.7, 28.5, 30.0, 30.5, 33.4, 40.3, 41.1, 41.1, 44.4 (C-13), 49.6, 63.4 (C-
16a), 69.05 (Bn-CH2), 73.8 (C-17), 112.5 (C-2), 114.3 (C-4), 126.9 (C-
1), 127.5 (C-2′ and C-6′), 127.7 (C-4), 128.4 (C-3′ and C-5′), 132.7 (C-
10), 137.4 (C-1′), 137.8 (C-5), 156.1 (C-3). Further elution with
CH2Cl2/ethyl acetate (95:5, v/v) gave 19a (1.0 g, 60%).
2.26. 3-Benzyloxy-16α-hydroxymethyl-13α-estra-1,3,5(10)-trien-17α-ol
acetonide (27c)
Compound 27a (393mg, 1mmol) was dissolved in acetone (3 ml)
and a catalytic amount of p-toluenesulfonic acid was added. The reac-
tion mixture was treated at reflux temperature for 1 h. It was then
neutralized with morpholine, diluted with CH2Cl2 and washed with
water. The organic layer was dried over Na2SO4 and evaporated in
vacuo. Purification by column chromatography on silica gel with
CH2Cl2/hexane (1:3, v/v) gives 27c (389mg, 90%). Mp: 134–136 °C;
Rf = 0.80 (ss B); [α]D25=−2 (c 1 in CHCl3). (Found: C, 80.67; H, 8.41.
C29H36O3 (432.67) requires: C, 80.52; H, 8.39%). 1H NMR (δ, ppm,
CDCl3): 0.93 (s, 3H, 18-H3), 1.25 and 1.39 (two s, 6H (CH3)2C), 2.80
(m, 2H, 6-H2), 3.74 (d, 1H, J=3.0 Hz, 16a-H2), 4.05 (dd, 1H,
J=11.5 Hz, J=4.0 Hz, 16a-H2), 5.04 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H),
6.80 (dd, 1H, J=8.5 Hz, J=2.5 Hz, 2-H), 7.23 (d, 1H, J=8.5 Hz, 1-
H), 7.33 (t, 1H, J=7.5 Hz, 4′-H), 7. 39 (t, 2H, J=7.5 Hz, 3′-H and 5′-
H), 7.45 (d, 2H, J=7.5 Hz, 2′-H and 6′-H). 13C NMR (δ, ppm, CDCl3):
19.8 (C-18), 28.6 and 29.0 (two C, (CH3)2C), 29.8, 29.9, 30.8, 32.5,
33.7, 36.4, 41.2, 44.5, 45.0 (C-13), 51.6, 62.1 (C-16′), 69.9 (Bn-CH2),
81.7 (C-17), 97.4 (CH3)2C), 112.43 (C-2), 114.3 (C-4), 127.4 (C-2′ and
C-6′), 127.5 (C-1), 127.8 (C-4), 127.8 (C-3′ and C-5′), 133.5 (C-10),
137.4 (C-1), 138.6 (C-5), 156.4 (C-3).
2.27. 3-Benzyloxy-16α-hydroxymethyl-13α-estra-1,3,5(10)-trien-17α-ol
phenylboronate (27d)
Compound 27a (130mg, 0.3 mmol) was dissolved in ethanol (6 ml)
and phenylboronic acid (45mg, 0.3mmol) was added. The precipitate
formed in 15min was filtered off and dried (27d: 132mg, 92%). Mp:
111–113 °C; Rf = 0.70 (ss B); [α]D25=−14.0 (c 1 in CHCl3). (Found:
C, 80.47; H, 7.23. C32H35BO3 (478.45) requires: C, 80.33; H, 7.37%.).
1H NMR (δ, ppm, CDCl3): 1.16 (s, 3H, 18-H3), 2.80 (m, 2H, 6-H2), 3.87
(dd, 1H, J=11.5 Hz, J=7.0 Hz, 16a-H2), 5.04 (s, 2H, Bn-CH2); 6.70
(d, 1H, J=2.0 Hz, 4-H); 6.82 (dd, 1H, J=8.5 Hz, J=2.5 Hz, 2-H),
7.21 (d, 1H, J=8.5 Hz, 1-H), 7.32 (t, 1H, J=7.5 Hz, 4′-H), 7.38 (dd,
4H, J=16.0 Hz, J=8.5 Hz, 3′- H and 5′-H, 3″-H and 5″-H), 7.44 (d,
3H, J=7.5 Hz, 2′-H and 6′-H, 4″-H), 7.86 (d, 2H, J=7.0 Hz, 2″-H and
6″-H). 13C NMR (δ, ppm, CDCl3): 23.8 (C-18), 26.7; 29.1, 30.4, 32.4,
35.9, 39.3, 41.4, 45.2 (C-13), 49.5, 63.7 (C-1″), 63.9 (C-16a), 70.0 (Bn-
CH2), 78.5 (C-17), 112.8 (C-2), 114.4 (C-4), 127.4 (C-2″ and C-6″),
127.5 (C-3″ and C-5″) 127.8 (C-1), 128.5 (C-2′ and C-6′), 133.5 (C-4″),
133.5 (C-10), 133.9 (C-3′ and C-5′), 137.3 (C-1′), 137.9 (C-5), 156.6 (C-
3).
2.28. 3-Benzyl-16α-p-toluenesulfonyloxymethyl-13α-estra-1,3,5(10)-trien-
17α-ol (31)
Compound 27a (393mg, 1mmol) was dissolved in anhydrous pyr-
idine (15ml) and a solution of p-toluenesulfonyl chloride (285mg,
1.5 mmol) in anhydrous pyridine (10ml) was added dropwise while
cooled in an ice-bath. The reaction mixture was allowed to stand for
24 h and then poured onto a mixture of ice (100 g) and sulfuric acid
(10ml). The precipitate was filtered off and crystallized from methanol
to give 31 (490mg, 89%). Mp: 115–116 °C; Rf = 0.85 (ss A). (Found: C,
72.67; H, 6.95. C33H38O5S (546.73) requires: C, 72.50; H, 7.01%). 1H
NMR (δ, ppm, CDCl3): 0.97 (s, 3H, 18-H3), 2.45 (s, 3H, Ts-H3), 2.78 (m,
2H, 6-H2), 4.07 (dd, 1H, J=9.5 Hz, J=7.0 Hz, 16a-H2), 4.12 (d, 1H,
J=8.5 Hz, 17-H), 4.28 (dd. 1H, J=9.5 Hz, J=7.0 Hz, 16a-H2), 5.03
(s, 2H, Bn-H2), 6.69 (d, 1H, J=2.0 Hz, 4-H), 6.79 (dd, 1H, J=8.5 Hz,
J=2.0 Hz, 2-H), 7.18 (d, 1H, J=9.0 Hz, 1-H), 7.35 (m, 5H, 2′-H, 3′-H,
4′-H, 5′-H and 6-H), 7.42 (d, 2H, J=7.0 Hz, 3″-H and 5″-H), 7.81 (d,
2H, J=8.0 Hz, 2″-H and 6″). 13C NMR (δ, ppm, CDCl3): 21.6 (C-18),
23.3 (Ts-CH3) 26.8, 28.8, 30.2, 30.3, 33.1, 39.2, 40.5, 40.7, 44.8 (C-13),
49.7 (C-14), 69.9 (C-16a), 71.9 (Bn-CH2), 75.5 (C-17), 112.7 (C-2),
114.5 (C-4), 127.0 (C-1), 127.4 (C-2′ and C-6′), 127.8 (C-4′), 127.9 (C-
2″ and C-6″), 128.5 (C-3′ and C-5), 129.8 (C-3″ and C-5″), 132.9 (C-10),
133.1 (C-1″), 137.3 (C-1′), 138.0 (C-5), 144.7 (C-4″), 156.7 (C-3).
2.29. 16α,17α-Epoxymethano-3-benzyloxy-13α-estra-1,3,5(10)-triene
(35)
Compound 31 (547mg, 1mmol) was dissolved in methanol (15ml)
and heated at reflux with NaOCH3 (162mg, 3mmol) for 2 h. The re-
action mixture was diluted with water, the precipitate was filtered off,
dried, and crystallized from a mixture of acetone/hexane to give 35
(325mg, 86%). Mp: 91–93 °C; Rf = 0.75 (ss B); [α]D25=+19.2 (c 1 in
CHCl3). (Found: C, 83.62; H, 7.92. C26H30O2 (374.53) requires: C,
83.38; H, 8.07%. 1H NMR (δ, ppm, CDCl3): 1.26 (s, 3H, 18-H3), 2.80 (m,
2H, 6-H2), 3.20 (m, 1H, 16-H), 4.15 (t, 1H, J=5.5 Hz, 16a-H2), 4.78 (t,
1H, J=7.0 Hz, 16a-H2), 4.85 (d, 1H, J=7.0 Hz, 17-H), 5.04 (s, 2H,
Bn-H2), 6.70 (d, 1H, J=2.0 Hz, 4-H), 6.80 (dd, 1H, J=8.5 Hz,
A. Kiss et al. Steroids 134 (2018) 67–77
72
J=2.5 Hz, 2-H), 7.19 (d, 1H, J=8.5 Hz, 1-H), 7.32 (t, 1H, J=7.0 Hz,
4′-H), 7.39 (t, 2H, J=7.5 Hz, 3′-H and 5′-H), 7.43 (d, 2H, J=7.5 Hz,
2′-H and 6′-H). 13C NMR (δ, ppm, CDCl3): 23.3 (C-18), 27.2, 29.2, 30.4,
32.1, 35.9, 37.3, 39.2, 42.4, 45.2 (C-13), 53.4, 69.9 (Bn-CH2), 75.8 (C-
16a), 94.2 (C-17), 112.6 (C-2), 114.5 (C-4), 127.2 (C-1), 127.4 (C-2′ and
C-6′), 127.8 (C-4′), 128.5 (C-3′ and C-5′), 133.3 (C-10), 137.3 (C-1′),
137.9 (C-5), 156.6 (C-3).
2.30. 3-Benzyloxy-16β-hydroxymethyl-13α-estra-1,3,5(10)-trien-17β-ol
(28a)
Compound 24 (2.2 g, 5 mmol) was dissolved in methanol (50ml)
and NaBH4 (570mg, 15mmol) was added in small portions at room
temperature. The reaction mixture was allowed to stand for 12 h, then it
was diluted with water and the precipitate was collected by filtration
and recrystallized from acetone/hexane to obtain 28a (890mg, 45%).
Mp: 119–121 °C; Rf = 0.50 (ss A); [α]D25=+31.9 (c 1 in CHCl3).
(Found: C, 79.33; H, 8.37. C26H32O3 (392.54) requires: C, 79.56; H,
8.22%). 1H NMR (δ, ppm, DMSO): 0.85 (s, 3H, 18-H3), 2.71 (s, 2H, 6-
H2), 4.38 (m, 2H, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.68 (s, 1H, 4-H), 6.75
(d, 1H, J=8.0 Hz, 2-H), 7.19 (d, 1H, J=8.5 Hz, 1-H), 7.31 (t, 1H,
J=6.5 Hz, 4′-H), 7.37 (t, 2H, J=7.5 Hz, 3′-H and 5′-H), 7.41 (d, 2H,
J=7.0 Hz, 2′-H and 6′-H). 13C NMR (δ, ppm, DMSO): 23.4 (C-18),
26.1; 27.8, 28.1, 30.0, 32.8, 41.9, 42.1, 43.4 (C-13), 45.0, 46.6, 63.6 (C-
16a), 68.9 (Bn-CH2), 72.9 (C-17), 112.3 (C-2), 114.2 (C-4), 126.7 (C-1),
127.4 (C-3′ and C-5′), 127.6 (C-4′), 128.3 (C-2′ and C-6′), 132.4 (C-10),
137.3 (C-1′), 137.8 (C-5), 156.0 (C-3).
2.31. 3-Benzyloxy-16β-hydroxymethyl-13α-estra-1,3,5(10)-trien-17β-ol
acetonide (28c)
Compound 28a (250mg, 0.64mmol) was dissolved in acetone
(25ml) and a catalytic amount of p-toluenesulfonic acid was added. The
reaction mixture was treated at reflux temperature for 1 h, neutralized
with morpholine, diluted with CH2Cl2 and then washed with water. The
organic layer was dried over Na2SO4 and evaporated in vacuo. The
crude product was recrystallized from methanol to give 28c (240mg,
86%). Mp: 118–120 °C; Rf = 0.70 (ss B); [α]D25=+2.0 (c 1 in CHCl3).
(Found: C, 80.36; H, 8.51. C29H36O3 (432.67) requires: C, 80.52; H,
8.39%). 1H NMR (δ, ppm, CDCl3): 0.93 (s, 3H, 18-H3), 1.25 and 1.39 (2
s, 6H, 2 (CH3)2C), 2.80 (m, 2H, 6-H2), 3.74 (d, 1H, J=4.0 Hz, 16a-H2),
4.05 (dd, 1H, J=11.5 Hz, J=4.0 Hz, 16a-H2), 6.72 (s, 1H, 4-H), 6.80
(dd, 1H, J=8.5 Hz, J=2.5 Hz, 2-H), 7.22 (d, 1H, J=8.5 Hz, 1-H),
7.31 (m, 1H, 4′-H), 7.45 (t, 2H, J=7.5 Hz, 3′- and 5′-H), 7.40 (d, 2H,
J=7.5 Hz, 2′- and 6′-H). 13C NMR (δ, ppm, CDCl3): 19.8 (C-18), 28.6
((CH3)2C), 29.0, 29.7 ((CH3)2C), 29.9, 30.8, 32.5, 33.7, 36.4, 41.2,
44.5, 45.0 (C-13), 51.6, 62.1 (C-16a), 69.9 (Bn-CH2), 81.7 (C-17), 97.4
((CH3)2C), 112.4 (C-2), 114.3 (C-4), 127.4 (C-2′ and -6′), 127.5 (C-1),
127.6 (C-4′), 128.5 (C-3′ and -5′), 133.5 (C-10), 137.4 (C-1′), 138.5 (C-
5), 156.4 (C-3).
2.32. 3-Benzyloxy-16β-hydroxymethyl-13α-estra-1,3,5(10)-trien-17β-ol
phenylboronate (28d)
Compound 28a (130mg, 0.33mmol) was dissolved in ethanol
(2 ml) and phenlyboronic acid (45mg, 0.3mmol) was added. The pre-
cipitate formed in 20min was filtered off and dried affording 28d
(147mg, 93%). Mp: 112–114 °C; Rf = 0.68 (ss B); [α]D25=−12 (c 1 in
CHCl3). (Found C, 80.57; H, 7.62. C32H35BO3 (478.45) requires: C,
80.33; H, 7.37%). 1H NMR (δ, ppm, CDCl3): 1.16 (s, 3H, 18-H3), 2.80
(m, 2H, 6-H2), 3.87 (dd, 1H, J=11.5 Hz, J=7.0 Hz, 16a-H2), 4.23 (d,
1H, J=7.5 Hz, 17-H), 4.26 (dd, 1H, J=11.5 Hz, J=6.0 Hz, 16a-H2),
5.04 (s, 2H, Bn-H2), 6.70 (d, 1H, J=2.0 Hz, 4-H), 6.82 (dd, 1H,
J=8.5 Hz, J=2.0 Hz, 2-H), 7.21 (d, 1H, J=8.5 Hz, 1H), 7.33 (t, 1H,
J=7.0 Hz, 4′-H), 7.38 (dd, 4H, J=16.0 Hz, J=8.5 Hz, 3′-H and 5′-H,
3″-H and 5″-H), 7.44 (d, 3H, J=7.0 Hz, 2′-H and 6′-H, 4″-H), 7.86 (d,
2H, J=7.0 Hz, 2″-H and 6″-H). 13C NMR (δ, ppm, CDCl3): 23.8 (C-18),
26.7, 29.1, 30.4, 30.5, 32.4; 35.9, 39.3, 41.4, 45.2 (C-13), 49.5, 63.7 (C-
1″), 63.9 (C-16a), 70.0 (Bn-CH2), 78.5 (C-17), 112.8 (C-2), 114.4 (C-4),
127.4 (C-2″ and C-6″), 127.5 (C-3″ and C-5″), 127.8 (C-1), 128.5 (C-2′
and C-6′), 130.6 (C-4″), 133.5 (C-10), 133.9 (C-3′ and C-5′), 137.7 (C-
1′), 137.9 (C-5), 156.6 (C-3).
2.33. 17β-Hydroxy-3-Benzyloxy-13α-estra-1,3,5,(10)-trien-16β-ylmethyl-
p-toluenesulfonate (32)
Compound 28a (393mg, 1mmol) was dissolved in anhydrous pyr-
idine (15ml) and a solution of p-toluenesulfonyl chloride (285mg,
1.5 mmol) in anhydrous pyridine (10ml) was added dropwise during
cooling with ice. The reaction mixture was allowed to stand for 24 h
and then poured onto a mixture of ice (100 g) and sulfuric acid (10ml).
The resulting precipitate was filtered off, dissolved in CH2Cl2 and
Scheme 1. Reagents and conditions: (i) NaOMe, HCOOEt, anhydrous toluene, 50 °C; (ii)
KBH4, MeOH; (iii) TsCl, pyridine; (iv) KOAc, AcOH.
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chromatographed on silica gel. CH2Cl2/hexane (1:1, v/v) eluted pure
32. Mp: 157–159 °C; Rf = 0.80 (ss A). (Found: C, 72.32; H, 6.87.
C33H38O5S (546.73) requires: C, 72.50; H, 7.01%). 1H NMR (δ, ppm,
CDCl3): 0.94 (s, 3H, 18-H3), 2.45 (s, 3H, Ts-H3), 2.73 (s, 2H, 6-H2), 3.78
(d, 1H, J=3.5 Hz, 17-H), 4.02 (dd, 1H, J=8.5 Hz, J=6.5 Hz, 16-H2),
4.25 (t, 1H, J=9.0 Hz, 16a-H2), 5.02 (s, 2H, Bn-H2), 6.67 (s, 1H, 4-H),
6.78 (d, 1H, J=8.0 Hz, 2-H), 7.17 (d, 1H, J=8.5 Hz, 1-H), 7.35 (m,
5H, 2′-H, 3′-H, 4′-H, 5′-H and 6′-H), 7.42 (d, 2H, J=7.5 Hz, 3″-H and
5″-H), 7.80 (d, 2H, J=7.5 Hz, 2″-H and 6″-H). 13C NMR (δ, ppm,
CDCl3): 21. 6 (C-18), 28.8, 29.0, 30.0 (Ts-CH3), 30.4, 31.5, 31.9, 39.9,
41.8, 43.7, 45.0 (C-13), 50.93 (C-14), 69.9 (C-16a), 70.9 (Bn-CH2), 82.2
(C-17), 112.7 (C-2), 114.4 (C-4), 127.4 (C-2′ and C-6′), 127.6 (C-1),
127.8 (C-4′), 127.9 (C-2″ and C-6″), 128.5 (C-3′ and C-5′), 129.9 (C-3″
and C-5″), 133.1 (C-1″), 133.4 (C-10), 137.3 (C-1′), 138.1 (C-5), 144.7
(C-4″), 156.5 (C-3).
2.34. 16β,17β-Epoxymethano-3-benzyloxy-13α-estra-1,3,5(10)-triene
(36)
Compound 32 (136mg, 0.3mmol) was dissolved in methanol
(15ml) and heated at reflux with NaOCH3 (54mg, 1mmol) until full
conversion (2.5 h). The solution was poured into water and mixed with
NH4Cl. The precipitate formed was filtered off, dried, and crystallized
from a mixture of acetone/hexane to give 36 (95mg, 84%). Mp:
118–120 °C; Rf = 0.70 (ss B); [α]D25=+17.0 (c 1 in CHCl3). (Found:
C, 83.56; H, 7.95. C26H30O2 (374.53) requires: C, 83.38; H, 8.07%). 1H
NMR (δ, ppm, CDCl3): 0.70 (s, 3H, 18-H3), 2.90 (m, 2H, 6-H2), 3.99 (dd,
1H, J=4.0 Hz, J=6.0 Hz, 16a-H2), 4.77 (t, 1H, J=7.0 Hz, 16a-H2),
4.80 (d, 1H, J=5.0 Hz, 17-H), 5.04 (s, 2H, Bn-H2), 6.73 (d, 1H,
J=1.5 Hz, 4-H), 6.79 (dd, 1H, J=8.5 Hz, J=1.5 Hz, 2-H), 7.24 (s,
1H, 1-H), 7.32 (t, 1H, J=7.5 Hz, 4′-H), 7.38 (t, 2H, J=7.5 Hz, 3′-H
and 5′-H), 7.44 (d, 2H, J=7.5 Hz, 2′-H and 6′-H). 13C NMR (δ, ppm,
CDCl3): 26.1 (C-18), 29.0, 29.5, 30.7, 32.7, 34.0, 38.0, 42.3, 42.5, 45
(C-13), 52.9, 69.9 (C-16a), 75.4 (Bn-CH2), 75.8 , 98.1 (C-17), 112.4 (C-
2), 114.5 (C-4), 127.2 (C-1), 127.4 (C-2′ and C-6′), 127.8 (C-4′), 128.5
(C-3′ and C-5′), 133.2 (C-10), 137.4 (C-1′), 138.4 (C-5), 156.6 (C-3).
Scheme 2. Reagents and conditions: (i) 1,2-phenylenediamine, AcOH, 110 °C; (ii) NaOMe, HCOOEt, anhydrous toluene, 50 °C; (iii) KBH4, MeOH; (iv) Ac2O, pyridine; (v) CrO3, acetone;
(vi) Li(OtBu)3H, diethyl ether; (vii) NaBH4, MeOH; (viii) acetone, TsOH; (ix) EtOH, PhB(OH)2.
Scheme 3. Reagents and conditions: (i) TsCl, pyridine; (ii) NaOMe, MeOH.
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2.35. 16α-Acetoxymethyl-3-benzyloxy-13α-estra-1,3,5(10)-trien-17β-
acetate (19c), 16β-acetoxymethyl-3-benzyloxy-13α-estra-1,3,5(10)-trien-
17α-acetate (20c), 16α-acetoxymethyl-3-benzyloxy-13α-estra-1,3,5(10)-
trien-17α-acetate (27b) and 16β-acetoxymethyl-3-benzyloxy-13α-estra-
1,3,5(10)-trien-17β-acetate (28b)
2.35.1. General procedure
Compound 19a, 20a, 27a or 28a (150mg, 0.38mmol) was dis-
solved in a mixture of pyridine (3 ml) and acetic anhydride (3 ml) and
the solution was allowed to stand at room temperature for 12 h. It was
then diluted with water and the oil separating out was extracted with
CH2Cl2 (3× 15ml). The organic phase was washed with NaHCO3 so-
lution and then with water, dried and evaporated. The residual oil was
chromatographed on silica gel with a mixture of CH2Cl2/hexane (1:3,
v/v). Product 19c (178mg, 98%) was crystallized from methanol. Mp:
109–111 °C; Rf = 0.62 (ss B); [α]D25=+8.5 (c 1 in CHCl3). (Found:
75.78; H, 7.85. C30H36O5 (476.61) requires: C, 75.60; H, 7.61%). 1H
NMR (δ, ppm, CDCl3): 1.08 (s, 3H, 18-H3), 2.00 (s, 3H, Ac-H3), 2.05 (s,
3H, Ac-H3), 2.82 (m, 2H, 6-H2), 4.15 (d, 2H, J=6.0 Hz, 16a-H2), 4.82
(d, 1H, J=5.0 Hz, 17-H), 5.04 (s, 2H, Bn-H2), 6.72 (d, 1H, J=2.0 Hz,
4-H), 6.80 (dd, 1H, J=8.5 Hz, J=2.0 Hz, 2-H), 7.21 (d, 1H,
J=8.5 Hz, 1-H), 7.32 (t, 1H, J=7.0 Hz, 4′-H), 7.38 (t, 2H, J=7.0 Hz,
3′-H and 5′-H), 7.43 (d, 2H, J=7.0 Hz, 2′-H and 6′-H). 13C NMR (δ,
ppm, CDCl3): 20.9 (Ac-CH3), 21.3 (Ac-CH3), 28.4, 29.1, 29.6; 29.8 (C-
18), 30.4, 33.1, 40.4, 40.8, 44.1 (C-13), 44.7, 51.9, 66.9 (C-16a), 69.9
(Bn-CH2), 84.6 (C-17), 112.6 (C-2), 114.4 (C-4), 127.3 (C-1), 127.5 (C-
2′ and C-6′), 127.8 (C-4′), 128.5 (C-3′ and C-5′), 132.9 (C-10), 137.3 (C-
1′), 138.5 (C-5), 156.6 (C-3), 170.6 (C=O); 171.0 (C=O). 20c: Mp:
71–72 °C; Rf = 0.60 (ss B); [α]D25=+11.5 (c 1 in CHCl3). (Found: C,
75.38; H, 7,71. C30H36O5 (476.61) requires: C, 75.60; H, 7.61%). 1H
NMR (δ, ppm, CDCl3): 1.02 (s, 3H, 18-H3); 2.00 (s, 3H, Ac-H3), 2.07 (s,
3H, Ac-H3), 2.82 (m, 2H, 6-H2), 4.05 (m, 2H, 16a-H2), 5.03 (s, 2H, Bn-
H2), 5.31 (d, 1H, J=9.0 Hz, 17-H), 6.70 (s, 1H, 4-H); 6.79 (dd, 1H,
J=9.0 Hz, J=2.0 Hz, 2-H), 7.22 (d, 1H, J=9.0 Hz, 1-H); 7.31 (t, 1H,
J=7.0 Hz, 4′-H), 7.38 (t, 2H, J=7.0 Hz, 3′-H and 5′-H), 7.43 (d, 2H,
J=7.0 Hz, 2′-H and 6′-H). 13C NMR (δ, ppm, CDCl3): 20.9 (Ac-CH3),
21.0 (Ac-CH3), 23.8 (18-CH3), 26.2, 28.3, 30.5, 33.1, 39.7, 42.1, 42.8,
44.1 (C-13), 48.8, 66.9 (C-16a), 70.0 (Bn-CH2), 76.5 (C-17), 112.6 (C-
2), 114.6 (C-4), 126.9 (C-1), 127.4 (C-2′ and C-6′), 127.8 (C-4′), 128.5
(C-3′ and C-5′), 132.4 (C-10), 137.3 (C-1′), 138.0 (C-5), 156.7 (C-3),
170.7 (C=O), 171.0 (C=O). 27b: Mp: 106–108 °C; Rf = 0.62 (ss B);
[α]D25=+ 15.6 (c 1 in CHCl3). (Found: C, 75.42; H, 7.96. C30H36O5
(476.61) requires: C, 75.60; H, 7.61%). 1H NMR (δ, ppm, CDCl3): 1.05
(s, 3H, 18-H3); 2.03 (s, 3H, Ac-H3), 2.07 (s, 3H, Ac-H3), 2.80 (m, 2H 6-
H2), 4.02 (dd, 1H, J=11.0 Hz, J=7.0 Hz, 16a-H2), 5.03 (s, 2H, Bn-
H2), 5.34 (d, 1H, J=9.0 Hz, 17-H), 6.70 (d, 1H, J=2.0 Hz, 4-H), 6.78
(dd, 1H, J=8.5 Hz, J=2.0 Hz, 2-H), 7.20 (d, 1H, J=8.5 Hz, 1-H),
7.32 (t, 1H, J=7.5 Hz, 4′-H), 7.38 (t, 2H, J=7.5 Hz, 3′-H and 5′-H),
7.38 (t, 2H, J=7.5 Hz, 3′-H and 5′-H), 7.43 (d, 2H, J=7.5 Hz, 2′-H
and 6′-H). 13C NMR (δ, ppm, CDCl3): 20.9 (Ac-CH3), 20.9 (Ac-CH3),
24.2 (C-18), 26.6, 28.7, 30.3, 30.5, 33.4; 36.9, 40.5, 41.2; 44.2 (C-13),
49.7, 65.1 (C-16a), 70.0 (Bn-CH2), 76.0 (C-17), 112.6 (C-2), 114.5 (C-
4), 126.9 (C-1), 127.4 (C-3′ and C-5′), 132.7 (C-10), 137.3 (C-1′), 138.0
(C-5), 156.7 (C-3), 170.8 (C=O), 170.9 (C=O). 28b: Mp: 104–106 °C;
Rf = 0.62 (ss B); [α]D25=+9.0 (c 1 in CHCl3). (Found: 75.44; H, 7.82.
C30H36O5 (476.61) requires: C, 75.60; H, 7.61%). 1H NMR (δ, ppm,
CDCl3): 1.26 (s, 3H, 18-H3), 2.00 (s, 3H, Ac-H3), 2.02 (s, 3H, Ac-H3),
2.80 (m, 2H, 6-H2), 4.01 (m, 16a-H2), 4.11 (m, 1H, 16a-H2), 5.03 (s, 2H,
Bn-H2), 5.12 (d, 1H, J=5.0 Hz, 17-H), 6.70 (s, 1H, 4-H), 6.80 (dd, 1H,
J=8.5 Hz, J=2.5 Hz, 2-H), 7.17 (d, 1H, J=8.5 Hz, 1-H), 7.32 (t, 1H,
Table 1
Antiproliferative activities of compounds 17a-20a and 25a-28a.
Compd. Conc. (μM) Growth Inhibition; % ± SEM [calculated IC50 value; μM]
231 MCF7 T47D 361 HeLa A2780
26a 10 <10 <10 16.66 ± 1.42 < 10 47.46 ± 1.10 36.14 ± 0.87
30 30.12 ± 0.98 26.81 ± 1.84 38.03 ± 0.68 17.83 ± 1.70 58.35 ± 1.52 55.23 ± 2.33
– – – – [11.04] [16.24]
17a 10 <10 <10 20.20 ± 1.74 22.87 ± 2.63 17.39 ± 2.03 23.62 ± 1.32
30 32.08 ± 2.51 21.61 ± 2.30 36.68 ± 0.77 31.18 ± 2.94 58.61 ± 1.69 54.37 ± 1.97
– – – – [24.68] [23.16]
18a 10 10.11 ± 1.71 11.91 ± 2.11 31.69 ± 1.23 < 10 55.38 ± 2.11 38.69 ± 0.65
30 40.43 ± 1.21 43.23 ± 1.64 57.02 ± 1.79 26.02 ± 1.29 66.04 ± 0.85 71.39 ± 0.56
– – [22.51] – [8.35] [13.34]
25a 10 27.10 ± 2.98 14.97 ± 2.16 28.01 ± 1.99 17.14 ± 1.26 56.54 ± 1.44 47.88 ± 1.89
30 42.75 ± 2.13 31.29 ± 1.43 44.32 ± 2.06 39.26 ± 2.52 56.42 ± 1.52 63.68 ± 1.25
– – – – [4.84] [10.67]
28a 10 24.43 ± 2.89 37.28 ± 1.54 44.35 ± 1.16 15.21 ± 2.30 70.48 ± 1.33 54.59 ± 1.31
30 88.29 ± 1.42 97.40 ± 0.34 93.46 ± 0.46 93.71 ± 0.25 98.05 ± 0.17 94.45 ± 0.81
[11.54] [11.95] [10.31] [13.23] [4.91] [7.94]
19a 10 18.24 ± 2.68 40.37 ± 1.69 46.30 ± 1.27 11.10 ± 1.85 50.87 ± 2.42 50.76 ± 0.79
30 89.04 ± 1.53 96.65 ± 0.16 93.71 ± 0.29 96.53 ± 0.45 97.47 ± 0.08 94.89 ± 0.68
[17.39] [10.66] [10.64] [17.36] [8.77] [9.29]
20a 10 20.57 ± 0.91 26.44 ± 1.59 29.68 ± 0.72 15.69 ± 2.86 76.73 ± 0.72 51.90 ± 1.36
30 94.18 ± 0.58 93.64 ± 0.65 46.81 ± 1.42 75.20 ± 1.10 89.60 ± 0.48 75.31 ± 0.69
[16.04] [14.62] – [13.54] [3.36] [7.74]
27a 10 22.31 ± 2.19 27.12 ± 1.96 44.31 ± 1.01 20.28 ± 2.84 55.27 ± 2.38 54.86 ± 1.86
30 94.41 ± 0.73 95.43 ± 0.18 94.09 ± 0.87 88.12 ± 0.93 96.80 ± 0.53 93.68 ± 0.48
[11.57] [14.64] [11.17] [12.34] [7.01] [8.68]
MRC-5
28a 10 <10
30 84.73 ± 0.98
[26.01]
19a 10 <10
30 86.87 ± 0.59
[15.65]
#IC50 values were calculated if the growth inhibition of the compound at 30mM was> 75%.
A. Kiss et al. Steroids 134 (2018) 67–77
75
J=7.5 Hz, 4′-H), 7.38 (t, 1H, J=7.5 Hz, 3′-H and 5′-H), 7.32 (d, 2H,
J=7.5 Hz, 4′-H), 7.38 (t, 2H, J=7.5 Hz, 3′-H and 5′-H), 7.43 (d, 2H,
J= 7.5Hz, 2′-H and 6′-H). 13C NMR (δ, ppm, CDCl3): 20.9 (Ac-CH3),
21.2 (Ac-CH3), 28.6, 29.7, 30.2 (C-18), 30.4, 31.3, 32.4, 39.9, 40.2,
43.5, 44.9 (C-13), 51.4, 64.0, (C-16a), 69.9 (Bn-CH2); 83.4 (C-17),
112.7 (C-2), 114.4 (C-4), 127.4 (C-2′ and C-6′), 127.6 (C-1), 127.8 (C-
4′), 128.5 (C-3′ and C-5′), 133.1 (C-10), 137.3 (C-1′), 138.1 (C-5), 156.6
(C-3), 170. 4 (C=O), 170.9 (C=O).
2.36. Cell cultures and antiproliferative assays
The growth-inhibitory effects of the compounds were tested in vitro
by means of the MTT assay on HeLa, A2780, MCF-7, T47D, MDA-MB-
231 and MDA-MB-361 cells, isolated from cervical, ovarian and breast
cancer, and on noncancerous human fibroblasts (MRC-5 cell line). The
growth-inhibitory effects of the compounds were tested in vitro by
means of the MTT assay on a panel containing four breast cancer cell
lines (MCF-7, T47D, MDA-MB-231 and MDA-MB-361), a cervical and
an ovarian cancer cell line (HeLa and A2780, respectively).
The cell lines were obtained from the European Collection of Cell
Cultures (Salisbury, UK). The cells were maintained in minimal essen-
tial medium supplemented with 10% fetal bovine serum (FBS), 1% non-
essential aminoacids and an antibiotic-antimycotic mixture (AAM). All
chemicals, if otherwise not specified, were purchased from Sigma-
Aldrich Ltd. (Budapest, Hungary). All cell lines were grown in a hu-
midified atmosphere of 5% CO2 at 37 °C. For pharmacological in-
vestigations, 10mM stock solutions of the tested compounds were
prepared with dimethyl sulfoxide (DMSO). The highest applied DMSO
concentration of the medium (0.3%) did not have any substantial effect
on the determined cellular functions. All cell types were seeded into 96-
well plates at a density of 5000 cells/well and allowed to stand over-
night under cell culturing conditions, and the medium containing the
tested compound was then added. After a 72 h incubation with two
concentrations (10 and 30 µM) of the compounds, viability was de-
termined by the addition of 20 µl 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) solution (5 mg/ml) for 4 h. The
precipitated formazan crystals were solubilized in DMSO and the ab-
sorbance was determined at 545 nm with an ELISA reader [11]; wells
with untreated cells were utilized as controls. Two independent ex-
periments were performed with 5 parallel wells; cisplatin, an agent
administered clinically in the treatment of certain gynecological ma-
lignancies, was used as positive control in the same concentration range
as the test compounds. For the most effective compounds, the assays
were repeated with a set of dilutions (0.03–30 µM), and sigmoidal do-
se–response curves were fitted to the measured data in order to de-
termine the IC50 values by means of Graphpad Prism 4.0 (Graphpad
Software; San Diego, CA, US).
3. Results and discussion
3.1. Synthetic studies
We have previously reported the preparation and determination of
the configurations of the four possible isomers of the 3-methoxy-and 3-
benzyloxy-16-hydroxymethyl-estra-1,3,5(10)-trien-17-ols (5a-8a and
9a-12a) of 13β-estrone derivatives. Treatment of 3-methoxy- and 3-
benzyloxyestra-1,3,6(10)-trienes (1 and 3) with NaOMe and ethyl for-
mate gave 3-methoxy- and 3-benzyloxy-16-hydroxymethylidene-estra-
1,3,5(10)-trien-17-ones (2 and 4). The 16-formyl compounds were re-
duced with KBH4 in methanol yielding a mixture of three (5a-7a and
9a-11a) of the four possible isomers of 3-methoxy- and 3-benzyloxy-16-
hydroxymethylestra-1,3,5(10)-trienes in a ratio of 50:45:5 in 94% yield.
Fourth isomers 8a and 12a were prepared from 16α-acetoxymethyl-
17β-p-toluenesulfonate mixed esters (6c and 10c) by neighboring group
participation during solvolysis in aqueous AcOH. The structures of the
isomers were confirmed unambiguously by their IR, 1H and 13C NMR
spectra [6–8] (Scheme 1).
In contrast to the intensive research on 13β-estrone derivatives,
reactions of 13α-estrones are much less studied [2,9,10,12]. Thus, due
to our ongoing interest in 16-hydroxymethyl,17-hydroxy steroids, we
extended the earlier investigations to 13α-estrone derivatives. In this
publication we describe an extension of the C-16 hydroxymethylation
to 3-methoxy- and 3-benzyloxy-13α-estra-1,3,5(10)-trien-17-ones (13
and 15). The 3-methoxy- and 3-benzyloxy-estra-1,3,5(10)-trien-17-ones
(1 and 3) were epimerized by the method of Yaremenko and Khvat [5],
resulting in 3-methoxy- and 3-benzyloxy-13α-estra-1,3,5(10)-trien-17-
ones (13 and 15) in good yield [9,10]. Formylation of 13 and 15 with
ethyl formate in the presence of NaOMe gave the 16-hydro-
xymethylidene-17-ketones (14 and 16) in high yield.
16-Hydroxymethylidene-17-ketones 14 and 16 were reduced with
KBH4 in methanol to give selectively 17, 18 and 19, 20. Two new chiral
centers are formed in this reaction, but only two of the possible four
isomers could be obtained in a 6:1 ratio. These compounds could not be
separated by flash chromatography on silica gel. Selective acetylation
of the primary hydroxyl groups was therefore carried out and the re-
sulting acetates (17b, 18b and 19b, 20b) were separated on a silica gel
column.
Compounds 17b, 19b and 18b, 20b were oxidized by the Jones
method to 3-methoxy- and 3-benzyloxy-17-oxo-13α-estra-1,3,5(10)-
trien-16α-ylmethyl acetates (21, 23), and 3-methoxy- and 3-benzyloxy-
17-oxo-13α-estra-1,3,5(10)-trien-16β-ylmethyl acetates (22, 24).
Reduction of 21 and 23 with lithium tri-tert-butoxyaluminum hydride
afforded isomeric 16α-hydroxymethyl-3-methoxy- and 3-benzyloxy-
16α-hydroxymethyl-13α-estra-1,3,5(10)-trien-17α-ols (25a and 27a)
and 16α-hydroxymethyl-3-methoxy- and 3-benzyloxy-16α-hydro-
xymethyl-13α-estra-1,3,5(10)-trien-17β-ols (17a and 19a) in a ratio of
1:2. These isomers (25a, 17a and 27a, 19a) are separable by flash
chromatography. Repeated Jones oxidation of 17b yields 21, whereas
the oxidation of 19b gives 23; both products can be reused in the re-
duction process.
Since reduction of the 17-ketone function in steroids normally yields
a 17β group (for a few exceptions, see ref. [13]), the reduction of 22
and 24 with KBH4 in methanol gave the isomers 16β-hydroxymethyl-3-
methoxy- and l6β-hydroxymethyl-3-benzyloxy-13α-estra-1,3,5(10)-
trien-17β-ols (26a and 28a) (Scheme 2).
For confirmation of the configurations assumed for 25a, 27a and
26a, 28a, transformations were carried out with the individual isomers.
Treatment of 25a, 27a and 26a, 28a with acetone in the presence of a
catalytic amount of p-toluenesulfonic acid afforded the corresponding
cyclic acetonide derivatives 25c, 27c and 26c, 28c. It is known from
our earlier observations that only the cis-diols participate in acetonide
building reaction [6]. Furthermore, they were reacted with phe-
nylboronic acid to give the corresponding cyclic phenylboronic esters
25d, 27d and 26d, 28d in very good yields.
When treated with p-toluenesulfonyl chloride in pyridine at low
temperature, the primary hydroxymethyl groups were tosylated
yielding 17α-hydroxy-3-methoxy- and 17α-hydroxy-3-benzyloxy-13α-
estra-1,3,5(10)-trien-16α-ylmethyl p-toluenesulfonates (29 and 31) and
17β-hydroxy-3-methoxy- and 17β-hydroxy-3-benzyloxy-13α-estra-
1,3,5(10)-trien-16β-ylmethyl p-toluenesulfonates (30 and 32).
The alkaline reaction of these 1,3-tosylhydrines leads to the for-
mation of oxetanes. The process can be regarded as a neighboring group
participation characterized by the general symbol (O--4). Oxethane
formation takes place readily when the participating groups are in a
favourable steric configuration [14].
On alkaline methanolysis of 29 and 31, α oxethanes 33 and 35 were
formed, condensed to ring D. Alkaline methanolysis of 30 and 32, in
turn, gave β oxethanes 34 and 36 (Scheme 3).
In conclusion, we have synthesized two new cis 16-hydro-
xymethyl,17-hydroxy isomer pairs 25, 27 and 26, 28 in the 3-methoxy-
and 3-benzyloxy-estra-13-epi-1,3,5(10)-triene-17-one series, respec-
tively. These compounds were transformed quantitatively into their
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cyclic acetonides and phenylboronic esters. Furthermore, alkaline me-
thanolysis of their 16-p-toluensulfonyloxymethyl-17-hydroxy deriva-
tives afforded the corresponding α and β oxetanes condensed to ring D
ring in the sterane skeleton.
3.2. Determination of the antiproliferative properties of the 16-
hydroxymethyl-3-methoxy- and 16-hydroxymethyl-3-benzyloxy-13α-estra-
1,3,5(10)-trien-17-ol isomers
The antiproliferative activities of compounds 17a–20a and
25a–28a were determined in vitro by means of MTT assays against HeLa
(cervical carcinoma), A2780 (ovarian carcinoma) and a set of breast
cancer cell lines differing in receptor status [16]. These cell lines in-
cluded MCF-7 (expressing estrogen and progesterone receptors), T47D
(expressing estrogen, progesterone and androgen receptors), MDA-MB-
361 (expressing estrogen and progesterone receptors and HER2), and a
triple-negative cell line MDA-MB-231 (Table 1).
The antiproliferative activities of the compounds depended on the
nature of the protecting group at the 3-hydroxy function and on the
steric orientation of the substituents at C-16 and C-17. The 3-methyl
ethers (17a, 18a, 25a, 26a) did not influence the proliferation of the
breast cancer cell lines markedly. Nevertheless, HeLa and A2780
seemed to be more sensitive to these compounds. 17α-Hydroxy deri-
vatives (18a and 25a) displayed outstanding cell growth-inhibitory
properties against HeLa with IC50 values in the low micromolar range.
The 16α,17β-diastereomer (17a) seemed to be the least potent in the
methyl ether series, exerting remarkable antiproliferative action on
HeLa and A2780 with IC50 values over 20 µM. This is in good agreement
with the findings of Poirier et al. showing that in the 13-epimeric 3,17-
estradiol series the 13α-methyl-3,17α-diol inhibits the proliferation of
certain cancer cell lines mostly [15].
The 3-benzyl ethers (19a, 20a, 27a, 28a), on the whole, proved to
be more potent in comparison with their 3-methyl ether counterparts
(17a, 18a, 25a, 26a). These compounds (19a, 20a, 27a, 28a) displayed
moderate inhibitory properties with IC50 values in the range of
10–20 µM against the panel of breast cancer cell lines. The receptor
status of the cells seems irrelevant, since no considerable cell line de-
pendent differences between the IC50 values were observed. The
16β,17β-isomer (28a) may be concerned as the most active on the
breast panel, because it displayed similar good potency against all four
cell lines. All 3-benzyl ethers (19a, 20a, 27a, 28a) inhibited the pro-
liferation of HeLa and A2780 cell lines markedly. The 16β,17α-dia-
stereomer (20a) was found to be the most potent and selective com-
pound with an IC50 value of 3.36 µM against HeLa and 7.74 µM against
A2780.
The two most potent 3-benzyl ethers (19a and 28a) were selected
for cancer selectivity investigations by means of the MTT assay, using
the non-cancerous human fibroblast cell line MRC-5. Compounds 19a
and 28a inhibited the proliferation of MRC-5 cell line dose-depen-
dently. The 16β,17β-isomer (28a) proved to be tumor-selective by
displaying IC50 values at least two times higher on healthy fibroblast
cells than on cancer cell lines. The 16β,17β-isomer (28a) exerted a si-
milar feature on fibroblasts in comparison with breast cancer cell lines
but only a limited cancer selectivity could be identified when compared
its action on HeLa or A2780 cells with that on MRC-5 cell line.
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A B S T R A C T
Novel 16-triazoles in the 13a-estrone series were synthesized via Cu(I)-catalyzed azide–alkyne
cycloaddition of the two diastereomeric (on C-16 and on C-17) 16-azido-13a-estra-1,3,5(10)-trien-17-ol
3-benzyl ethers with substituted phenylacetylenes. The new heterocyclic derivatives were evaluated in
vitro by means of MTT assays for antiproliferative activity against a panel of human adherent cancer cell
lines (HeLa, MCF-7, A431, A2780, T47D, MDA-MB-231 and MDA-MB-361). The inversion of the
configurations at C-16 and C-17 selectively affected the growth-inhibitory properties of the tested
compounds. The 16b,17a isomers generally proved to be potent on all cell lines, with IC50 values
comparable to those of the reference agent cisplatin. Change of the substitution pattern of the phenyl
group of the acetylene led to great differences in antiproliferative properties. Exclusively the p-phenyl-
substituted triazoles exerted high cytostatic effects. One of the most potent compounds activated
caspase-3 and caspase-9 without influencing caspase-8, confirming the induction of apoptosis via the
intrinsic pathway.
ã 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Structural modifications of estrone may lead to estrone-based
anticancer agents [1–14]. There is a strict requirement in the
development of this kind of drugs: the lack of estrogenic activity.
Homologization of ring B or D or substitution at C-2 of the estrane
skeleton usually leads to the complete loss of hormonal behavior
[15,16,17–20]. An investigation of the effects of the inversion of the
configuration at C-13 and/or C-17 of estradiol on the in vitro and in
vivo estrogenic activity [20] revealed that the C-13 epimers of
estradiol possess low affinity for the estrogen receptor, with no
uterotropic activity when tested on mice. The probable
explanation of the negligible receptor binding ability of the
13-epi-estradiols is the conformational change resulting from the
cis junction of rings C andD [21,22].13a-Estrone is readily available
from natural estrone by the epimerization method of Yaremenko
and Khvat, using 1,2-phenylenediamine and acetic acid [23]. As the
13a-estradiols possess low affinity for the ER and are readily
available, we chose these compounds as scaffolds for the design of
13a-estrone derivatives as potential antitumor agents. We set out
to incorporate triazole rings into the 13a-estradiols in order to
enhance their solubility and bioavailability and to diversify the
drug structure [24]. Triazoles are attractive units because of their
stability against metabolic degradation and their ability to form
hydrogen-bonds. Additionally, these heterocycles are excellent
mimetics of peptide bonds [25]. Cu(I)-catalyzed azide–alkyne
cycloaddition (CuAAC) is a widely applicable and facile method for
the introduction of a triazole moiety into natural products [26].
This regioselective reaction can be achieved with many com-
pounds as Cu(I) catalysts and solvents and is unaffected bya variety
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of functional groups. We recently reported the stereoselective
synthesis of steroidal azidoalcohols and their CuAACwith terminal
alkynes [27–31]. The triazoles formed by the ‘click’ reactions
exerted moderate or pronounced cell-growth inhibition in vitro on
human malignant cell lines.
In this paper, we describe CuAACs of the two diastereomeric (on
C-16 and on C-17) trans-16-azido-13a-estra-1,3,5(10)-trien-17-ol
3-benzyl ethers with substituted phenylacetylenes. The trans-16-
azido-17-alcohols were prepared by the ring-opening reactions of
16,17-epoxides with NaN3. Novel 16-triazolyl-13a-methyl-17-
estradiols and their precursors were tested in vitro on HeLa,
MCF-7, A431 and A2780 cells, using MTT assays. The most potent
derivatives were subjected to additional investigations on a panel
of breast cancer cell lines. The effects of the configurations at C-
16 and C-17 of the triazoles and the substitution patterns of the
phenylacetylenes used as reagents were additionally examined. In
order to clarify the mechanisms of antiproliferative action of the
compounds, cell cycle analyseswere performed by flowcytometry,
and the caspase-3, caspase-8 and caspase-9 activities of one of the
most potent derivatives were determined. The effects of the tested
compounds on the mRNA expression pattern of p21 were
investigated through real-time PCR analyses.
2. Methods and materials
2.1. Chemical synthesis
2.1.1. General methods
Melting points (mp) were determined with a Kofler hot-stage
apparatus and are uncorrected. Elemental analyses were per-
formed with a PerkinElmer CHN analyzer model 2400. Thin-layer
chromatography: silica gel 60 F254; layer thickness 0.2mm
(Merck); eluents: (A) EtOAc/hexane= 15/85, (B) EtOAc/hexane =
30/70; detection with iodine or UV (365nm) after spraying with
5% phosphomolybdic acid in 50% aqueous phosphoric acid and
heating at 100–120 C for 10min. Flash chromatography: silica gel
60, 40–63mm (Merck). 1H NMR spectra were recorded in CDCl3
solution (if not otherwise stated) with a Bruker DRX-500 instru-
ment at 500MHz,withMe4Si as internal standard. 13CNMR spectra
were recorded with the same instrument at 125MHz under the
same conditions. Full scan mass spectra of the compounds were
acquired in the range 50–800 m/z with an Agilent 500MS Ion trap
mass spectrometer equipped with an electrospray ionization
source. Analyses were performed in positive ionmode. The spectra
were collected by continous infusion of the steroid solution at a
concentration of 10ngml1 in MeCN/5mM ammonium formate
50/50 (v/v %) at a flow rate of 15mlmin1. The analytical HPLC
measurements were performed on an Agilent 1260 Infinity HPLC
equipped with a Micro Vacuum Degasser, Binary Pump, Standard
Autosampler, Thermostatted Column Compartment, and Variable
Wavelength Detector. The chromatographic separation was
achieved on Gemini NX C-18 analytical column (3mm,
1502mm) from Phenomenex, equipped with a C-18 guard
column, at 40 C using gradient elution. Mobile phase Awas water
(Sigma–Aldrich Ltd., Budapest, Hungary), while mobile phase B
was acetonitrile (Merck Ltd., Budapest, Hungary). A linear gradient
was applied from 20% B to 100% B in 10min (holding time: 5min)
then B content was lowered to 20% in 5min and finally the column
was re-equilibrated for 5min. The flow rate was set to 0.2ml/min.
2.1.2. Epoxidation of 3-benzyloxy-13a-estra-1,3,5(10), 16-tetraene (1)
A solution of 3-benzyloxy-13a-estra-1,3,5(10), 16-tetraene (1)
(345mg, 1.0mmol) in CH2Cl2 (7ml) was treated with a solution of
magnesium monoperoxyphthalate hexahydrate (85%, 1.9 g, 4
mmol) in MeOH (7ml) and the reaction mixture was stirred at
room temperature for 24h. Aqueous NaHSO3 solution was then
added. The mixture was diluted with CH2Cl2 (7ml), the organic
phase was separated and the aqueous phase was extracted with
CH2Cl2. The combined organic phases were washed with water
until neutral, dried over Na2SO4 and evaporated in vacuo. The crude
product, analyzed by 1H NMR spectroscopy, was a mixture of
16b,17b-epoxide (2) and 16a,17a-epoxide (3) in a ratio of 75:25.
The residue was purified by flash chromatography with EtOAc/
hexane= 10/90 as eluent. First-eluted compound 2was obtained as
a white solid after evaporation of the eluent (187mg, 52%), mp
137–139 C, Rf = 0.65 (ss A); 1H NMR: dH 0.96 (s, 3H, 18-CH3), 1.10–
1.27 (overlapping multiplets, 3H), 1.50–1.64 (overlapping multip-
lets, 4H), 1.87–2.00 (overlapping multiplets, 3H), 2.12 (m, 1H),
2.21–2.26 (overlapping multiplets, 2H), 2.74–2.87 (m, 2H, 6-H2),
3.10 (m, 1H) and 3.38 (m, 1H): 16-H and 17-H, 5.03 (s, 2H, OCH2),
6.69 (d, 1H, J =2.2Hz, 4-H), 6.77 (dd, 1H, J =8.6Hz, J =2.2Hz, 2-H),
7.22 (d, 1H, J =8.6Hz, 1-H), 7.32 (t, 1H, J =7.3Hz, 40-H), 7.38 (t, 2H,
J =7.3Hz, 30-H and 50-H), 7.43 (d, 2H, J =7.3Hz, 20-H and 60-H). 13C
NMR: dC 26.7 (C-18), 27.8 (CH2), 29.1 (CH2), 30.6 (CH2), 30.8 (CH2),
35.4 (CH2), 41.0 (C-13), 42.4 (CH), 44.5 (CH), 46.0 (CH), 54.1 and
66.0 (C-16 and C-17), 69.9 (OCH2), 112.3 (C-2), 114.6 (C-4), 126.9 (C-
1), 127.4 (2C: C-20,60), 127.8 (C-40), 128.5 (2C: C-30,50), 132.9 (C-10),
137.4 (C-10), 138.4 (C-5), 156.6 (C-3). MS m/z (%): 361 (100,
[M+H]+), 91 (50, Bn). Anal. Calcd. for C25H28O2: C, 83.29; H, 7.83.
Found: C, 83.35; H, 8.02. Purity from HPLC: 98.9%. Continued
elutionyielded amixture of the epoxides 2 and 3 (102mg, 28%) and
finally compound 3 (53mg, 15%), mp 97–99 C, Rf = 0.57 (ss A); 1H
NMR: dH 1.27 (s, 3H, 18-CH3), 1.22–1.34 (overlapping multiplets,
5H),1.42–1.61 (overlappingmultiplets, 4H),1.91 (m,1H), 2.44–2.65
(overlapping multiplets, 3H), 2.75 (m, 2H, 6-H2), 3.07 (m, 1H) and
3.48 (m, 1H): 16-H and 17-H, 5.02 (s, 2H, OCH2), 6.66 (d, 1H,
J =2.2Hz, 4-H), 6.79 (dd, 1H, J=8.6Hz, J =2.2Hz, 2-H), 7.10 (d, 1H,
J =8.6Hz,1-H), 7.31 (t,1H, J =7.3Hz, 40-H), 7.38 (t, 2H, J =7.3Hz, 30-H
and 50-H), 7.42 (d, 2H, J =7.3Hz, 20-H and 60-H). 13C NMR: dC 23.6 (C-
18), 26.2 (CH2), 26.5 (CH2), 29.3 (CH2), 30.2 (CH2), 34.6 (CH), 36.4
(CH2), 41.2 (C-13), 43.0 (CH), 47.1 (CH), 58.4 and 67.1 (C-16 and C-
17), 70.0 (OCH2),113.1 (C-2),114.1 (C-4),127.4 (2C: C-20,60),127.8 (C-
40), 128.0 (C-1), 128.5 (2C: C-30,50), 134.4 (C-10), 137.3 (C-10), 137.4
(C-5), 156.4 (C-3). MSm/z (%): 361 (100, [M+H]+), 91 (23, Bn). Anal.
Calcd. for C25H28O2: C, 83.29; H, 7.83. Found: C, 83.42; H, 7.98.
Purity from HPLC: 98.5%.
2.1.3. General procedure for the cleavage of epoxides 2 or 3 with
hydrazoic acid
Epoxide 2 (360mg, 1.0mmol) or epoxide 3 (360mg, 1.0mmol)
or a mixture of 2 and 3 (360mg, 1.0mmol) was dissolved in abs.
DMSO (10ml), and AcOH (1ml) and NaN3 (455mg, 7.0mmol) were
added. The mixture was refluxed for 3h. After cooling to room
temperature, the mixture was poured into ice–water, treated with
NaCl and extracted with CH2Cl2. The combined organic phases
were washed with water until neutral, dried over Na2SO4 and
evaporated in vacuo. The residue was purified by flash chromatog-
raphy with EtOAc/hexane =30/70 as eluent.
2.1.3.1. 16a-Azido-3-benzyloxy-13a-estra-1,3,5(10)-trien-17b-ol
(4). As described in Section 2.1.3, epoxide 2 (360mg, 1.0mmol)
was reacted with NaN3 (455mg, 7.0mmol). Compound 4 was
obtained as a white solid (351mg, 87%), mp 86–88 C, Rf = 0.43 (ss
A); 1H NMR: dH d 1.16 (s, 3H, 18-CH3), 1.21–1.35 (overlapping
multiplets, 3H), 1.44–1.54 (overlapping multiplets, 2H), 1.63 (m,
1H),1.73 (m,1H),1.82–1.88 (overlappingmultiplets, 2H), 2.00–2.05
(overlapping multiplets, 2H), 2.33–2.46 (overlapping multiplets,
2H), 2.78 (m, 2H, 6-H2), 3.65 (t, 1H, J =5.1Hz, 17-H), 3.82 (m, 1H,
16-H), 5.03 (s, 2H, OCH2), 6.69 (d, 1H, J =2.2Hz, 4-H), 6.80 (dd,
1H, J =8.6Hz, J =2.2Hz, 2-H), 7.14 (d, 1H, J =8.6Hz, 1-H), 7.32 (t, 1H,
J =7.3Hz, 40-H), 7.38 (t, 2H, J =7.3Hz, 30-H and 50-H), 7.43 (d, 2H,
J =7.3Hz, 20-H and 60-H). 13C NMR: dC 27.2 (CH2), 27.9 (CH2), 28.7 (C-
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18), 28.8 (CH2), 30.2 (CH2), 31.5 (CH2), 37.7 (CH), 41.1 (CH), 42.1 (C-
13), 49.0 (CH), 66.9 (C-16), 70.0 (OCH2), 86.2 (C-17), 112.9 (C-2),
114.2 (C-4),127.4 (2C: C-20,60),127.6 (C-1),127.8 (C-40),128.5 (2C: C-
30,50), 133.8 (C-10), 137.3 (C-10), 137.7 (C-5), 156.5 (C-3). MSm/z (%):
404 (57, [M+H]+), 145 (100), 91 (89, Bn). Anal. Calcd. for
C25H29N3O2: C, 74.41; H, 7.24. Found: C, 74.32; H, 7.37. Purity
from HPLC: 97.9%.
2.1.3.2. 16b-Azido-3-benzyloxy-13a-estra-1,3,5(10)-trien-17a-ol
(5). As described in Section 2.1.3, epoxide 3 (360mg, 1.0mmol)
was reacted with NaN3 (455mg, 7.0mmol). Compound 5 was
obtained as a white solid (343mg, 85%), mp 97–99 C, Rf = 0.37 (ss
A); 1H NMR: dH 0.98 (s, 3H, 18-CH3), 1.13–1.17 (m, 1H), 1.22–1.46
(overlapping multiplets, 5H), 1.52 (m, 1H), 1.79 (m, 1H), 1.94 (m,
2H), 2.25 (m, 2H), 2.50 (m,1H), 2.82 (m, 2H, 6-H2), 3.86 (m,1H) and
4.03 (m, 1H): 16-H and 17-H, 5.04 (s, 2H, OCH2), 6.71 (d, 1H,
J =2.2Hz, 4-H), 6.80 (dd, 1H, J =8.6Hz, J =2.2Hz, 2-H), 7.21 (d, 1H,
J =8.6Hz,1-H), 7.32 (t,1H, J=7.3Hz, 40-H), 7.38 (t, 2H, J=7.3Hz, 30-H
and 50-H), 7.43 (d, 2H, J =7.3Hz, 20-H and 60-H). 13C NMR: dC 23.0 (C-
18), 26.5 (CH2), 28.3 (CH2), 30.3 (CH2), 31.3 (CH2), 33.2 (CH2), 42.0
(CH), 43.0 (C-13), 43.1 (CH), 48.3 (CH), 66.9 (C-16), 69.9 (OCH2),
79.2 (C-17), 112.6 (C-2), 114.6 (C-4), 126.9 (C-1), 127.4 (2C: C-20,60),
127.8 (C-40), 128.5 (2C: C-30,50), 132.1 (C-10), 137.2 (C-10), 138.2 (C-
5), 156.7 (C-3). MS m/z (%): 404 (100, [M+H]+), 91 (54, Bn). Anal.
Calcd. for C25H29N3O2: C, 74.41; H, 7.24. Found: C, 74.45; H, 7.18.
Purity from HPLC: 98.6%.
2.1.4. General procedure for the preparation of triazoles 7 and 8
To a stirred solution of 16a-azido-3-benzyloxy-13a-estra-1,3,5
(10)-trien-17b-ol 4 (100mg, 0.25mmol) or 16b-azido-3-benzy-
loxy-13a-estra-1,3,5(10)-trien-17a-ol 5 (100mg, 0.25mmol) in
toluene (5ml), Ph3P (13mg, 0.05mmol), CuI (4.7mg, 0.025mmol),
DIPEA (0.13ml, 0.75mmol) and the appropriate terminal alkyne (6,
1.1 equiv.) were added. The reaction mixture was refluxed for 2h,
allowed to cool and evaporated in vacuo. The residue was purified
by flash chromatography with EtOAc/hexane =20/80 as eluent.
2.1.4.1. 3-Benzyloxy-16a-[4-phenyl-1H-1,2,3-triazol-1-yl]-13a-estra-
1,3,5(10)-trien-17b-ol (7a). As described in Section 2.1.4,
azidoalcohol 4 (100mg, 0.25mmol) was reacted with
phenylacetylene (6a, 0.030ml). Compound 7a was obtained as a
white solid (123mg, 97%), mp 95–97 C, Rf = 0.41 (ss B); 1H NMR: dH
1.31 (s, 3H, 18-CH3), 1.29–1.36 (overlapping multiplets, 3H), 1.40–
1.47 (overlapping multiplets, 2H), 1.62–1.71 (overlapping
multiplets, 2H), 1.82 (m, 1H), 2.05 (m, 1H), 2.29 (m, 1H), 2.43
(m,1H), 2.49–2.56 (overlappingmultiplets, 2H), 2.81 (m, 2H, 6-H2),
4.19 (m,1H,17-H), 4.77 (m,1H,16-H), 5.04 (s, 2H, OCH2), 6.70 (d,1H,
J =2.2Hz, 4-H), 6.82 (dd, 1H, J=8.6Hz, J=2.2Hz, 2-H), 7.17 (d, 1H,
J =8.6Hz, 1-H), 7.32 (overlapping multiplets, 2H, 40-H and 400-H),
7.39 (overlapping multiplets, 4H, 30-H, 300-H, 50-H, 500-H), 7.43 (d,
2H, J =7.3Hz, 20-H and 60-H), 7.76 (d, 2H, J =7.5Hz, 200-H and 600-H),
7.79 (s, 1H, C¼CH). 13C NMR: dC 27.0 (CH2), 27.5 (CH2), 28.7 (C-18),
28.9 (CH2), 30.2 (CH2), 31.9 (CH2), 37.4 (CH), 41.0 (CH), 42.1 (C-13),
48.6 (CH), 66.2 (C-16), 70.0 (OCH2), 85.3 (C-17), 113.0 (C-2), 114.2
(C-4), 119.4 (C¼CH), 125.6 (2C) and 128.8 (2C): C-200,300,500,600; 127.4
(2C: C-20,60), 127.7 (C-1), 127.8 (C-40), 128.1 (C-400), 128.5 (2C: C-
30,50), 130.5 (C-100), 133.8 (C-10), 137.3 (C-10), 137.6 (C-5), 147.3
(C¼CH),156.6 (C-3). MSm/z (%): 506 (100, [M+H]+), 146 (23). Anal.
Calcd. for C33H35N3O2: C, 78.38; H, 6.98. Found: C, 78.54; H, 7.05.
Purity from HPLC: 97.3%.
2.1.4.2. 3-Benzyloxy-16a-[4-(3-tolyl)-1H-1,2,3-triazol-1-yl]-13a-
estra-1,3,5(10)-trien-17b-ol (7b). As described in Section 2.1.4,
azidoalcohol 4 (100mg, 0.25mmol) was reacted with
3-ethynyltoluene (6b, 0.036ml). Compound 7b was obtained as
a white solid (125mg, 96%), mp 149–150 C, Rf = 0.43 (ss B);
1H NMR: dH 1.26 (s, 3H, 18-CH3), 1.29–1.36 (overlapping multiplets,
2H), 1.41–1.47 (overlappingmultiplets, 2H), 1.62–1.72 (overlapping
multiplets, 3H), 1.83 (m, 1H), 2.05 (m, 1H), 2.30 (m, 1H), 2.41–2.51
(overlappingmultiplets, 3H), 2.39 (s, 3H, tolyl-CH3), 2.81 (m, 2H, 6-
H2), 4.18 (d, 1H, J =7.9Hz, 17-H), 4.77 (m, 1H, 16-H), 5.04 (s, 2H,
OCH2), 6.70 (d, 1H, J=2.2Hz, 4-H), 6.82 (dd, 1H, J =8.6Hz, J =2.2Hz,
2-H), 7.14 (d, 1H, J =7.3Hz, 400-H), 7.17 (d, 1H, J =8.6Hz, 1-H), 7.29 (t,
1H, J=7.3Hz, 500-H), 7.32 (t,1H, J=7.3Hz, 40-H), 7.38 (t, 2H, J=7.3Hz,
30-H and 50-H), 7.43 (d, 2H, J =7.3Hz, 20-H and 60-H), 7.56 (d, 1H,
J =7.3Hz, 600-H), 7.62 (s, 1H, 200-H), 7.79 (s, 1H, C¼CH). 13C NMR: dC
21.4 (tolyl-CH3), 27.0 (CH2), 27.5 (CH2), 28.7 (C-18), 28.9 (CH2), 30.2
(CH2), 31.9 (CH2), 37.4 (CH), 41.0 (CH), 42.1 (C-13), 48.6 (CH), 66.1
(C-16), 70.0 (OCH2), 85.3 (C-17), 113.0 (C-2), 114.2 (C-4), 119.3
(C¼CH), 122.7 (C-600), 126.3 (C-200), 127.4 (2C: C-20,60), 127.7 (C-1),
127.8 (C-40), 128.5 (2C: C-30,50), 128.7 and 128.9 (C-400 and C-500),
130.5 (C-100), 133.8 (C-10), 137.3 (C-10), 138.5 (C-300), 137.6 (C-5),
147.5 (C¼CH),156.6 (C-3). MSm/z (%): 520 (100, [M+H]+), 160 (29).
Anal. Calcd. for C34H37N3O2: C, 78.58; H, 7.18. Found: C, 78.67; H,
7.05. Purity from HPLC: 96.9%.
2.1.4.3. 3-Benzyloxy-16a-[4-(4-tolyl)-1H-1,2,3-triazol-1-yl]-13a-
estra-1,3,5(10)-trien-17b-ol (7c). As described in Section 2.1.4,
azidoalcohol 4 (100mg, 0.25mmol) was reacted with 4-
ethynyltoluene (6c, 0.035ml). Compound 7c was obtained as a
white solid (121mg, 93%), mp 96–98 C, Rf = 0.43 (ss B); 1H NMR: dH
1.27 (s, 3H, 18-CH3), 1.38–1.47 (overlapping multiplets, 3H), 1.61–
1.70 (overlapping multiplets, 4H), 1.83 (m, 1H), 2.05 (m, 1H), 2.27
(m, 1H), 2.42 (m, 1H), 2.47–2.54 (overlapping multiplets, 2H), 2.37
(s, 3H, tolyl-CH3), 2.80 (m, 2H, 6-H2), 4.17 (d, 1H, J =7.9Hz, 17-H),
4.76 (m, 1H, 16-H), 5.04 (s, 2H, OCH2), 6.70 (d, 1H, J =2.2Hz, 4-H),
6.82 (dd, 1H, J =8.6Hz, J =2.2Hz, 2-H), 7.17–7.21 (overlapping
multiplets, 3H,1-H, 300-H and 500-H), 7.32 (t,1H, J =7.3Hz, 40-H), 7.38
(t, 2H, J =7.3Hz, 30-H and 50-H), 7.44 (d, 2H, J =7.3Hz, 20-H and 60-H),
7.65 (d, 2H, J =7.5Hz, 200-H and 600-H), 7.75 (s, 1H, C¼CH). 13C NMR:
dC 21.3 (tolyl-CH3), 27.0 (CH2), 27.5 (CH2), 28.7 (C-18), 28.9 (CH2),
30.2 (CH2), 31.9 (CH2), 37.4 (CH), 41.0 (CH), 42.1 (C-13), 48.6 (CH),
66.2 (C-16), 70.0 (OCH2), 85.3 (C-17), 113.0 (C-2), 114.2 (C-4), 119.0
(C¼CH),125.5 (2C) and 129.5 (2C): C-200,300,500,600; 127.4 (2C: C-20,60),
127.6 (C-100),127.7 and 127.8 (C-1 and C-40),128.5 (2C: C-30,50),133.9
(C-10), 137.3 and 137.6 and 137.9 (C-10 and C-5 and C-40), 147.4
(C¼CH),156.6 (C-3). MSm/z (%): 520 (54, [M+H]+), 160 (100). Anal.
Calcd. for C34H37N3O2: C, 78.58; H, 7.18. Found: C, 78.42; H, 7.35.
Purity from HPLC: 98.9%.
2.1.4.4. 3-Benzyloxy-16a-[4-{4-(trifluoromethyl) phenyl}-1H-1,2,3-
triazol-1-yl]-13a-estra-1,3,5(10)-trien-17b-ol (7d). As described
in Section 2.1.4, azidoalcohol 4 (100mg, 0.25mmol) was reacted
with 1-ethynyl-4-(trifluoromethyl) benzene (6d, 0.039ml).
Compound 7d was obtained as a white solid (136mg, 95%), mp
133–135 C, Rf = 0.52 (ss B); 1H NMR: dH 1.32 (s, 3H, 18-CH3), 1.33
(m, 1H), 1.44 (m, 1H), 1.64–1.74 (overlapping multiplets, 4H), 1.81
(m, 1H), 2.05 (m, 1H), 2.29 (m, 1H), 2.43 (m, 1H), 2.51–2.61
(overlapping multiplets, 2H), 2.81 (m, 2H, 6-H2), 3.26 (d, 1H,
J =4.7Hz, OH), 4.21 (m, 1H, 17-H), 4.78 (m, 1H, 16-H), 5.04 (s, 2H,
OCH2), 6.70 (d, 1H, J=2.2Hz, 4-H), 6.82 (dd, 1H, J =8.6Hz, J =2.2Hz,
2-H), 7.18 (d, 1H, J =8.6Hz, 1-H), 7.32 (t, 1H, J =7.3Hz, 40-H), 7.39 (t,
2H, J=7.3Hz, 30-H and 50-H), 7.43 (d, 2H, J =7.3Hz, 20-H and 60-H),
7.62 (d, 2H, J =8.2Hz, 200-H and 600-H), 7.82 (d, 2H, J =8.2Hz, 300-H
and 500-H), 7.87 (s, 1H, C¼CH). 13C NMR: dC 26.7 (CH2), 27.1 (CH2),
28.5 (C-18), 28.8 (CH2), 30.1 (CH2), 31.6 (CH2), 37.1 (CH), 40.9 (CH),
41.8 (C-13), 48.2 (CH), 66.6 (C-16), 69.9 (OCH2), 85.1 (C-17), 112.9
(C-2), 114.1 (C-4), 120.6 (C¼CH), 123.9 (d, J =272.5Hz, CF3), 125.3
(2C: C-200 and C-600), 125.6 (d, 2C, J =3.4Hz, C-300 and C-500), 127.4
(2C: C-20,60), 127.7 (C-1), 127.8 (C-40), 128.4 (2C: C-30,50), 129.7 (d,
J =32.6Hz, C-400), 133.5 (C-100), 133.8 (C-10), 137.2 (C-10), 137.5 (C-5),
145.3 (C¼CH), 156.5 (C-3). MSm/z (%): 574 (58, [M+H]+), 145 (64),
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115 (100). Anal. Calcd. for C34H34F3N3O2: C, 71.19; H, 5.97. Found: C,
71.37; H, 6.11. Purity from HPLC: 97.9%.
2.1.4.5. 3-Benzyloxy-16a-[4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl]-
13a-estra-1,3,5(10)-trien-17b-ol (7e). As described in
Section 2.1.4, azidoalcohol 4 (100mg, 0.25mmol) was reacted
with 1-ethynyl-4-ethynylbenzene (6e, 0.039ml). Compound 7e
was obtained as a white solid (127mg, 95%), mp 100–101 C,
Rf = 0.46 (ss B); 1H NMR: dH 1.30 (s, 3H, 18-CH3), 1.26 (t, 3H,
J =7.6Hz, CH2–CH3), 1.32 (m, 1H), 1.38–1.47 (overlapping
multiplets, 2H), 1.61–1.71 (overlapping multiplets, 4H), 1.83
(m, 1H), 2.05 (m, 1H), 2.27 (m, 1H), 2.43 (m, 1H), 2.49–2.55
(overlapping multiplets, 2H), 2.66 (q, 2H, J =7.6Hz, CH2–CH3),
2.81 (m, 2H, 6-H2), 3.26 (s, 1H, OH), 4.19 (m, 1H, 17-H), 4.75 (m,
1H, 16-H), 5.04 (s, 2H, OCH2), 6.70 (d, 1H, J =2.2Hz, 4-H), 6.82
(dd, 1H, J =8.6Hz, J =2.2Hz, 2-H), 7.17 (d, 1H, J =8.6Hz, 1-H), 7.22
(d, 2H, J=7.9Hz, 300-H and 500-H), 7.32 (t, 1H, J =7.3Hz, 40-H), 7.39
(t, 2H, J =7.3Hz, 30-H and 50-H), 7.44 (d, 2H, J=7.3Hz, 20-H and
60-H), 7.66 (d, 2H, J =7.9Hz, 200-H and 600-H), 7.75 (s, 1H, C¼CH).
13C NMR: dC 15.5 (CH2–CH3), 26.9 (CH2), 27.4 (CH2), 28.6 (CH2),
28.7 (C-18), 28.9 (CH2), 30.2 (CH2), 31.9 (CH2), 37.4 (CH), 41.0
(CH), 42.1 (C-13), 48.5 (CH), 66.1 (C-16), 70.0 (OCH2), 85.3 (C-17),
113.0 (C-2), 114.2 (C-4), 119.1 (C¼CH), 125.6 (2C) and 128.3 (2C):
C-200,300,500,600; 127.4 (2C: C-20,60), 127.7 (C-1), 127.8 (C-40), 127.9
(C-100), 128.5 (2C: C-30,50), 133.9 (C-10), 137.3 (C-10), 137.6 (C-5),
144.3 and 147.4 (C-400 and C¼CH), 156.5 (C-3). MS m/z (%): 534
(100, [M+H]+), 174 (55). Anal. Calcd. for C35H39N3O2: C, 78.77; H,
7.37. Found: C, 78.95; H, 7.52. Purity from HPLC: 96.9%.
2.1.4.6. 3-Benzyloxy-16b-[4-{4-(tert-butyl) phenyl}-1H-1,2,3-triazol-
1-yl]-13a-estra-1,3,5(10)-trien-17a-ol (7f). As described in
Section 2.1.4, azidoalcohol 4 (100mg, 0.25mmol) was reacted
with 4-(tert-butyl) phenylacetylene (6f, 0.050ml). Compound 7f
was obtained as a white solid (129mg, 92%), mp 90–92 C, Rf = 0.54
(ss B); 1HNMR: dH 1.30 (s, 3H,18-CH3),1.35 (s, 9H, C(CH3)3),1.32 (m,
1H), 1.44 (m, 1H), 1.61–1.71 (overlapping multiplets, 4H), 1.82 (m,
1H), 2.05 (m,1H), 2.21 (m,1H), 2.27 (m,1H), 2.43 (m,1H), 2.50–2.57
(overlapping multiplets, 2H), 2.81 (m, 2H, 6-H2), 4.18 (d, 1H,
J =7.9Hz, 17-H), 4.75 (m, 1H, 16-H), 5.04 (s, 2H, OCH2), 6.70 (d, 1H,
J =2.2Hz, 4-H), 6.82 (dd, 1H, J=8.6Hz, J =2.2Hz, 2-H), 7.18 (d, 1H,
J =8.6Hz, 1-H), 7.34 (t, 1H, J =7.3Hz, 40-H), 7.37–7.44 (overlapping
multiplets, 6H, 20-H, 60-H, 30-H, 50-H, 300-H and 500-H), 7.60 (d, 2H,
J =7.5Hz, 200-H and 600-H), 7.76 (s, 1H, C¼CH). 13C NMR: dC 27.0
(CH2), 27.4 (CH2), 28.7 (C-18), 28.9 (CH2), 30.2 (CH2), 31.3 (3C: C
(CH3)3), 31.8 (CH2), 37.4 (CH), 41.0 (CH), 42.1 (C-13), 48.5 (CH), 51.1
(C(CH3)3), 66.1 (C-16), 70.0 (OCH2), 85.3 (C-17), 113.0 (C-2), 114.2
(C-4), 119.2 (C¼CH), 125.3 (2C) and 125.7 (2C): C-200,300,500,600; 127.4
(2C: C-20,60), 127.6 (C-100), 127.7 and 127.8 (C-1 and C-40), 128.5 (2C:
C-30,50), 133.9 (C-10), 137.2 (C-10), 137.6 (C-5), 147.2 (C¼CH), 151.1
(C-400), 156.6 (C-3). MS m/z (%): 562 (100, [M+H]+), 202 (44). Anal.
Calcd. for C37H43N3O2: C, 79.11; H, 7.72. Found: C, 79.28; H, 7.95.
Purity from HPLC: 98.9%.
2.1.4.7. 3-Benzyloxy-16b-[4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl]-
13a-estra-1,3,5(10)-trien-17a-ol (7g). As described in
Section 2.1.4, azidoalcohol 4 (100mg, 0.25mmol) was reacted
with 4-bromophenylacetylene (6g, 50mg). Compound 7g was
obtained as a white solid (129mg, 88%), mp 72–74 C, Rf = 0.39 (ss
B); 1H NMR: dH 1.31 (s, 3H,18-CH3), 1.33 (m,1H), 1.43 (m,1H), 1.62–
1.72 (overlapping multiplets, 3H), 1.81 (m, 1H), 2.05 (m, 1H), 2.29
(m, 1H), 2.43 (m, 1H), 2.52 (m, 2H), 2.81 (m, 2H, 6-H2), 4.18 (d,
1H, J =7.9Hz, 17-H), 4.77 (m, 1H, 16-H), 5.04 (s, 2H, OCH2), 6.70 (d,
1H, J =2.2Hz, 4-H), 6.81 (dd, 1H, J =8.6Hz, J=2.2Hz, 2-H), 7.17
(d, 1H, J =8.6Hz, 1-H), 7.32 (t, 1H, J =7.3Hz, 40-H), 7.38 (t, 2H,
J =7.3Hz, 30-H and 50-H), 7.43 (d, 2H, J =7.3Hz, 20-H and 60-H), 7.52
(d, 2H, J=7.5Hz, 200-H and 600-H), 7.63 (d, 2H, J =7.5Hz, 300-H and 500-
H), 7.81 (s, 1H, C¼CH). 13C NMR: dC 27.0 (CH2), 27.5 (CH2), 28.7 (C-
18), 28.9 (CH2), 30.2 (CH2), 31.8 (CH2), 37.4 (CH), 41.0 (CH), 42.1 (C-
13), 48.6 (CH), 66.3 (C-16), 70.0 (OCH2), 85.4 (C-17), 113.1 (C-2),
114.3 (C-4), 119.6 (C¼CH), 122.0 (C-400), 127.1 (2C, C-200 and C-600),
127.4 (2C, C-20 and C-60),127.7 (C-1),127.9 (C-40),128.5 (2C, C-30 and
C-50), 129.4 (C-100), 132.0 (2C, C-300 and C-500), 133.8 (C-10), 137.3 (C-
10), 137.5 (C-5), 148.2 (C¼CH), 156.6 (C-3). MS m/z (%): 584 (100,
[M+H]+). Anal. Calcd. for C33H34BrN3O2: C, 67.81; H, 5.86. Found: C,
69.28; H, 6.15. Purity from HPLC: 97.4%.
2.1.4.8. 3-Benzyloxy-16b-[4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl]-
13a-estra-1,3,5(10)-trien-17a-ol (7h). As described in
Section 2.1.4, azidoalcohol 4 (100mg, 0.25mmol) was reacted
with 4-fluorophenylacetylene (6h, 33mg). Compound 7h was
obtained as a white solid (113mg, 86%), mp 84–86 C, Rf = 0.41 (ss
B); 1H NMR: dH 1.31 (s, 3H, 18-CH3), 1.44 (m, 1H), 1.62–1.74
(overlapping multiplets, 4H), 1.81 (m, 1H), 2.05 (m, 1H), 2.27 (m,
1H), 2.43 (m, 1H), 2.50–2.54 (overlapping multiplets, 2H), 2.81 (m,
2H, 6-H2), 4.19 (d, 1H, J=8.0Hz, 17-H), 4.76 (m, 1H, 16-H), 5.04 (s,
2H, OCH2), 6.70 (d, 1H, J =2.2Hz, 4-H), 6.82 (dd, 1H, J =8.6Hz,
J =2.2Hz, 2-H), 7.08 (t, 2H, J =7.8Hz, 300-H and 500-H), 7.18 (d, 1H,
J =8.6Hz,1-H), 7.32 (t,1H, J=7.3Hz, 40-H), 7.38 (t, 2H, J =7.3Hz, 30-H
and 50-H), 7.42 (d, 2H, J =7.3Hz, 20-H and 60-H), 7.72 (m, 2H, 200-H
and 600-H), 7.77 (s, 1H, C¼CH). 13C NMR: dC 26.9 (CH2), 27.5 (CH2),
28.7 (C-18), 28.9 (CH2), 30.1 (CH2), 31.6 (CH2), 37.4 (CH), 41.0 (CH),
42.1 (C-13), 48.5 (CH), 66.3 (C-16), 69.9 (OCH2), 85.3 (C-17), 113.0
(C-2), 114.2 (C-4), 115.8 (d, 2C, J =21.7Hz, C-300 and C-500), 119.3
(C¼CH), 126.6 (C-100), 127.3 (d, 2C, J =8.0Hz, C-200 and C-600), 127.4
(2C: C-20,60), 127.7 (C-1), 127.8 (C-40), 128.5 (2C: C-30,50), 133.7 (C-
10), 137.3 (C-10), 137.5 (C-5), 146.4 (C¼CH), 156.5 (C-3), 162.6 (d,
J =247.6Hz, C-400). MS m/z (%): 524 (100, [M+H]+). Anal. Calcd. for
C33H34FN3O2: C, 75.69; H, 6.54. Found: C, 76.53; H, 7.06. Purity from
HPLC: 98.9%.
2.1.4.9. 3-Benzyloxy-16b-[4-phenyl-1H-1,2,3-triazol-1-yl]-13a-estra-
1,3,5(10)-trien-17a-ol (8a). As described in Section 2.1.4,
azidoalcohol 5 (100mg, 0.25mmol) was reacted with
phenylacetylene (6a, 0.030ml). Compound 8a was obtained as a
white solid (116mg, 92%), mp 132–134 C, Rf = 0.33 (ss B); 1H NMR:
dH 1.11 (s, 3H, 18-CH3), 1.27–1.50 (overlapping multiplets, 5H), 1.56
(m, 1H), 1.97–2.02 (overlapping multiplets, 2H), 2.11 (m, 1H), 2.24–
2.30 (overlapping multiplets, 2H), 2.72–2.81 (overlapping
multiplets, 2H), 2.89 (m, 2H, 6-H2), 4.57 (d, 1H, J = 8.0Hz, 17-H),
4.80 (m, 1H, 16-H), 5.02 (s, 2H, OCH2), 6.70 (d, 1H, J = 2.2Hz, 4-H),
6.77 (dd, 1H, J = 8.6Hz, J =2.2Hz, 2-H), 7.19 (d, 1H, J =8.6Hz, 1-H),
7.28–7.33 (overlapping multiplets, 2H, 40-H and 400-H), 7.36–7.39
(overlapping multiplets, 4H, 30-H, 300-H, 50-H, 500-H), 7.43 (d, 2H,
J =7.3Hz, 20-H and 60-H), 7.73 (d, 2H, J=8.4Hz, 200-H and 600-H), 7.74
(s, 1H, C¼CH). 13C NMR: dC 23.0 (C-18), 26.5 (CH2), 28.4 (CH2), 30.4
(CH2), 31.7 (CH2), 33.1 (CH2), 42.0 (CH), 42.9 (CH), 43.2 (C-13), 48.4
(CH), 66.5 (C-16), 69.9 (OCH2), 78.8 (C-17), 112.7 (C-2), 114.6 (C-4),
119.5 (C¼CH), 125.6 (2C) and 128.8 (2C): C-200,300,500,600, 127.0 (C-1),
127.4 (2C: C-20,60), 127.8 (C-40), 128.0 (C-400), 128.5 (2C: C-30,50),
130.5 (C-100), 132.1 (C-10), 137.3 (C-10), 138.2 (C-5), 147.4 (C¼CH),
156.7 (C-3). MS m/z (%): 506 (100, [M+H]+), 146 (29). Anal. Calcd.
for C33H35N3O2: C, 78.38; H, 6.98. Found: C, 78.54; H, 7.06. Purity
from HPLC: 97.1%.
2.1.4.10. 3-Benzyloxy-16b-[4-(3-tolyl)-1H-1,2,3-triazol-1-yl]-13a-
estra-1,3,5(10)-trien-17a-ol (8b). As described in Section 2.1.4,
azidoalcohol 5 (100mg, 0.25mmol) was reacted with 3-
ethynyltoluene (6b, 0.036ml). Compound 8b was obtained as a
white solid (122mg, 94%), mp 114–116 C, Rf = 0.37 (ss B); 1H NMR:
dH 1.11 (s, 3H, 18-CH3), 1.25–1.58 (overlapping multiplets, 7H), 1.56
(m,1H),1.96–2.03 (overlappingmultiplets, 2H), 2.09 (m,1H), 2.24–
2.31 (overlapping multiplets, 2H), 2.71–2.91 (overlapping
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multiplets, 3H), 2.36 (s, 3H, tolyl-CH3), 2.81 (m, 2H, 6-H2), 4.55 (m,
1H, 17-H), 4.80 (m, 1H, 16-H), 5.02 (s, 2H, OCH2), 6.70 (d, 1H,
J =2.2Hz, 4-H), 6.76 (dd, 1H, J =8.6Hz, J =2.2Hz, 2-H), 7.11 (d, 1H,
J =7.3Hz, 400-H), 7.19 (d, 1H, J=8.6Hz, 1-H), 7.27 (t, 1H, J =7.7Hz, 500-
H), 7.31 (t, 1H, J =7.3Hz, 40-H), 7.38 (t, 2H, J =7.3Hz, 30-H and 50-H),
7.43 (d, 2H, J =7.3Hz, 20-H and 60-H), 7.52 (d, 1H, J =7.7Hz, 600-H),
7.56 (s, 1H, 200-H), 7.72 (s, 1H, C¼CH). 13C NMR: dC 21.4 (tolyl-CH3),
23.0 (C-18), 26.5 (CH2), 28.4 (CH2), 30.4 (CH2), 31.8 (CH2), 33.2
(CH2), 42.0 (CH), 42.9 (CH), 43.2 (C-13), 48.4 (CH), 66.4 (C-16), 69.9
(OCH2), 78.7 (C-17), 112.7 (C-2), 114.6 (C-4), 119.4 (C¼CH),122.7 (C-
600), 126.3 (C-200), 127.0 (C-1), 127.4 (2C: C-20,60), 127.8 (C-40), 128.5
(2C: C-30,50), 128.7 and 128.8 (C-400 and C-500), 130.3 (C-100), 132.1 (C-
10),137.3 (C-10), 138.4 (C-300), 138.2 (C-5),147.6 (C¼CH),156.7 (C-3).
MS m/z (%): 520 (100, [M+H]+), 160 (38). Anal. Calcd. for
C34H37N3O2: C, 78.58; H, 7.18. Found: C, 78.63; H, 7.31. Purity
from HPLC: 96.9%.
2.1.4.11. 3-Benzyloxy-16b-[4-(4-tolyl)-1H-1,2,3-triazol-1-yl]-13a-
estra-1,3,5(10)-trien-17a-ol (8c). As described in Section 2.1.4,
azidoalcohol 5 (100mg, 0.25mmol) was reacted with 4-
ethynyltoluene (6c, 0.035ml). Compound 8c was obtained as a
white solid (118mg, 91%), mp 151–153 C, Rf = 0.37 (ss B); 1H NMR:
dH 1.11 (s, 3H,18-CH3),1.29–1.58 (overlappingmultiplets, 7H),1.96–
2.03 (overlapping multiplets, 2H), 2.09 (m, 1H), 2.24–2.32
(overlapping multiplets, 2H), 2.35 (s, 3H, tolyl-CH3), 2.71–2.92
(overlapping multiplets, 3H), 4.55 (d, 1H, J =8.0Hz, 17-H), 4.80 (m,
1H, 16-H), 5.02 (s, 2H, OCH2), 6.71 (d, 1H, J =2.2Hz, 4-H), 6.77 (dd,
1H, J =8.6Hz, J=2.2Hz, 2-H), 7.17–7.20 (overlappingmultiplets, 3H,
1-H, 300-H and 500-H), 7.32 (t, 1H, J=7.3Hz, 40-H), 7.38 (t, 2H,
J =7.3Hz, 30-H and 50-H), 7.43 (d, 2H, J=7.3Hz, 20-H and 60-H), 7.61
(d, 2H, J =7.5Hz, 200-H and 600-H), 7.69 (s, 1H, C¼CH). 13C NMR: dC
21.2 (tolyl-CH3), 23.0 (C-18), 26.5 (CH2), 28.4 (CH2), 30.4 (CH2), 31.8
(CH2), 33.1 (CH2), 42.0 (CH), 42.9 (CH), 43.2 (C-13), 48.4 (CH), 66.4
(C-16), 70.0 (OCH2), 78.7 (C-17), 112.7 (C-2), 114.6 (C-4), 119.1
(C¼CH), 125.5 (2C) and 129.4 (2C): C-200,300,500,600; 127.0 (C-1), 127.4
(2C: C-20,60), 127.6 (C-100), 127.8 (C-40), 128.5 (2C: C-30,50), 132.2 (C-
10), 137.3 and 137.9 and 138.2 (C-10 and C-400 and C-5), 147.5
(C¼CH), 156.7 (C-3). MSm/z (%): 520 (100, [M+H]+), 160 (41). Anal.
Calcd. for C34H37N3O2: C, 78.58; H, 7.18. Found: C, 78.42; H, 7.35.
Purity from HPLC: 98.4%.
2.1.4.12. 3-Benzyloxy-16b-[4-{4-(trifluoromethyl) phenyl}-1H-1,2,3-
triazol-1-yl]-13a-estra-1,3,5(10)-trien-17a-ol (8d). As described in
Section 2.1.4, azidoalcohol 5 (100mg, 0.25mmol) was reacted with
1-ethynyl-4-(trifluoromethyl) benzene (6d, 0.039ml). Compound
8d was obtained as a white solid (132mg, 92%), mp 104–105 C,
Rf = 0.38 (ss B); 1H NMR: dH 1.11 (s, 3H, 18-CH3), 1.26–1.59
(overlapping multiplets, 7H), 1.99–2.01 (overlapping multiplets,
2H), 2.14 (m, 1H), 2.26–2.33 (overlapping multiplets, 2H), 2.73–
2.90 (overlapping multiplets, 3H), 4.57 (d, 1H, J =8.1Hz, 17-H), 4.82
(m, 1H, 16-H), 5.02 (s, 2H, OCH2), 6.71 (d, 1H, J =2.2Hz, 4-H), 6.78
(dd, 1H, J=8.6Hz, J =2.2Hz, 2-H), 7.19 (d, 1H, J =8.6Hz, 1-H), 7.32 (t,
1H, J =7.3Hz, 40-H), 7.38 (t, 2H, J =7.3Hz, 30-H and 50-H), 7.43 (d, 2H,
J =7.3Hz, 20-H and 60-H), 7.61 (d, 2H, J =7.5Hz, 200-H and 600-H), 7.83
(d, 2H, J =7.5Hz, 300-H and 500-H), 7.84 (s, 1H, C¼CH). 13C NMR: dC
23.0 (C-18), 26.4 (CH2), 28.4 (CH2), 30.4 (CH2), 31.7 (CH2), 33.1
(CH2), 41.9 (CH), 42.9 (CH), 43.2 (C-13), 48.4 (CH), 66.6 (C-16), 69.9
(OCH2), 78.9 (C-17), 112.7 (C-2), 114.6 (C-4), 120.4 (C¼CH), 123.9 (d,
J =272.5Hz, CF3), 125.6 (2C: C-200 and C-600), 125.8 (d, 2C, J=3.4Hz,
C-300 and C-500), 127.0 (C-1), 127.4 (2C: C-20,60), 127.8 (C-40), 128.5
(2C: C-30,50), 129.8 (d, J=32.7Hz, C-400), 132.0 (C-10), 133.9 (C-100),
137.3 (C-10), 138.1 (C-5), 146.1 (C¼CH), 156.3 (C-3). MSm/z (%): 596
(100, [M+Na]), 574 (88, [M+H]+), 214 (97). Anal. Calcd. for
C34H34F3N3O2: C, 71.19; H, 5.97. Found: C, 71.28; H, 6.15. Purity from
HPLC: 98.2%.
2.1.4.13. 3-Benzyloxy-16b-[4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl]-
13a-estra-1,3,5(10)-trien-17a-ol (8e). As described in
Section 2.1.4, azidoalcohol 5 (100mg, 0.25mmol) was reacted
with 1-ethynyl-4-ethynylbenzene (6e, 0.039ml). Compound 8e
was obtained as a white solid (125mg, 94%), mp 162–164 C,
Rf = 0.36 (ss B); 1H NMR: dH 1.11 (s, 3H,18-CH3),1.25 (t, 3H, J=7.6Hz,
CH2–CH3), 1.26–1.59 (overlapping multiplets, 7H), 1.97–2.03
(overlapping multiplets, 2H), 2.11 (m, 1H), 2.25–2.32
(overlapping multiplets, 2H), 2.66 (q, 2H, J=7.6Hz, CH2–CH3),
2.72–2.93 (overlappingmultiplets, 3H), 4.56 (m,1H,17-H), 4.80 (m,
1H, 16-H), 5.02 (s, 2H, OCH2), 6.70 (d, 1H, J =2.2Hz, 4-H), 6.77 (dd,
1H, J =8.6Hz, J =2.2Hz, 2-H), 7.19 (d, 1H, J =8.6Hz, 1-H), 7.21 (d, 2H,
J =7.9Hz, 300-H and 500-H), 7.31 (t, 1H, J =7.3Hz, 40-H), 7.38 (t, 2H,
J =7.3Hz, 30-H and 50-H), 7.43 (d, 2H, J =7.3Hz, 20-H and 60-H), 7.65
(d, 2H, J =7.5Hz, 200-H and 600-H), 7.71 (s, 1H, C¼CH). 13C NMR: dC
15.5 (CH2–CH3), 23.0 (C-18), 26.5 (CH2), 28.4 (CH2), 28.6 (CH2), 30.4
(CH2), 31.7 (CH2), 33.2 (CH2), 42.0 (CH), 42.9 (CH), 43.2 (C-13), 48.4
(CH), 66.4 (C-16), 69.9 (OCH2), 78.8 (C-17), 112.7 (C-2), 114.6 (C-4),
119.1 (C¼CH), 125.6 (2C) and 128.3 (2C): C-200,300,500,600; 126.9 (C-1),
127.4 (2C: C-20,60), 127.8 (C-40), 127.9 (C-100), 128.5 (2C: C-30,50),
132.1 (C-10), 137.2 (C-10), 138.2 (C-5),144.3 and 147.6 (C¼CH and C-
400), 156.7 (C-3). MS m/z (%): 534 (100, [M+H]+), 174 (49). Anal.
Calcd. for C35H39N3O2: C, 78.77; H, 7.37. Found: C, 78.95; H, 7.42.
Purity from HPLC: 97.8%.
2.1.4.14. 3-Benzyloxy-16b-[4-{4-(tert-butyl) phenyl}-1H-1,2,3-
triazol-1-yl]-13a-estra-1,3,5(10)-trien-17a-ol (8f). As described
in Section 2.1.4, azidoalcohol 5 (100mg, 0.25mmol) was reacted
with 4-(tert-butyl) phenylacetylene (6f, 0.050ml). Compound 8f
was obtained as a white solid (126mg, 90%), mp 187–190 C,
Rf = 0.44 (ss B); 1H NMR: dH 1.11 (s, 3H, 18-CH3), 1.27–1.55
(overlapping multiplets, 7H), 1.33 (s, 9H, C(CH3)3), 1.96–2.03
(overlapping multiplets, 2H), 2.08 (m, 1H), 2.24–2.29 (overlapping
multiplets, 2H), 2.72–2.89 (overlappingmultiplets, 3H), 4.55 (d,1H,
J =8.0Hz, 17-H), 4.79 (m, 1H, 16-H), 5.01 (s, 2H, OCH2), 6.70 (d, 1H,
J =2.2Hz, 4-H), 6.76 (dd, 1H, J =8.6Hz, J =2.2Hz, 2-H), 7.19 (d, 1H,
J =8.6Hz, 1-H), 7.32 (t, 1H, J =7.3Hz, 40-H), 7.37 (overlapping
multiplets, 4H, 30-H, 50-H, 300-H and 500-H), 7.42 (d, 2H, J=7.3Hz, 20-
H and 60-H), 7.60 (d, 2H, J=7.5Hz, 200-H and 600-H), 7.68 (s, 1H,
C¼CH). 13C NMR: dC 23.0 (C-18), 26.5 (CH2), 28.3 (CH2), 30.4 (CH2),
31.3 (3C: C(CH3)3), 31.8 (CH2), 33.2 (CH2), 41.9 (CH), 42.9 (CH), 43.1
(C-13), 48.4 (CH), 51.2 (C(CH3)3), 66.5 (C-16), 69.9 (OCH2), 78.7 (C-
17), 112.6 (C-2), 114.6 (C-4), 119.2 (C¼CH), 125.3 (2C) and 125.6
(2C): C-200,300,500,600; 127.0 (C-1), 127.4 (2C: C-20,60), 127.5 (C-100),
127.8 (C-40), 128.5 (2C: C-30,50), 132.2 (C-10), 137.3 (C-10), 137.8 (C-
5), 147.3 (C¼CH), 151.0 (C-400), 156.7 (C-3). MS m/z (%): 584 (82,
[M+Na]), 562 (100, [M+H]+), 202 (53). Anal. Calcd. for
C37H43N3O2: C, 79.11; H, 7.72. Found: C, 79.43; H, 7.96. Purity
from HPLC: 98.9%.
2.1.4.15. 3-Benzyloxy-16b-[4-(4-bromophenyl)-1H-1,2,3-triazol-1-
yl]-13a-estra-1,3,5(10)-trien-17a-ol (8g). As described in
Section 2.1.4, azidoalcohol 5 (100mg, 0.25mmol) was reacted
with 4-bromophenylacetylene (6g, 50mg). Compound 8g was
obtained as a white solid (127mg, 87%), mp 87–89 C, Rf = 0.31 (ss
B); 1H NMR: dH 1.11 (s, 3H, 18-CH3), 1.26–1.59 (overlapping
multiplets, 5H), 1.96–2.02 (overlapping multiplets, 2H), 2.11 (m,
1H), 2.25–2.32 (overlapping multiplets, 2H), 2.75–2.92
(overlapping multiplets, 3H), 4.55 (m, 1H, 17-H), 4.80 (m, 1H, 16-
H), 5.02 (s, 2H, OCH2), 6.70 (d, 1H, J =2.2Hz, 4-H), 6.77 (dd, 1H,
J =8.6Hz, J =2.2Hz, 2-H), 7.19 (d, 1H, J=8.6Hz, 1-H), 7.31 (t, 1H,
J =7.3Hz, 40-H), 7.38 (t, 2H, J =7.3Hz, 30-H and 50-H), 7.42 (d, 2H,
J =7.3Hz, 20-H and 60-H), 7.50 (d, 1H, J =7.7Hz, 200-H and 600-H), 7.61
(d, 2H, 300-H and 500-H), 7.78 (s, 1H, C¼CH). 13C NMR: dC 23.0 (C-18),
26.5 (CH2), 28.4 (CH2), 30.4 (CH2), 31.7 (CH2), 33.1 (CH2), 41.9 (CH),
42.9 (CH), 43.2 (C-13), 48.4 (CH), 66.6 (C-16), 69.9 (OCH2), 78.8 (C-
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17), 112.7 (C-2), 114.6 (C-4), 119.6 (C¼CH), 122.1 (C-400), 127.0 (C-1),
127.1 (2C: C-200 and C-600), 127.4 (2C: C-20 and C-60), 127.8 (C-40),
128.5 (2C: C-30 and C-50), 129.4 (C-100), 132.0 (2C, C-300 and C-500),
132.1 (C-10), 137.3 (C-10), 138.2 (C-5),146.3 (C¼CH),156.8 (C-3). MS
m/z (%): 584 (100, [M+H]+). Anal. Calcd. for C33H34BrN3O2: C,
67.81; H, 5.86. Found: C, 68.13; H, 6.06. Purity from HPLC: 99.0%.
2.1.4.16. 3-Benzyloxy-16b-[4-(4-fluorophenyl)-1H-1,2,3-triazol-1-
yl]-13a-estra-1,3,5(10)-trien-17a-ol (8h). As described in
Section 2.1.4, azidoalcohol 5 (100mg, 0.25mmol) was reacted
with 4-fluorophenylacetylene (6h, 33mg). Compound 8h was
obtained as a white solid (110mg, 84%), mp 76–78 C, Rf = 0.29 (ss
B); 1H NMR: dH 1.11 (s, 3H, 18-CH3), 1.26–1.58 (overlapping
multiplets, 5H), 1.97–2.02 (overlapping multiplets, 2H), 2.12 (m,
1H), 2.25–2.33 (overlapping multiplets, 2H), 2.73–2.93
(overlapping multiplets, 3H), 4.56 (d, 1H, J=7.8Hz, 17-H), 4.82
(m, 1H, 16-H), 5.02 (s, 2H, OCH2), 6.71 (d, 1H, J =2.2Hz, 4-H), 6.78
(dd,1H, J=8.6Hz, J=2.2Hz, 2-H), 7.08 (t, 2H, J =7.8Hz, 300-H and 500-
H), 7.19 (d,1H, J =8.6Hz,1-H), 7.31 (t,1H, J =7.3Hz, 40-H), 7.38 (t, 2H,
J =7.3Hz, 30-H and 50-H), 7.42 (d, 2H, J =7.3Hz, 20-H and 60-H), 7.78
(m, 3H, C¼CH, 200-H and 600-H). 13C NMR: dC 23.0 (C-18), 26.5 (CH2),
28.4 (CH2), 30.4 (CH2), 31.7 (CH2), 33.1 (CH2), 42.0 (CH), 42.9 (CH),
43.2 (C-13), 48.4 (CH), 66.6 (C-16), 69.9 (OCH2), 78.8 (C-17), 112.7
(C-2), 114.6 (C-4), 115.8 (d, 2C, J =21.7Hz, C-300 and C-500), 119.3
(C¼CH), 126.5 (C-100), 127.3 (d, 2C, J =8.0 Hz, C-200 and C-600), 127.4
(2C: C-20,60), 127.7 (C-1), 127.8 (C-40), 128.5 (2C: C-30,50), 132.1 (C-
10), 137.3 (C-10), 138.2 (C-5), 146.5 (C¼CH), 156.8 (C-3), 161.7 (d,
J =247.6Hz, C-400). MS m/z (%): 524 (100, [M+H]+). Anal. Calcd. for
C33H34FN3O2: C, 75.69; H, 6.54. Found: C, 77.13; H, 6.96. Purity from
HPLC: 98.9%.
2.1.4.17. 16b-[4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-yl]-3-hydroxy-
13a-estra-1,3,5(10)-trien-17a-ol (9). A suspension of 8e
(100mg, 0.19mmol) and Pd/C (0.30 g, 10%) in EtOAc (10ml) was
subjected to 20bar of H2 pressure at room temperature for 3h. The
catalystwas then removed byfiltration through a short pad of silica
gel. After evaporation of the solvent in vacuo, the residue was
purified by flash chromatography with CH2Cl2 as eluent.
Compound 9 was obtained as a white solid (70mg, 82%), mp
115–117 C, Rf = 0.12 (ss B); 1H NMR: dH 0.99 (s, 3H, 18-CH3), 1.21–
1.37 (overlapping multiplets, 7H), 1.50 (m, 1H), 1.80 (m, 1H), 1.87–
1.94 (overlapping multiplets, 2H), 2.20 (m, 2H), 2.61 (q, 2H,
J =6.6Hz, CH2–CH3), 2.73 (m, 2H, 6-H2), 4.39 (m,1H,17-H), 4.84 (m,
1H,16-H), 5.20 (d, 1H, J =5.7Hz,17-OH), 6.64 (d,1H, J=2.2Hz, 4-H),
6.54 (dd, 1H, J =8.6Hz, J =2.2Hz, 2-H), 7.12 (d, 1H, J =8.6Hz, 1-H),
7.26 (d, 2H, J =7.3Hz, 300-H and 500-H), 7.75 (d, 2H, J =7.5 Hz, 200-H
and 600-H), 8.85 (s, 1H, C¼CH), 9.01 (s, 1H, 3-OH). 13C NMR: dC 15.4
(CH2–CH3), 22.9 (C-18), 27.8 (CH2), 28.0 (CH2), 28.9 (CH2), 29.2
(CH2), 31.2 (CH2), 32.0 (CH2), 41.6 (CH), 42.4 (CH), 42.6 (C-13), 47.4
(CH), 65.6 (C-16), 76.9 (C-17),112.9 (C-2),114.7 (C-4), 119.2 (C¼CH),
125.0 (2C) and 128.1 (2C): C-200,300,500,600; 126.6 (C-1), 128.4 (C-100),
143.2 (C-10), 146.1 (C-5), 148.1 and 148.4 (C¼CH and C-400), 154.8
(C-3). MSm/z (%): 444 (100, [M+H]+). Anal. Calcd. for C28H33N3O2:
C, 75.81; H, 7.50. Found: C, 76.05; H, 7.40. Purity from HPLC: 97.9%.
2.2. Pharmacology
2.2.1. Cell cultures and antiproliferative assays
The human cancer cell lines HeLa, A2780 and A431 (isolated
from cervical, ovarian and skin carcinoma, respectively), four
breast cancer cell lines (MCF7, T47D, MDA-MB-231 and MDA-MB-
361) and noncancerous MRC5 fibroblasts (isolated from a fetal
human lung) were maintained in minimal essential medium
supplemented with 10% fetal bovine serum, 1% non-essential
aminoacids and an antibiotic–antimycotic mixture. These cell lines
were purchased from the European Collection of Cell Cultures
(Salisbury, UK) and maintained in a humidified atmosphere of 5%
CO2 at 37 C. All the chemicals, if otherwise not specified, were
purchased from Sigma–Aldrich Ltd. (Budapest, Hungary). For
pharmacological investigations, 10mM stock solutions of the
tested compounds were prepared with DMSO. The highest applied
DMSO concentration of the medium (0.3%) did not have a
substantial effect on the measured cellular functions. The
antiproliferative effects were determined in vitro by means of
theMTTassay. Cells were seeded onto 96-well plates at a density of
5000 cells/well and allowed to stand overnight, after which the
medium containing the tested compound was added. After a 72-h
incubation, viability was determined by the addition of 20ml of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide solu-
tion (5mgml1). The precipitated formazan crystals were solubi-
lized in DMSO and the absorbance was determined at 545nmwith
an ELISA reader [32]. Two independent experiments were
performed with 5 parallel wells. Cisplatin, an agent administered
clinically in the treatment of certain gynecological malignancies,
was used as a positive control. For the most effective compounds,
the assays were repeated with a set of dilutions, and sigmoidal
dose–response curves were fitted to the measured data in order to
determine the IC50 values by means of GraphPad Prism 4.0
(GraphPad Software; San Diego, CA, USA).
2.2.2. Cell cycle analysis by flow cytometry
Flow cytometric analysis was performed in order to character-
ize the cellular DNA content of treated HeLa cells. After treatment
for 24 or 48h, cells (200,000 per condition) were trypsinized
(Gibco BRL, Paisley, U.K.), washed with phosphate-buffered saline
(PBS) and fixed in 1.0ml of cold 70% EtOH. After twowashing steps
in cold PBS, DNA was stained with propidium iodide (10mgml1)
in the presence of RNA-ase (50mgml1). The samples were then
analyzed with CyFlow (Partec GmbH, Münster, Germany). In each
analysis, 20,000 events were recorded, and the percentages of the
cells in the different cell-cycle phases (subG1, G1, S andG2/M)were
calculated by using ModFit LT (Verity Software House, Topsham,
ME, USA) [33].
2.2.3. Hoechst 33258 – propidium iodide double staining
Near-confluent HeLa cells were seeded onto a 96-well plate
(5000 cells/well). After incubation for 24h with the test
compound, Hoechst 33,258 and propidium iodide were added to
the culturemedium to give final concentrations of 5 and 2mgml1,
respectively. The cells were incubated with the staining mixture
for 1h at 37 C and were then photographed by means of a Nikon
Eclipse microscope equipped with an epifluorescence attachment
containing the appropriate optical blocks and a QCapture CCD
camera. The staining allowed the identification of live, early-
apoptotic, late-apoptotic and necrotic cells. Hoechst 33258 per-
meates all the cells and makes the nuclei appear blue. Apoptosis
was revealed by nuclear changes such as chromatin condensation
and nuclear fragmentation. The necrotic and the late-apoptotic
cells were identified as cells with propidium iodide uptake, which
indicates the loss of membrane integrity, the cell nuclei being
stained red [34].
2.2.4. Determination of in situ caspase-3 activity
The activity of caspase-3 from treated cells was determined in
triplicate by means of a commercially available colorimetric kit in
accordance with the instructions of the supplier (Sigma–Aldrich,
Budapest, Hungary). Briefly, near-confluent HeLa cells were seeded
in tissue culture flasks (106 cells/flask) and grown overnight under
standard cell culturing conditions. The cells were next incubated
with two concentrations (3 and 10mM) of the test compound for
48h and then scraped, counted and resuspended in lysis buffer
(10ml for 106 cells). The caspase-3 activity was measured by the
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addition of substrate (Ac-DEVD-pNA) and the amount of product
(pNA, p-nitroaniline) was measured at 405nm after incubation for
2h. Results on treated cells are given as fold increase by direct
comparison with the untreated control results.
2.2.5. Determination of in situ caspase-8 activity
Caspase-8 activity was determined by using a colorimetric
assay kit (Sigma–Aldrich Ltd., Budapest, Hungary), Ac-IETD-pNA
serving as substrate. During the assay, the peptide substrate was
cleaved by caspase-8, resulting in the release of pNA, which was
measured on a microplate reader at an absorbance wavelength of
405nm. All further conditions were identical with those of the
caspase-3 assay.
2.2.6. Determination of in situ caspase-9 activity
The activity of caspase-9 from treated cells was determined in
triplicate by means of a commercially available colorimetric kit in
accordance with the instructions of the supplier (Invitrogen;
Carlsbad, CA, USA). Caspase-9 was determined similarly as for
caspase-3, but the substrate utilizedwas LEHD-pNA; the amount of
pNA was measured as described above.
2.2.7. Quantitative real-time PCR (QPCR)
Total RNA samples were prepared with TRizol from HeLa cells
treated for 24 or 48h with 8e (200,000/well). First-strand cDNA
was synthetized by using TaqMan Reverse Transcription Reagents
(Applied Biosystems, Life Technologies). QPCR reactions were
performed on the PikoReal 96 Real-Time PCR System (Thermo
Scientific), using SYBR Green chemistry. Primers (see Table 1) were
designed by Primer3 software [35]. Rps11 ribosomal protein was
used as internal control. The Ct value for each studied mRNA was
normalized to the internal control and the changes in expression
levels of the examined genes were calculated by the DDCt method
[36]. The presented results were obtained from three independent
experiments.
2.2.8. Statistical analysis
Statistical analysis of the obtained data was carried out by
analysis of variance (ANOVA), followed by the Dunnett post-test.
All analyses were performed with GraphPad Prism 4.0 (GraphPad
Software, San Diego, CA, USA).
3. Results and discussion
3.1. Chemical synthesis
The 16-olefin (1) was readily synthetized from 13a-estrone 3-
benzyl ether as described in the literature for 3-methyl ether
derivatives [37]. The epoxidation of 1 with magnesium monop-
eroxyphthalate resulted in a 3:1 mixture of the 16b,17b- (2) and
the 16a,17a-epoxide (3, Scheme 1). This diastereomeric ratio was
higher than that described earlier in the 3-methyl ether series
(ratio b-epoxide:a-epoxide = 56:44) [37]. The opening of the
epoxides with NaN3 gave the new trans 16-azido-17-alcohols (4
and 5) regioselectively.
The 16-azido-17-hydroxy derivatives (4 or 5) were subjected to
azide–alkyne ‘click’ reactions with substituted phenylacetylenes
according to the earlier-published synthetic procedure (6,
Scheme 2, [28]). Full conversion of the starting materials was
achieved by using a catalytic amount of CuI as catalyst and PPh3 as
stabilizing ligand. Reactions were carried out in refluxing toluene
with an excess of DIPEA as base. Each of the reactions proceeded in
a regioselective manner, yielding the desired triazoles (7 or 8) in
excellent yields (Entries 1–12, Table 2). Removal of the benzyl
protecting group from 8e furnished 9.
The structures of the new compounds (1–8) were confirmed by
1H and 13C NMR measurements. In the 13C NMR spectra of trans-
azidoalcohols 4 and 5, the signals of C-16 and C-17 appear at higher
chemical shifts (around 70 and 80ppm) than in the spectra of
epoxides 2 and 3 (around 55–58 and 66ppm). These upfield shifts
clearly indicate the ring opening of the epoxide and the formation
of alcoholic hydroxy and azido functions on C-17 and C-16. The
multiplets of 16-H and 17-H appear at around 4.2 and 4.7 ppm in
the 1H NMR spectra of triazoles 7, but at around 4.5 and 4.8 ppm in
the spectra of 8. In the 13C spectra of 7d and 8d, signals of CF3, C-400
and C-300 C-500 appear together as doublets with coupling
constants of around 270Hz, 30Hz and 3Hz, indicating the
presence of the CF3 function on C-4”.
3.2. Characterization of antiproliferative properties of the newly
synthetized compounds
In the light of the significant cytostatic properties of our
recently synthetized triazoles [27–31] and the low affinity of the
readily available 13a-estradiols for the ER [21], we combined the
triazole and 13a-estradiol moieties and investigated the cell-
growth-inhibitory potencies of the resulting heterocyclic com-
pounds. The aims of our present study included characterization of
the synthetized triazoles (7, 8) and their precursors (1–5) on a
panel of human adherent cancer cell lines (HeLa, MCF-7, A431 and
Table 1
Nucleotide sequences of the utilized primers.
Target gene Forward primer (50-30) Reverse primer (50-30)
p21 GGATTAGGGCTTCCTCTTGG GACTCTCAGGGTCGAAAACG
Rps11 GCTGCTGCCCCTTTCTTTTT TTGAAGCCCAGACCGATGTT
[(Scheme_1)TD$FIG]
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Scheme 1. Synthesis of trans-16,17-azidoalcohols in the 13a-estrone series. Reagents and conditions: (i) magnesium monoperoxyphthalate hexahydrate (4 equiv.), CH2Cl2/
MeOH, rt, 24h; (ii) NaN3 (7 equiv.), DMSO/MeCOOH=10/1, reflux, 3 h.
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A2780). Compounds 1–5 exerted only moderate cell-growth
inhibition, since none of the derivatives at 10mM achieved 50%
cell-growth inhibition, but compounds 7 and 8 exhibited higher
antiproliferative activities. We set out to determine the impact of
inversion of the configurations at C-16 and C-17 on the in vitro
biological activity. In order to investigate the structure–activity
relationships, the effect of the substitution pattern (considering
the nature and the electronic properties of the 400-substituent) of
the phenyl ring of the terminal alkyne was additionally tested.
Compounds containing 16b,17a functions (8) proved more
efficient than their 16a,17b counterparts, except for the haloge-
nated derivatives 7g and 7h, which exerted substantial growth
inhibition selectively on Hela cells (Table 3). The potency of
compounds 8 depended greatly on the substitution pattern of the
phenyl ring derived from the phenylacetylene. The unsubstituted
(8a) or m-ethyl (8b) derivatives were less active than the p-
tolyltriazole (8c). In order to establish whether the alkyl moiety is
necessary for the cytostatic effect, the p-trifluoromethyl com-
pound (8d) was also tested; it displayed a similar antiproliferative
effect to that of the methyl derivative (8c). The p-alkylphenyl
derivatives bearing an ethyl or tert-butyl group (8e and 8f) proved
to be the most potent against all the tested cell lines, with IC50
values in the range 2.4–3.4mM, displaying a broad spectrum of
activities. Halogen-containing derivatives 8g and 8h were less
potent than their alkyl-substituted counterparts. Compound 9,
containing 3-OH was totally inactive, indicating that the benzyl
ether protecting group is necessary for the antiproliferative
activity.
The potent derivatives (8c–g) were subjected to additional
investigations in order to determine their antiproliferative
properties against a panel of breast cancer cell lines differing in
receptorial status [38]: T47D (expressing estrogen, progesterone
and androgen receptors), MDA-MB-361 (expressing estrogen
receptor and HER2) and triple-negativeMDA-MB-231. Compounds
8c–g proved to be antiproliferative against all three cell lines, with
IC50 values in the range 5–11mM (Table 4), 8d and 8g exerting the
lowest growth inhibition. The activities of the triazoles exceeded
that of cisplatin on T47D and on MDA-MB-231.
The cancer selectivity of the selected potent compound (8e)
was tested by means of the MTT assay, using noncancerous
MRC5 human fibroblast cells. Treatmentwith 30mM 8e resulted in
a 22.22.9% inhibition of the proliferation ofMRC5 cells, while the
reference agent cisplatin at the same concentration caused a more
substantial inhibition (70.71.3%). Since 8e exhibited limited
growth inhibition againstMRC5 cells at 30mM,while its calculated
IC50 values on cancer cell lines were 2.4–6.5mM, it can be
considered cancer-selective.
In order to shed light on the growth-inhibitory action of
compound 8e, cell cycle analyses were performed after exposure
for 24h or 48h. A 24-h treatment of HeLa cells with 10mM 8e
resulted in significant increase in the ratio of cells in the S and G2/
M states at the expense of the G1 phase (Fig. 1). After a 48-h
exposure, marked increases in the subdiploid (subG1) and G2/M
populations were observed, again with decreased presence of
G1 cells. These results indicate blockade of the cell cycle at the G2–
M transition and apoptosis induction.
The presence of apoptosis or necrosis was determined
according to the nuclear morphology and membrane integrity.
HeLa cells were incubated with increasing concentrations of 8e
(3 and 10mM) for 24 or 48h. Separate photos were recorded, in
which Hoechst 33258 and propidium iodide fluorescence served as
morphological markers. At 10mM, 8e significantly increased the
ratio of early apoptotic and secondary necrotic cells at the expense
[(Scheme_2)TD$FIG]
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Scheme 2. Synthesis of 16-triazoles in the 13a-estradiol series. Reagents and conditions: (i) CuI (0.1 equiv.), Ph3P (0.2 equiv.), DIPEA (3 equiv.), reflux, 2 h; (ii) H2 (20bar), Pd/C,
EtOAc, 3 h.
Table 2
Synthesis of 16-triazoles (7,8) in the 13a-estradiol series.
Entry Azide Alkyne Product Yield (%)
1 4 6a 7a 89
2 4 6b 7b 91
3 4 6c 7c 90
4 4 6d 7d 88
5 4 6e 7e 92
6 4 6f 7f 93
7 4 6g 7g 88
8 4 6h 7h 86
9 5 6a 8a 94
10 5 6b 8b 91
11 5 6c 8c 91
12 5 6d 8d 89
13 5 6e 8e 93
14 5 6f 8f 90
15 5 6g 8g 87
16 5 6h 8h 84
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Table 3
Antiproliferative properties of the synthetized compounds.
Comp. Concn. (mM) Inhibition (%) SEM
[calculated IC50 value]a
HeLa MCF7 A2780 A431
1 10 –b – – –
30 – 27.31.6 24.60.4 –
2 10 – – – –
30 28.90.8 48.31.2 36.31.0 46.71.1
3 10 – – – –
30 39.91.4 48.81.3 44.80.6 68.81.2
4 10 21.50.7 36.21.4 33.30.8 –
30 98.30.1 90.30.4 96.40.2 97.70.1
5 10 20.40.5 34.61.4 39.01.0 –
30 96.00.4 77.31.3 96.00.4 82.31.1
7a 10 64.71.7 – 46.51.1 44.90.9
30 80.30.4 – 50.72.0 36.11.3
7b 10 23.90.9 28.31.0 38.90.2 –
30 27.41.0 30.00.5 38.60.4 –
7c 10 57.32.4 35.22.0 46.90.8 –
30 55.51.0 37.62.0 56.50.9 36.60.4
7d 10 58.31.0 42.91.2 53.51.5 25.52.6
30 56.71.2 43.60.4 55.41.1 19.04.4
7e 10 28.11.4 30.40.6 41.40.5 –
30 24.11.2 28.72.3 40.50.3 –
7f 10 46.22.4 36.41.4 43.60.7 38.70.4
30 52.02.4 39.62.1 51.01.4 37.01.1
7g 10 61.22.7 22.91.5 38.80.98 18.52.8
30 65.12.0
[2.0mM]
27.91.0 39.81.2 33.72.1
7h 10 55.51.0 22.32.0 40.22.2 13.10.5
30 62.82.2 23.40.8 36.81.4 26.22.8
8a 10 45.72.7 – 33.31.6 –
30 84.90.5 74.70.7 81.70.8 53.40.4
8b 10 58.40.1 41.51.9 56.40.6 –
30 79.30.4 66.81.5 82.91.0 –
8c 10 72.02.0 82.00.9 80.92.3 49.31.3
30 88.31.3
[7.6mM]
93.60.3
[6.0mM]
88.81.5
[6.0mM]
64.82.4
[10.2mM]
8d 10 75.81.0 67.72.6 69.52.6 44.90.5
30 89.20.9
[8.8mM]
94.30.2
[9.3mM]
90.71.8
[7.5mM]
46.81.1
8e 10 93.50.2 83.32.1 92.70.2 87.50.7
30 97.30.1
[2.6mM]
89.51.1
[2.4mM]
96.90.1
[2.6mM]
92.30.6
[2.9mM]
8f 10 76.00.8 73.50.9 88.40.9 68.60.6
30 89.60.5
[3.4mM]
84.80.5
[2.9mM]
95.00.3
[2.9mM]
76.60.3
[3.2mM]
8g 10 60.51.1 35.12.6 47.81.0 31.21.2
30 86.30.9
[8.5mM]
73.51.2 58.52.1 42.61.4
8h 10 31.62.4 18.42.4 16.72.4 4.31.4
30 49.60.4 34.22.3 38.11.7 12.82.8
9 10 24.31.6 8.81.0 9.90.9 4.61.1
30 24.51.9 57.90.9 39.01.0 30.01.3
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of intact cells, even after incubation for 24h (Fig. 2). This tendency
was substantially more pronounced after exposure for 48h. While
substances that predominantly initiate apoptotic cell death are
preferred during the development of anticancer agents, treatment
with 8e resulted in necrosis too.
The latter observation was supported by the results obtained
from the determination of the apoptosis executive enzyme
caspase-3. After the incubation of HeLa cells for 48h with
10mM 8e, the caspase-3 concentrationwas significantly increased
(Fig. 3). Since the intrinsic or mitochondrial pathway of
programmed cell death is initiated by caspase-9, the activity of
this apoptotic enzyme was additionally determined under the
same conditions. Compound 8e at 10mM increased the activity of
caspase-9, which indicates that a mitochondrial dysfunction may
contribute to the activation of the apoptotic machinery. In order to
clarify the role of the extrinsic pathway of apoptosis in the action of
8e, the activity of caspase-8was determined in the sameway. Since
no caspase-8 activation was detected, the involvement of extrinsic
apoptotic initiation can be excluded.
To the best of our knowledge, there is only one literature
example of an efficient antiproliferative 13a-estrone derivative on
the malignant cell lines that we tested [39]. The 16-oxime
propionate in the 3-benzyl ether series caused a cell cycle blokade
of HeLa cells at the G1–S transition with induction in the
subdiploid ratio after exposure for 48h, indicating apoptotic cell
death [39]. Its noteworthy that 16-triazolyl derivative 8e led to
blockade at a later phase (G2–M) of the cell cycle, in contrast with
the effect of the oxime ester on the first checkpoint (G1–S).
I-
n
order to investigate the reason for the G2–Marrest, HeLa cellswere
treated with low and high concentrations of 8e. 24 and 48h later,
the mRNA levels of p21, one of the key regulators of a G2–M arrest
[40], were determined byQPCR. The induction of p21was observed
Table 3 (Continued)
Comp. Concn. (mM) Inhibition (%) SEM
[calculated IC50 value]a
HeLa MCF7 A2780 A431
Cisplatin 10 42.62.3 53.02.3 83.61.2 88.60.5
30 99.90.3
[12.4mM]
86.91.3
[9.6mM]
95.00.3
[1.3mM]
90.21.8
[2.8mM]
a Mean value from two independent determinations with five parallel wells; standard deviation <15%.
b Inhibition values <20% are not presented.
Table 4
Antiproliferative properties of 8c–g.
Comp. Concn. (mM) Inhibition (%) SEM
[calculated IC50 value]a
T47D MDA-MB-231 MDA-MB-361
8c 10 85.91.1 84.51.01 83.60.6
30 92.00.4
[5.9mM]
94.50.5
[6.5mM]
89.20.5
[5.3mM]
8d 10 58.4  0.9 41.8  2.5 57.2  1.8
30 90.9  0.5
[9.7 mM]
82.2  0.7
[10.3 mM]
74.1  1.2
[9.7 mM]
8e 10 85.60.6 85.31.8 74.10.9
30 92.00.4
[5.9mM]
92.40.9
[6.5mM]
83.61.6
[5.4mM]
8f 10 65.40.8 57.01.3 61.40.3
30 87.70.6
[6.2mM]
84.50.7
[8.3mM]
74.31.2
[6.6mM]
8g 10 56.51.0 48.51.5 56.02.0
30 81.11.4
[9.0mM]
76.91.9
[10.3mM]
73.71.3
[8.8mM]
Cisplatin 10 51.02.0 20.080.8 67.51.0
30 57.91.4
[9.8mM]
71.71.2
[19.1mM]
87.71.1
[3.7mM]
a Mean value from two independent determinations with five parallel wells; standard deviation.
[(Fig._1)TD$FIG]
Fig. 1. Compound 8e causes disturbance in the cell cycle distribution of HeLa cells
after incubation for 24 or 48h. ** and *** indicate p<0.01 and p<0.001,
respectively, as compared with the control cells.
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both 24 and 48h after exposure to 10mM 8e (Fig. 4). At 3mM 8e,
the mRNA levels of p21 were significantly increased only 48h after
the treatment, indicating that 8e has the capacity to induce p21 in a
time- and concentration-dependent manner.
4. Conclusions
In summary, novel 16-triazolyl-17-estradiol 3-benzyl ethers
were synthetized in the 13a-estrone series. Some compounds
proved to exert in vitro cytostatic activity against the examined
human adherent cancer cell lines, with IC50 values comparable
to those of the reference agent cisplatin. The antiproliferative
activities of the tested compounds were greatly affected by
the configurations at C-16 and C-17 and by the substitution
pattern of the triazolyl-phenyl ring. It can be stated that 16b,17a
isomers bearing p-alkyl substituents on the triazolyl-phenyl ring
displayed outstanding activities. It was confirmed that one of the
most potent compounds (8e) induces apoptosis via the intrinsic
pathway. Our results indicate that 17a-hydroxy-13a-estradiol
3-benzyl ether is a promising scaffold for the design of hormonally
inactive cytostatic derivatives, especially with a 16b-heterocyclic
substituent.
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